

- Yibchok-Anun, S., 1461  
 Yin, D.Y., 1075  
 Yingst, D.R., 1167  
 Ylikorkala, O., 892  
 Yokokawa, K., 1256  
 Yokoyama, J., 1089  
 Yonemitsu, S., 1570  
 Yoo, H.J., 1141  
 Yoo, J.-H., 1047  
 Yoshikawa, J., 1256  
 Yoshimasa, Y., 1570  
 Yoshimura, A., 865  
 Yoshino, K., 1418  
 Young, M.M.-S., 651  
 Young, V.R., 1378  
 Younger, M.S., 390  
 Yuan, X., 173  
 Zambón, D., 47  
 Zanetti, M., 1564  
 Zavaroni, I., 989  
 Zelissen, P.M.J., 314  
 Zhang, Y., 1033  
 Zhang, Z., 1203  
 Zhou, X., 681  
 Zhou, Y.-P., 857  
 Zhu, J.-S., 965  
 Zhu, M., 477  
 Ziegler, R., 1236  
 Zijlstra, W.G., 1082  
 Zimmermann, J., 1236  
 Ziv, E., 1549  
 Zmuda, J.M., 822  
 Zorić, S., 525  
 Zuccarelli, A., 989

## SUBJECT INDEX

- A, *see* Androstenedione in PCOS  
 AAs, *see* Amino acids  
 Abdominal adipocytes in transsexuals, effects of cross-sex hormone therapy on lipolytic activity of, 1371-1377  
 Abdominal adipose tissue (AT)  
   acarbose effects on, 350  
   in GH-deficient adults, effects of GH therapy and its withdrawal on, 1390  
   in NIDDM, changes in capillary angioarchitecture of islets of Langerhans and, 479  
   response of total body fat and, to exercise, HERITAGE Family Study of, 1278-1286  
   serum lipids, GH secretion and, in older men and women, 1426, 1428  
 Abdominal obesity, circulating TNF- $\alpha$  concentrations in peripheral versus, 1332-1335  
 Acarbose in prevention and reversal of metabolic abnormalities in obese DM subjects, 347-354  
 Acetate, effects of soy protein/soluble fiber diet on, 813  
 Acetic acid, plasma dihydroxyphenyl, and activities of HPA axis and SNS, 396  
 Acetoacetate in whole-body lipolysis, hypoosmolality effects on, 474, 475  
 Acetyl coenzyme A (CoA)  
   insulin and exercise activation of PDH complex and, 866, 867  
   LA effects on, 508  
 N-Acetylcysteine (NAC), effects of vitamin E and, on PS externalization and coagulation induction in glucose-treated erythrocytes, 957-959  
 N-Acetyl- $\beta$ -L-glucuronidase ( $\beta$ -GlcNAx-ase), RBC membrane, activity of, in NIDDM, 817-821  
 Acetylhydrolase, plasma PAF-, in HIV infection and AIDS, 1524-1531  
 Acidosis, chronic hyperchloremic, GH therapy effects on renal N wasting, renal Mg wasting, and renal phosphate depletion induced by, 763-770  
 Acipimox  
   effects of, on PP lipemia, 245-251  
   metabolic effects of FFA decrease with, in hyperthyroidism, 1318-1321  
 Acquired immunodeficiency syndrome (AIDS), plasma PAF-AH in, 1524-1531  
 ACTH (adrenocorticotropin hormone), *see* Corticotropin  
 Actin, effects of disruption of filamentous, on Ca<sup>2+</sup> signaling in liver, 1241-1247  
 Acute discontinuation of epinephrine, impact of, on hepatic glucose metabolism during stress hormone infusion, 910-914  
 Acute effects of adrenergic-mediated ischemia on MNCV in NIDDM, 495-500  
 Acute hyperglycemia, cochlear dysfunction in NIDDM independently of neuropathy and, 1346-1350  
 Acute hyperinsulinemia, effects of, on urinary nitrite/nitrate excretion and plasma ET-1 levels in normotensive and essentially hypertensive men, 887-891  
 Acute myocardial infarction (MI), high concentration of proinsulin preceding, in nondiabetics, 1197-1202  
 Acylcarnitine  
   LA effects on, 508  
   renal, renal glucose oxidation and, 709-710  
 Acyl-coenzyme A (CoA) dehydrogenase, medium-chain, 2-octynoic acid simulating deficiency of, 685-688  
 Acyltransferase, lecithin:cholesterol, in cornea of human apo A-II transgenic mice with functional deficiency of, 415-421  
 ADA (adenosine deaminase), BMI and, in NIDDM, 949-951  
 Adenosine, F and xylitol effects on plasma concentrations and urinary excretion of, 520-524  
 Adenosine deaminase (ADA), BMI and, in NIDDM, 949-951  
 Adenosine diphosphate (ADP), liver mitochondria, in NIDDM, 1118  
 Adenosine monophosphate, *see* cAMP  
 Adenosine triphosphatase, *see* Na/K-ATPase  
 Adenosine triphosphate, *see* ATP in NIDDM  
 Adipocytes  
   BM 17.0744 effects on glucose uptake and consumption by, 36  
   in essential HTN, effects of enalapril and losartan on insulin resistance in, 1041-1046  
   in hyperinsulinemia, 468-470  
   hypertrophy of subcutaneous, metabolic risk factors for CHD and, 355-362  
   lipolysis by, *see* Lipolysis by adipocytes  
   TSH effects on leptin production in, 1570-1574  
 Adipose tissue (AT; body fat)  
   acarbose effects on, 352  
   and decrease in SM capillary density in men, 1268  
   diet and, *see* Adipose tissue, diet and  
   distribution of, in NIDDM men, troglitazone effects on, 1102-1107;  
     *see also* Subcutaneous adipose tissue; Visceral adipose tissue  
   exercise and, *see* Adipose tissue in exercising men; Adipose tissue in exercising women  
   in GH-deficient adults, GH therapy effects on, 309-310  
   and HPA axis and SNS activities, 396  
   in hyperinsulinism, sex hormones and, 108  
   leptin and, *see* Adipose tissue, leptin and  
   in NIDDM, *see* Adipose tissue in NIDDM  
   parametrial, BC/SKF38393 effects on lipolysis in, 1037  
   in RA, 748  
   T<sub>3</sub> effects on, 1605

- Adipose tissue (AT; body fat) (*Continued*)  
 total, *see* Total body fat  
*see also* Adipocytes; Adipose tissue lipoprotein lipase activity; Fat mass; Obesity
- Adipose tissue (AT; body fat), diet and  
 brown AT, effects of high-sucrose diet with EPA-E ester and/or lard on, 1093-1094  
 in malnourished older cancer subjects, 292, 294
- Adipose tissue (AT; body fat), leptin  
 energy expenditure and determination of plasma leptin AT in male subjects, 1272-1277  
*see also* Adipose tissue, serum leptin and; Leptin
- Adipose tissue (AT; body fat), serum leptin and  
 aging-related changes in sex hormones and sex difference in serum leptin independently of changes in AT, 378-384  
 and association of serum leptin and serum uric acid concentrations in obesity, 678-680  
 in NIDDM, macroalbuminuria, microalbuminuria and, 1291, 1292
- Adipose tissue (AT; body fat) in exercising men  
 and effects of apo E genotype and exercise on plasma HDL-C and HDL<sub>2</sub>-C in obese men, 944  
 and metabolic adaptation to HF diet, 1510  
 prior exercise reducing PP lipemia independently of AT and CHO contributions to energy expenditure during exercise, 245-251  
 in weight-reduced men, 17  
*see also* Adipose tissue in older exercising men and women
- Adipose tissue (AT; body fat) in exercising women  
 diet composition and timing of exercise effects on, 1597  
 Mexican American and non-Hispanic, PP insulin responses and, 972  
*see also* Adipose tissue in older exercising men and women
- Adipose tissue (AT; body fat) in NIDDM  
 and acute effects of adrenergic-mediated ischemia on MNCV, 496  
 with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 NE-mediated vasoconstriction and, 1538
- Adipose tissue (AT; body fat) in older exercising men and women  
 AT-LPL activity and, 185  
 chromium picolinate supplementation effects in, 549  
 exercise effects on HDL-C and, 985  
 GH secretion, serum lipids and, 1424-1431
- Adipose tissue lipoprotein lipase (AT-LPL) activity  
 BC/SKF38393 effects on, 1036  
 in sedentary and exercising middle-aged and older men, leptin and obesity but not CV fitness as predictors of, 183-189
- Adolescents  
 apo E polymorphism and changes in TC and LDL-C in adolescent girls, 285-290  
 temporal association between obesity and hyperinsulinemia in, 928-934
- ADP (adenosine diphosphate), liver mitochondria, in NIDDM, 1118
- Adrenergic-mediated ischemia, acute effects of, on MNCV in NIDDM, 495-500
- $\beta_3$ -Adrenergic receptor, *see entries beginning with terms*: Trp64Arg variant of  $\beta_3$ -AR gene
- $\alpha$  (alpha)<sub>2D</sub>-Adrenergic receptors (ARs), and effects of amitraz and BTS 27271 on insulin and glucagon secretion, 1461-1469
- Adrenocortical cells, CLA-1 as source of C ester necessary to steroidogenesis in, 627-630
- Adrenocorticotropin hormone, *see* Corticotropin
- ADT-G (androsterone glucuronide), effects of long-term exercise-induced weight loss in young identical male twins on, 1120-1127
- Adult growth hormone deficiency, *see* Growth hormone, therapy of adult GH deficiency with
- Adult hypopituitarism  
 kinetics of VLDL apo B-100 in, 1057-1062  
*see also* Growth hormone, therapy of adult GH deficiency with
- Adverse and side effects  
 of gemfibrozil and lovastatin therapy of FCHL, 49  
 of GH therapy in GH-deficient adults, 310  
 of metformin, 516, 901  
 of pramlintide, 938
- African-Americans, *see* Race and ethnicity
- Age  
 of AIDS subjects, 1526  
 of CHD subjects, 653, 854  
 of cirrhotic subjects, *see* Age of cirrhotic subjects  
 of CT subjects, 234  
 and decrease in SM capillary density in men, 1268  
 of diabetic retinopathy subjects, 1173  
 of epileptic subjects on anticonvulsants, 1048, 1050  
 and ERT effects on vascular reactivity, 228  
 of ESRD patients on HD, 632  
 of exercising subjects with combined hyperlipidemia, 1520; *see also* Age of exercising men; Age of exercising women  
 of FCHL subjects, 47  
 FM and toxin-induced infections and, 947  
 of galactosemic subjects, 1295  
 of HCL subjects, *see* Age of HCL subjects  
 HPA axis and SNS activities and, 396  
 of HTG and NTG subjects, 303  
 and HTN, *see* Age of HTN subjects  
 of hyperinsulinemic subjects, *see* Age of hyperinsulinemic subjects  
 of hyperinsulinic subjects, sex hormones and, 108  
 of hyperthyroidic subjects, and FFA decrease with acipimox, 1319  
 of hyperuricemic Taiwanese aborigines, 132  
 of hypogonadal men, 591  
 and hypopituitarism, VLDL apo B-100 kinetics and, 1058; *see also* Age of GH-deficient adults  
 of IBD subjects, 953  
 of IDDM subjects, *see* Age of IDDM subjects  
 and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 782  
 of MHL subjects, 62  
 of multiple-trauma victims, 1398  
 of NIDDM-prone subjects, and peripheral tissue glucose uptake after OGTT, 81  
 of NIDDM subjects, *see* Age of NIDDM subjects  
 of nondiabetic subjects, *see* Age of nondiabetic subjects  
 of normolipidemic subjects with peripheral vascular disease, 1363  
 of obese subjects, *see* Age of obese subjects  
 of PCOS women, *see* Age of PCOS women  
 of PH subjects, 299  
 of pregnant subjects, *see* Age of pregnant subjects  
 of premenopausal women, and association of plasma leptin with plasma PAI-1, 961, 962  
 of RA subjects, 748  
 race and, *see* Age, race and ethnicity and  
 serum leptin and, *see* Age, serum leptin and  
 and serum 25OHD levels, 1029  
 of smokers, *see* Age of smokers  
 soy protein with very low C diet effects and, 490  
 splanchnic utilization of enteral alanine and, 916  
 Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and, 1368, 1369  
*see also* Adolescents; Aging-related changes in sex hormones; Children; Middle-aged men; Older subjects and *entries beginning with term*: Young

- Age, race and ethnicity and  
 low serum insulin and, 1217  
 and racial differences in PP TGs, postheparin and hepatic TG lipase, 750
- Age, serum leptin and  
 and relationship between serum leptin, IGF-I, IGFBP-1, and IGFBP-3, 841  
 and twenty-four hour variation in serum leptin, 1012, 1013
- Age of cirrhotic subjects  
 and effects of paracentesis of ascites on DEXA BMD and BMC measurements, 374  
 hepatic glucose metabolism and, 1261  
 and vitamin E effects on cirrhosis, 87
- Age of exercising men  
 and long-term weight maintenance in weight-reduced men, 17  
 and metabolic adaptation to HF diet, 1510  
 of obese men, and effects of apo E genotype and exercise on plasma HDL-C and HDL<sub>2</sub>-C, 944  
*see also* Older men and women, exercising; Young men, exercising
- Age of exercising women  
 and diet composition and timing of exercise effects on sympathoadrenal function, 1597  
 Mexican American and non-Hispanic, PP insulin responses and, 972  
*see also* Older men and women, exercising
- Age of GH-deficient adults  
 of childhood-onset GH-deficient adults, 1004  
 insulin secretion and, effects of GH therapy and its withdrawal on, 1390  
 sex and, and response to GH therapy, 309, 315
- Age of HCL subjects  
 of children, stiffness of aortic wall and, 57  
 simvastatin effects and, 69
- Age of HTN subjects  
 with acute hyperinsulinemia, 888  
 with essential HTN, effects of long-term lisinopril therapy and, 1257
- Age of hyperinsulinemic subjects  
 with hyperlipidemia, fasting hyperinsulinemia and prediction of atherosclerotic CV disease and, 1428-1440, 1442  
 obesity and, 929  
 and prediction of NIDDM, HTN, and CHD, 990, 992, 993
- Age of IDDM subjects  
 cardiac sympathetic dysinnervation and, 93  
 childhood-onset IDDM subjects with CAD, 532, 533  
 and octreotide effects on endothelial dysfunction in IDDM, 1237  
 with osteomyelitis of foot, 923  
 and urinary excretion of apo A fragments, 370
- Age of NIDDM subjects  
 and activity of RBC membrane glycohydrolases, 818  
 and acute effects of adrenergic-mediated ischemia on MNCV, 496  
 with angiopathy, 1482  
 with CAD, 433  
 cochlear dysfunction and, 1347, 1348  
 dimorphism of NIDDM phenotype and, 477-483  
 fish and exercise effects on urinary excretion of F<sub>2</sub>-isoprostane and, 1404  
 and glycated Hb in NIDDM erythrocytes, 206  
 and LDL composition and metabolism, 119  
 lipid peroxidation and, *see* Age of NIDDM subjects, lipid peroxidation and  
 with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 NE-mediated vasoconstriction and, 1538  
 with osteomyelitis of foot, 923  
 and *rad* gene polymorphism, 174  
 tHcy, nephropathy and, 1097
- Age of NIDDM subjects (*Continued*)  
 and total depletion of antioxidant capacity, 1415  
 and troglitazone effects on AT distribution, 1103
- Age of NIDDM subjects, lipid peroxidation and  
 and gliclazide effects versus effects of metformin on peroxidation, 898  
 in NIDDM erythrocytes, 206
- Age of nondiabetic subjects  
 with MI, 1199  
 of nondiabetic offspring of NIDDM subjects, 979, 981
- Age of obese subjects  
 and association of serum leptin and serum uric acid concentrations, 678  
 circulating TNF- $\alpha$  and, 1333  
 and effects of apo E genotype and exercise on plasma HDL-C and HDL<sub>2</sub>-C in obese men, 944  
 hyperinsulinemia and, 929  
 with insulin resistance, *FABP2* gene polymorphism and, 656  
 and lean subjects, HR variability and, 756  
 VAT and risk for CHD and, 357  
*see also* Age of obese subjects, Trp64Arg variant of  $\beta_3$ -AR gene and; Age of obese women
- Age of obese subjects, Trp64Arg variant of  $\beta_3$ -AR gene and  
 in Japanese men, *UCP1* gene mutation and, 637, 638  
 in Thai subjects, relationship of mutation to total body fat but not to percent body fat and insulin level, 565
- Age of obese women  
 with PCOS, 169  
 race and, S<sub>1</sub> and serum TGs and, 196  
*see also* Age of obese subjects
- Age of PCOS women  
 metformin-induced resumption of normal menses and, 512  
 obese, 169
- Age of pregnant subjects  
 NTDs and, 272  
 preeclamptic, insulin resistance and, 893  
 and tyrosine and Phe metabolism in late pregnancy, 850
- Age of smokers  
 BW, plasma leptin and, 805  
 and chronic smoking effects on BF and glucose uptake by SM, 240
- Aging  
 blunting of GH secretion in exercising men related to, SRIH tone and, 665-670  
 changes in tissue-specific glucose metabolism due to, 1445-1449  
*see also* Aging-related changes in sex hormones
- Aging-related changes in sex hormones  
 in corticosterone secretion in female subjects, 535-541  
 effects of, on sex difference in serum leptin, 378-384
- AIDS (acquired immunodeficiency syndrome), plasma PAF-AH in, 1524-1531
- Ala, *see* Alanine
- Alanine (Ala)  
 blood, CGRP effects on, 605  
 effects of, on plasma and urinary concentrations of uric acid and uridine, 1024  
 effects of acute epinephrine discontinuation on hepatic uptake of, 913  
 enteral, splanchnic utilization of, 915-921  
 plasma, *see* Plasma alanine  
 RBC, circadian variations in, in men on diet with or without added MSG, 1455-1460  
 [2-<sup>13</sup>C]Alanine (Ala), [2-<sup>13</sup>C]-SAD effects on hepatocyte output of, 103  
 [3-<sup>13</sup>C]Alanine (Ala), [3-<sup>13</sup>C]-SAD effects on hepatocyte output of, 103  
 L-Alanine (Ala), and leucine kinetics, 1379

- Alanine transaminase (ALT), levels of, and F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases, 521
- Albumin  
F and xylitol effects on, 521  
serum, *see* Serum albumin  
in uremic subjects on CAPD, long-term effects of rhEPO on, 211  
*see also* Albuminuria in IDDM; Macroalbuminuria; Microalbuminuria; Proteinuria
- Albuminuria in IDDM, 1099  
cardiac sympathetic dysinnervation and, 93  
microalbuminuria in childhood-onset IDDM with CAD, 532  
and urinary excretion of apo A fragments, 370
- Alcohol intake  
chronic, effects of, on hepatic  $\beta$ -galactoside 2,6-ST mRNA, 797-803  
gout and, 132  
in IDDM, and urinary excretion of apo A fragments, 370  
in NIDDM, *see* Alcohol intake in NIDDM  
by postmenopausal women, VAT and, 1147  
and racial differences in PP TGs, postheparin lipase, and hepatic TG lipase, 750
- Alcohol intake in NIDDM  
effects of, on postexercise metabolic responses, 597-602  
effects of red wine, tannic acid, and ethanol on starch digestibility and glucose tolerance, 1179-1183
- Alcoholic liver disease, vitamin E in, 87
- Aldose reductase inhibitor (ARI), protective effects of, against diabetic bone loss in galactose-fed subjects, polyol pathway involvement in bone metabolism and, 904-909
- Aldosterone  
Na/K-ATPase inhibition effects on production of, 1167-1171  
plasma, F effects, 523  
RAA system in PH before and after surgery, 298-300  
testosterone inhibiting production of, 1108-1114
- Alfalfa meal in cereal-based diet with C, 401
- Alpha ( $\alpha$ )<sub>2D</sub>-adrenergic receptors (ARs), and effects of amitraz and BTS 27271 on insulin and glucagon secretion, 1461-1469
- Alpha ( $\alpha$ )-carotene, serum, effects of campestanol/sitostanol mixture with variable fat intake on level of, 578
- Alpha ( $\alpha$ )-L-fucosidase, activity of RBC membrane, in NIDDM, 817-821
- Alpha ( $\alpha$ )-D-galactosidase, activity of RBC membrane, in NIDDM, 817-821
- Alpha ( $\alpha$ )-D-glucosidase ( $\alpha$ -D-GLC-ase), activity of RBC membrane, in NIDDM, 817-821
- Alpha ( $\alpha$ )-glucosidase inhibitor, metabolic abnormalities in obese DM subjects prevented and reversed with, 347-354
- 7Alpha ( $\alpha$ )-hydroxylase, hepatic cholesterol, regulation of hepatic sterol 27-hydroxylase and, compared, 1542-1548
- Alpha-ketoisocaproate, *see*  $\alpha$ -Ketoisocaproate
- Alpha-lipoprotein, *see* High-density lipoprotein(s)
- Alpha ( $\alpha$ )-D-mannosidase, activity of RBC membrane, in NIDDM, 817-821
- Alpha ( $\alpha$ )-2,6-sialyltransferase (2,6-ST) mRNA (messenger ribonucleic acid), hepatic, effects of chronic alcohol intake on, 797-803
- Alpha-tocopherol, *see* Vitamin E
- ALT (alanine transaminase), and F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases, 521
- ALVA-101 prostate cancer cells, regulation of, by TGF- $\beta$ 1, TGF- $\beta$ 2, and their type II receptor, 1075-1081
- Amenorrheic women with PCOS, metformin-induced resumption of normal menses in, 511-519
- AMGN (aminoguanidine), effects of, on lipid peroxidation in STZ-DM, 1141-1145
- Amine oxidase, activity of serum semicarbazide-sensitivity, correlated with BMI and serum TGs in NIDDM, 113-117
- Amino acids (AAs)  
differences in protein synthesis following unbalanced infusion of, 1564-1569  
effects of, on plasma and urinary concentrations of uric acid and uridine, 1023-1027  
effects of glucose and, on exercise-induced gut and SM proteolysis, 161-166  
urinary, isotopic enrichment of, following infusions of L-[1-<sup>13</sup>C]Phe and L-[1-<sup>13</sup>C]lysine, 732-737  
*see also specific amino acids*
- Aminoguanidine (AMGN), effects of, on lipid peroxidation in STZ-DM, 1141-1145
- Amitraz (*N*'-[2,4-dimethyl]-*N*-(2,4-dimethylphenyl)imino)-*N*-methylmethanimidamide), effects of BTS 27271 and, on insulin and glucagon secretion,  $\alpha$ <sub>2D</sub>-ARs and, 1461-1469
- Ammonia (NH<sub>3</sub>), plasma levels of, and altered purine and glycogen metabolism in SM during exercise by heart failure subjects, 484-488
- Amylin (islet amyloid polypeptide; IAPP)  
amyloid deposition in islets of transgenic mice expressing human, and in human islets transplanted in nude mice, compared, 448-454  
pramlintide as analog of, effects of, on glycemic control of, and PP glucagon concentrations in IDDM, 935-941
- Amyloids, deposition of, in islets of human IAPP transgenic mice and in human islets transplanted in nude mice, compared, 448-454
- Androgens  
hCG effects on secretion of, in Leydig tumor cells, 694-695, 697  
*see also specific androgens*
- Androstane-3 $\alpha$ , effects of long-term exercise-induced weight loss in young identical male twins on, 1120-1127
- Androstenedione (A;  $\Delta$ <sub>4</sub>-DIONE) in PCOS  
insulin and obesity effects on, 169  
metformin-induced resumption of normal menses and, 512, 516  
and PAI as risk factor for miscarriage, 1590
- Androsterone glucuronide (ADT-G), effects of long-term exercise-induced weight loss in young identical male twins on, 1120-1127
- Anger, hostility, and VAT in postmenopausal women, 1146-1151
- Angioarchitecture, capillary, of islets of Langerhans, NIDDM and changes in, coinciding with impaired beta cell function but not insulin resistance in lean and obese subjects, 477-483
- Angiopathy, NIDDM with, RBC susceptibility to oxidation in, 1481-1484
- Angiotensin I, F effects on, 523
- Angiotensin II, F effects on, 523
- Angiotensin-converting enzyme (ACE) inhibitor(s)  
in essential HTN, *see* Angiotensin-converting enzyme inhibitor(s) in essential HTN  
imidapril as, improves S<sub>i</sub> by enhancing signal transduction via IRS proteins and improving vascular resistance, 1248-1255
- Angiotensin-converting enzyme (ACE) inhibitor(s) in essential HTN  
with insulin resistance in adipocytes, enalapril and losartan effects on, 1041-1046  
long-term lisinopril therapy of HTN, plasma NO and related vasoactive factors following, 1256-1259
- ANPs (atrial natriuretic peptides), and early renal failure in STZ-DM, 771-778
- Antibodies  
monoclonal, effects of immunoblockade of GLP-1 by, on insulin response to intragastric glucose in conscious subjects, 41-46  
to TGF- $\beta$ 1, TGF- $\beta$ 2, and their type II receptors, effects of, on ALVA-101 human prostate cancer cells, 1077

- Anticonvulsant therapy of epilepsy, hyperhomocysteinemia, MTHFR genotype and, 1047-1051
- Antihyperlipidemic agents, *see specific antihyperlipidemic agents*
- Antimitogenic heparan sulfate (HS) arising from mesangial cell-surface proteoglycans, 1220-1229
- Antioxidant(s), MNCV and levels of, in STZ-DM, 442-447
- Antioxidant capacity, total depletion of, in NIDDM, 1414-1417
- Antiretroviral therapy of AIDS, effects of, on plasma PAF-AH activity, 1528
- Aortic membranes in hyperinsulinemia, 469
- Aortic wall, stiffness of, in HCL children, 55-59
- Aortopulmonary shunts, arterial glucose concentrations with, in CHD, 1082-1088
- Apheresis, LDL, LDL oxidizability before and after, 881-886
- Apo(s), *see specific apolipoproteins*
- Apolipoprotein(s) (apo)  
   serum, *see* Serum apolipoprotein(s)  
   soy protein/soluble fiber diet effects on, 811-812  
   *see also specific apolipoproteins*
- Apolipoprotein A (apo A)  
   ACTH effects on, 344  
   in IDDM, urinary excretion of fragments of, 369-372
- Apolipoprotein A (apo A) phenotype, relationship between troglitazone-induced Lp(a) increase and, in HTN, 1-2
- Apolipoprotein A-I (apo A-I)  
   containing HDL particles, effects of triphasic OCs with desogestrel or LN on, 658-664  
   and decrease in SM capillary density in men, 1268  
   exercise and, *see* Apolipoprotein A-I in exercising men  
   in FCHL, gemfibrozil and lovastatin effects on, 48, 49, 51  
   in gout, 132  
   in hyperinsulinemia, 110  
   in MHL, 62, 63  
   and MI, *see* Apolipoprotein A-I, MI and  
   in normolipidemia with peripheral vascular resistance, 1363  
   TFAs and, in young women, 873  
   *see also* Apolipoprotein A-I, effects of C-lowering diets on
- Apolipoprotein A-I (apo A-I), effects of C-lowering diets on  
   of NCEP diet, 824  
   serum, soy protein/soluble fiber diet effects on, 812
- Apolipoprotein A-I (apo A-I), MI and  
   in nondiabetic subjects, 1199  
   in young adults, 1158, 1159
- Apolipoprotein A-I (apo A-I) in exercising men  
   diet and exercise effects on, in obese NIDDM men, 643  
   weight-reduced men, 19
- Apolipoprotein A-II (apo A-II)  
   effects of triphasic OCs with desogestrel or LN on, 660, 661  
   FC deposition in cornea of human apo A-II transgenic mice with functional LCAT deficiency, 415-421  
   in MHL, 62  
   *see also* Apolipoprotein A-II, diet effects on
- Apolipoprotein A-II (apo A-II), diet effects on  
   diet and exercise effects on, in obese NIDDM men, 643  
   of NCEP C-lowering diet, 824
- Apolipoprotein B (apo B)  
   effects of triphasic OCs with desogestrel or LN on, 660  
   exercise effects on, in weight-reduced men, 19  
   in FCHL, gemfibrozil and lovastatin effects on, 48, 49, 51  
   in gout, 132  
   in hyperinsulinemia, 110  
   in MHL, 62  
   in normolipidemia with peripheral vascular resistance, 1363  
   serum, *see* Serum apolipoprotein B  
   TFAs and, in young women, 873
- Apolipoprotein B (apo B) (*Continued*)  
   and VAT and LDL particle size, 1324, 1325  
   in young adults with MI, 1158, 1159  
   *see also* Apolipoprotein B, effects of C-lowering diets on
- Apolipoprotein B (apo B), effects of C-lowering diets on  
   of NCEP diet, 824  
   serum, of soy protein/soluble fiber diet, 812
- Apolipoprotein B-48 (apo B-48) in HTG and NTG, CAD and, 303-304
- Apolipoprotein B-100 (apo B-100)  
   in AIDS, plasma PAF-AH and, 1527  
   in HTG and NTG, CAD and, 303-304  
   VLDL, kinetics of, in adult hypopituitarism, 1057-1062
- Apolipoprotein C-III (apo C-III) in MHL, 63
- Apolipoprotein E (apo E)  
   effects of desialylation of, on its binding to HDL and its ability to deliver esterified C to liver, 1184-1192  
   in MHL, 62, 63  
   *see also* Apolipoprotein E genotype
- Apolipoprotein E (apo E) genotype  
   and changes in TC and LDL-C in adolescent girls, 285-290  
   in HTG and NTG, CAD and, 303  
   inducing plasma HDL-C and HDL<sub>2</sub>-C increases in obese exercising men, 943-945
- Apoptosis (programmed cell death) of beta cells, TNF- $\alpha$  in, 1485-1492
- $\alpha$  (alpha)<sub>2D</sub>-AR(s) (adrenergic receptors), and effects of amitraz and BTS 27271 on insulin and glucagon secretion, 1461-1469
- $\beta$  (beta)<sub>3</sub>-AR gene, *see entries beginning with terms:* Trp64Arg variant of  $\beta_3$ -AR gene
- Arachidonic acid, TFAs and, 873
- Arginine (Arg)  
   effects of, on plasma and urinary concentrations of uric acid and uridine, 1024  
   *see also* D-NAME; L-NAME and *entries beginning with terms:* Trp64Arg variant of  $\beta_3$ -AR gene
- L-Arginine  
   effects of reduced NO production due to deficiency of, intravascular coagulation in LPI, 1136-1140  
   and leucine kinetics, 1379
- ARI (aldose reductase inhibitor), protective effects of, against diabetic bone loss in galactose-fed subjects, polyol pathway involvement in bone metabolism and, 904-909
- Arterial blood gas, hypoxemia effects on, 741
- Arterial contractions, elevated glucose effects on PKC-induced intracellular Ca release and, 1015-1022
- Arterial glucose, concentrations of, with aortopulmonary shunts, after fast, 1082-1088
- Arterial pressure, *see* Blood pressure
- Arthritis, rheumatoid, disease activity and serum leptin in, 745-748
- Ascites, effects of paracentesis of, on DEXA measurements of BMD or BMC, 373-377
- Ascorbic acid (vitamin C) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Asp<sup>B10</sup> insulin, differences between cellular processing of Lys<sup>B28</sup>Pro<sup>B29</sup>, native insulin and, 611-617
- Aspartate transaminase (AST), and F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases, 521
- Aspartic acid (Asp), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- L-Aspartic acid (Asp), and leucine kinetics, 1379
- AST (aspartate transaminase), and F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases, 521
- AT, *see* Adipose tissue

- Atherosclerotic cardiovascular (CV) disease, fasting hyperinsulinemia and prediction of, in hyperlipidemia, 1437-1444
- Athletes, *see* Exercise
- AT-LPL, *see* Adipose tissue lipoprotein lipase activity
- ATP (adenosine triphosphate) in NIDDM  
with CAD, K channels sensitive to, in insulin-mediated glucose transport, 432-436  
liver mitochondria, 1118
- ATPase (adenosine triphosphatase) *see* Na/K-ATPase
- Atrial natriuretic peptides (ANPs), and early renal failure in STZ-DM, 771-778
- Autonomic neuropathy, diabetic, 92-101
- Bacteria, colonic, serum lipids and, as risk factors for CV disease, 264-268
- Basal metabolic rate (BMR) in IBD, 953, 954
- Basic fibroblast growth factor (bFGF) mRNA (messenger ribonucleic acid), regulation of, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178
- BAT (brown adipose tissue), effects of high-sucrose diet with EPA-E ester and/or lard on, 1093-1094
- Bay m1099 (miglitol), effects of, on glucose tolerance and insulin resistance in obesity, 701-706
- BBMs (brush border membranes), small intestine, L-leucine transport in, 1432-1436
- BC (bromocriptine)/SKF38393, effects of, on dyslipidemia in obesity, 1033-1040
- Benzo(a)pyrene catalyzed by 3-MC-induced cytochrome P-450 1A1, retinoids inhibiting metabolism of, 689-692
- Beta<sub>3</sub>-adrenergic receptor, *see entries beginning with terms:* Trp64Arg variant of  $\beta_3$ -AR gene
- Beta-carotene, *see*  $\beta$ -Carotene
- Beta ( $\beta$ ) cells  
function of, during IM-IVGTT, C-peptide minimal model in assessment of, 1162-1166  
in NIDDM, *see* Beta cells in NIDDM  
in STZ-DM, lithium effects on, 558-563  
TNF- $\alpha$  role in apoptosis of, 1485-1492  
*see also* Islets of Langerhans
- Beta ( $\beta$ ) cells in NIDDM  
in lean subjects, changes in capillary angioarchitecture of islets of Langerhans coinciding with impaired function of, but not insulin resistance, 477-483  
with obesity, *see* Insulin resistance in NIDDM with obesity, beta cell function and
- Beta ( $\beta$ )-D-galactosidase, activity of RBC membrane, in NIDDM, 817-821
- Beta ( $\beta$ )-galactoside  $\alpha$ (alpha)2,6-sialyltransferase (2,6-ST) mRNA (messenger ribonucleic acid), hepatic, effects of chronic alcohol intake on, 797-803
- Beta ( $\beta$ )-D-Glc-ase ( $\beta$ -D-glucosidase), activity of RBC membrane, in NIDDM, 817-821
- Beta ( $\beta$ )-D-GlcA-ase ( $\beta$ -D-glucuronidase), activity of RBC membrane, in NIDDM, 817-821
- Beta ( $\beta$ )-GlcNAx-ase (N-acetyl- $\beta$ -L-glucuronidase), activity of RBC membrane, in NIDDM, 817-821
- Beta ( $\beta$ )-D-glucosidase ( $\beta$ -D-Glc-ase), activity of RBC membrane, in NIDDM, 817-821
- Beta ( $\beta$ )-D-glucuronidase ( $\beta$ -GlcA-ase), activity of RBC membrane, in NIDDM, 817-821
- Beta-hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone sulfate in PCOS
- Beta-hydroxybutyrate, *see*  $\beta$ -Hydroxybutyrate
- 11Beta ( $\beta$ )-hydroxylase, aging and activity of, 535-541
- 21Beta ( $\beta$ )-hydroxylase, aging and activity of, 535-541
- Beta-hydroxysteroid dehydrogenase, *see* 3 $\beta$ -Hydroxysteroid dehydrogenase; 11 $\beta$ -Hydroxysteroid dehydrogenase
- Beta-lipoprotein, *see* Low-density lipoprotein(s)
- Beta ( $\beta$ )<sub>2</sub>-microglobulin in AIDS, PAF-AH and, 1527
- BF, *see* Blood flow
- bFGF (basic fibroblast growth factor) mRNA (messenger ribonucleic acid), regulation of, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178
- Bicarbonate (HCO<sub>3</sub>), aortopulmonary shunts and, 1084
- Bile acid(s)  
effects of, on hepatic sterol 27-hydroxylase and hepatic cholesterol 7 $\alpha$ -hydroxylase regulation, 1542-1548  
enhanced secretion of, following PV blockade of hepatic HMG-CoA reductase, 618-626  
*see also* Bile acid(s), diet effects on
- Bile acid(s), diet effects on  
cereal-based diet with C effects on fecal excretion of, 400-405  
effects of soy protein/soluble fiber diet on output of, 812, 813
- Biliary cholesterol (C)  
effects of PV blockade of hepatic HMG-CoA reductase on, 618-626  
*see also* Biliary cholesterol, diet effects on
- Biliary cholesterol (C), diet effects on  
of cereal-based diet with C, 400-405  
of soy protein with very low dietary C diet, 489-494
- Biliary lipids  
soy protein and very low dietary C effects on, 489-494  
*see also* Biliary cholesterol; Biliary phospholipids
- Biliary phospholipids (PLs), PV effects on, 618-626
- Bilirubin, serum vitamin E and, in cirrhosis, 89
- Binding protein, *see: FABP2 gene and entries beginning with terms:* Insulin-like growth factor-binding protein
- Bioenergetics, altered liver mitochondria, in NIDDM, 1115-1119
- Biotin in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Biphasic effects of insulin on hCG to induce ovarian cysts, 995-1002
- Black Americans, *see* Race and ethnicity
- Blood, ex vivo, leukocyte lactate output and glycolysis in sepsis and, 779-785
- Blood alanine (Ala), CGRP effects on, in conscious subjects, 605
- Blood flow (BF)  
aortopulmonary shunts and, 1084  
chronic smoking effects on S<sub>i</sub>, SM glucose uptake and, 239-244  
effects of local sympathetic blockade on, during hypoglycemia, 1575-1583  
hepatic, *see* Hepatic blood flow  
to muscle, imidapril effects on, 1249
- Blood gas  
arterial, hypoxemia effects on, 741  
*see also specific blood gases*
- Blood glucose  
in nutritionally induced NIDDM, 1550, 1551  
pramlintide effects on, in IDDM, 937  
in pregnancy, insulin resistance and, 1340  
renal glucose oxidation and, 709, 710  
*see also* Fasting blood glucose
- Blood glutathione (GSH), lithium effects on, in STZ-DM, 561
- Blood glutathione peroxidase (GSH-Px), lithium effects on, in STZ-DM, 561
- Blood glycerol, CGRP effects on, in conscious subjects, 605, 607
- Blood  $\beta$ -hydroxybutyrate ( $\beta$ -OHB), CGRP effects on, in conscious subjects, 607
- Blood lactate  
CGRP effects on, in conscious subjects, 605  
renal glucose oxidation and, 709, 710  
*see also* Blood lactate, exercise and

- Blood lactate, exercise and  
 acipimox and exercise effects on blood lactate, 247  
 levels of, in exercising heart failure subjects, 484-488
- Blood lactic acid, glucose effects on, 339-341
- Blood lipid(s), fasting, effects of soy protein/soluble fiber diet on, 811-812
- Blood lipid peroxide (LPO) in STZ-DM, lithium effects on, 561
- Blood pressure (BP)  
 aortopulmonary shunts and, 1084  
 CGRP effects on, in conscious subjects, 607  
 chronic smoking effects on, 240  
 effects of gut and hepatic clearance of E and NE on, 261  
 effects of local sympathetic blockade on, 1573  
 and ERT effects on vascular reactivity, 228  
 and exercise, *see* Blood pressure, and exercise  
 in hyperinsulinemia, 108, 110  
 in IDDM, diabetic autonomic neuropathy and, 97  
 imidapril effects on, 1249, 1250  
 and insulin-induced internal carotid artery vasodilation, 1472  
 of lean subjects, HR variability and, 756  
 low serum insulin and, ethnicity and, 1217  
 of malnourished older cancer subjects, 292, 295  
 in NIDDM, *see* Blood pressure in NIDDM  
 of nondiabetic offspring of NIDDM subjects, 979  
 of nondiabetic subjects with MI, 1199  
 of obese subjects, *see* Blood pressure of obese subjects  
 in PCOS, metformin-induced resumption of normal menses and, 512, 514, 516  
 in PH, 299  
 of pregnant subjects with preeclampsia, insulin resistance and, 893  
 soy protein/soluble fiber diet effects on, 813  
 in STZ-DM, C-AD effects on, 831  
 Trp64Arg variant of  $\beta_3$ -AR gene, *see* Blood pressure, Trp64 variant of  $\beta_3$ -AR gene and  
*see also* Hypertension
- Blood pressure (BP), and exercise  
 exercise effects on, 985  
 in subjects with heart failure, 485
- Blood pressure (BP), Trp64 variant of  $\beta_3$ -AR gene and  
 in CHD, 653, 854, 855  
 in insulin resistance, 893, 1368  
 in obese Japanese men, *UCP1* gene mutation and, 637, 638
- Blood pressure (BP) in NIDDM  
 and acute effects of adrenergic-mediated ischemia on MNCV, 496  
 with insulin resistance, *FABP2* gene polymorphism and, 656  
 NE-mediated vasoconstriction and, 1538  
 tHcy, nephropathy and, 1097
- Blood pressure (BP) of obese subjects  
 HR variability and, 756  
 of obese Japanese men with Trp64Arg variant of  $\beta_3$ -AR gene and *UCP1* gene mutation, 637, 638
- Blood superoxide dismutase (SOD) in STZ-DM, lithium effects on, 561
- Blood urea nitrogen, *see* BUN
- Blood vessels  
 in DM, 406-409  
*see also* entries beginning with terms: Arterial, Capillary, Intravascular, Vascular and element: Vaso-
- Blood volume in STZ-DM, 774
- BM 17.0744 [2,2-dichloro-12-(*p*-chlorophenyl)-dodecanoic acid], as insulin sensitizer and antihyperlipidemic agent, 34-40
- BMC (bone mineral content), effects of paracentesis of ascites on DEXA of, 373-377
- BMD (bone mineral density), effects of paracentesis of ascites on DEXA of, 373-377
- BMI, *see* Body mass and body mass index
- BMR (basal metabolic rate) in IBD, 953, 954
- Body composition  
 differential effects of exercise and, on Lp-lipid profile in older men and women, 1474-1480  
 effects of long-term exercise by young identical male twins on, 1121;  
*see also* Body composition in older exercising men and women  
 exercise and, *see* Body composition, exercise and  
 of GH-deficient adults, *see* Body composition of GH-deficient adults  
 with HF diet and, 1232  
*see also* Adipose tissue; Fat-free mass; Fat mass
- Body composition of GH-deficient adults  
 childhood-onset deficiency, 1005  
 GH therapy and withdrawal effects on, 1389, 1390
- Body composition in older exercising men and women  
 and chromium picolinate supplementation effects on glucose metabolism, 546-553  
 differential effects of body composition and exercise on Lp-lipid profile, 1474-1480
- Body fat, *see* Adipose tissue
- Body mass and body mass index (BMI)  
 of CHD subjects, 653, 854, 855  
 and decrease in SM capillary density in men, 1268  
 diet effects on, *see* Body mass and body mass index, diet effects on  
 and ERT effects on vascular reactivity, 228  
 of ESRD subjects, *see* Body mass and body mass index of ESRD subjects  
 and exercise, and combined hyperlipidemia associated with muscle protein release, 1520; *see also* Body mass and body mass index of exercising men; Body mass and body mass index of exercising women  
 of FCHL subjects, 47  
 of GH-deficient adults, *see* Body mass and body mass index of GH-deficient adults  
 of HCL subjects, *see* Body mass and body mass index of HCL subjects  
 of HTG and NTG subjects, 303-305  
 in HTN subjects, 888  
 of hyperinsulinemic subjects, *see* Body mass and body mass index of hyperinsulinemic subjects  
 of hyperinsulinic subjects, 108, 110  
 of hyperthyroidic subjects, and FFA decrease with acipimox, 1319  
 of hyperuricemic subjects, 132  
 of hypogonadal men, 591  
 of IBD subjects, 953, 954  
 of IDDM subjects, *see* Body mass and body mass index of IDDM subjects  
 of MHL subjects, 62  
 of multiple-trauma victims, 1398  
 of NIDDM-prone subjects, and peripheral tissue glucose uptake after OGTT, 81  
 of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects  
 of nondiabetic subjects, *see* Body mass and body mass index of nondiabetic subjects  
 of normolipidemic subjects with peripheral vascular disease, 1363  
 of obese subjects, *see* Body mass and body mass index of obese subjects  
 of older subjects, *see* Body mass and body mass index of older subjects  
 of PCOS subjects, *see* Body mass and body mass index of PCOS women  
 of pregnant subjects, *see* Body mass and body mass index of pregnant subjects  
 of premenopausal women, plasma leptin associated with plasma

- Body mass and body mass index (BMI) (*Continued*)  
 PAI-1 irrespective of FM, plasma insulin, metabolic parameters and, 960-964  
 of RA subjects, 748  
 race and, *see* Body mass and body mass index, race and ethnicity and  
 serum leptin and, *see* Body mass and body mass index, serum leptin and  
 of smokers, *see* Body mass and body mass index of smokers  
 T<sub>3</sub> effects on, 1605  
 Trp64Arg variant of  $\beta_3$ -AR gene and, *see* Body mass and body mass index, Trp64Arg variant of  $\beta_3$ -AR gene and  
 VAT and LDL particle size and, 1323
- Body mass and body mass index (BMI), C-lowering diet effects on  
 of soy protein and low dietary C diet, 490  
 of unsaturated fat diet, 201
- Body mass and body mass index (BMI), diet effects on  
 effects of campestanol/sitostanol mixture with variable fat intake on, 576  
 of malnourished older cancer subjects, 292, 294  
 of obese NIDDM subjects, diet and exercise effects on, 642  
*see also* Body mass and body mass index, C-lowering diet effects on
- Body mass and body mass index (BMI), race and ethnicity and  
 low serum insulin and, 1217  
 PP TGs, postheparin lipase, hepatic TG lipase and, 750
- Body mass and body mass index (BMI), serum leptin and  
 aging-related changes in sex hormones and serum leptin, 380, 382  
 and relationship between serum leptin, IGF-I, IGFBP-1, and IGFBP-3, 841  
 and twenty-four hour variation in serum leptin, 1012, 1013
- Body mass and body mass index (BMI), Trp64Arg variant of  $\beta_3$ -AR gene and  
 insulin resistance and, 1368, 1369  
 relationship of Trp64Arg variant of  $\beta_3$ -AR gene to total body fat but not to percent body fat and insulin level, 565
- Body mass and body mass index (BMI) of ESRD subjects  
 on CAPD, long-term rhEPO effects on, 211  
 on HD, vitamin B<sub>12</sub> effects and, 632
- Body mass and body mass index (BMI) of exercising men  
 diet and exercise effects on BMI of obese NIDDM men, 642  
 and long-term weight maintenance in weight-reduced men, 17  
 middle-aged men, AT-LPL activity and, 185  
 young identical male twins, effects of long-term exercise on, 1121  
*see also* Body mass and body mass index of older exercising men and women
- Body mass and body mass index (BMI) of exercising women  
 Mexican American and non-Hispanic, PP insulin responses and, 972  
*see also* Body mass and body mass index of older exercising men and women
- Body mass and body mass index (BMI) of GH-deficient adults  
 of childhood-onset GH-deficient adults, 1005  
 VLDL apo B-100 kinetics and, 1058  
*see also* Body mass and body mass index of GH-deficient adults, GH therapy and
- Body mass and body mass index (BMI) of GH-deficient adults, GH therapy and  
 effects of GH therapy on, 309, 1390, 1393  
 effects of GH therapy withdrawal on, 1390, 1393  
 and predictors of GHBP response to GH therapy, 314-318
- Body mass and body mass index (BMI) of HCL subjects  
 HCL children, stiffness of aortic wall and, 57  
 simvastatin effects and, 69
- Body mass and body mass index (BMI) of hyperinsulinemic subjects  
 and prediction of HTN, NIDDM, and CHD, 990, 992, 993  
 and temporal association of obesity with hyperinsulinemia, 930, 932
- Body mass and body mass index (BMI) of IDDM subjects  
 childhood-onset IDDM subjects with CAD, 532, 533  
 and urinary excretion of apo A fragments, 370
- Body mass and body mass index (BMI) of NIDDM subjects  
 and activity of RBC membrane glycohydrolases, 818  
 and acute effects of adrenergic-mediated ischemia on MNCV, 496  
 ADA and, 949-951  
 with angiopathy, 1482  
 with CAD, 433  
 and effects of fish and exercise on urinary excretion of F<sub>2</sub>-isoprostane, 1404  
 and glitazide versus metformin effects on lipid peroxidation, 898  
 LDL composition and metabolism and, 119, 121  
 NE-mediated vasoconstriction and, 1538  
 obese, diet and exercise effects on, 642  
*rad* gene polymorphism and, 174  
 serum SSAO activity correlated with, 113-117  
 and total depletion of antioxidant capacity, 1415  
 and troglitazone effects on AT distribution, 1103
- Body mass and body mass index (BMI) of nondiabetic subjects  
 with MI, 1199  
 of nondiabetic offspring of NIDDM subjects, 979, 981
- Body mass and body mass index (BMI) of obese subjects  
 and association of serum leptin and serum uric acid concentrations in obesity, 678-680  
 circulating TNF- $\alpha$  and, 1333  
 hyperinsulinemic, 930, 932  
 with insulin resistance, *FABP2* gene polymorphism and, 656  
 and lean subjects, HR variability and, 756  
 and long-term weight maintenance by weight-reduced men, 17  
 with NIDDM, effects of diet and exercise on, 642  
 of obese Japanese men with Trp64Arg variant of  $\beta_3$ -AR gene and *UCPI* gene mutation, 637, 638  
 with VAT, risk for CHD and, 357
- Body mass and body mass index (BMI) of older subjects  
 of malnourished cancer subjects, diet effects on, 292, 294  
 relationship between GH secretion, AT, and serum lipids in, 1426, 1428  
*see also* Body mass and body mass index of older exercising men and women
- Body mass and body mass index (BMI) of older exercising men and women  
 AT-LPL activity and, 185  
 chromium picolinate supplementation effects on, 549  
 differential effects of exercise and body composition on, 1476  
 and exercise effects on HDL-C, 985
- Body mass and body mass index (BMI) of PCOS women  
 and impact of insulin and PCOS on metabolic and endocrine variables, 167-172  
 metformin-induced resumption of normal menses and, 512, 514, 516  
 and PAI as risk factor for miscarriage, 1590
- Body mass and body mass index (BMI) of pregnant subjects  
 and history of pregnancy complicated by NTDs, 272  
 insulin resistance and preeclamptic pregnancy, 893  
 tyrosine and Phe metabolism in late pregnancy and, 850
- Body mass and body mass index (BMI) of smokers  
 chronic smoking effects on BMI, 240  
 plasma leptin and, 805, 806
- Body weight (BW)  
 acarbose effects on, 348-349, 351  
 aging-related changes in sex hormones and, 380  
 chronic leptin administration effects on, 672  
 of cirrhotic subjects, *see* Body weight of cirrhotic subjects  
 diet effects on, *see* Body weight, diet effects on  
 and dose-response relationships of insulin to glucose fluxes, 966



- Body weight (BW) (*Continued*)
- in dyslipidemia, BC/SKF38393 effects on, 1035
  - effects of respiratory infection on, 1609
  - effects of smoking and its cessation on plasma leptin levels and, 804-808
  - exercise and, *see* Body weight, exercise effects on
  - FM and toxin-induced infections and, 947
  - galactose effects on, 905
  - GH secretion and, *see* Body weight, GH secretion and
  - of HCL subjects, simvastatin effects and, 69
  - HPA axis and SNS activities and, 396
  - in HTN subjects, insulin secretion and, 4
  - of hyperinsulinemic subjects, 333
  - of hyperinsulinic subjects, sex hormones and, 108, 110
  - of IBD subjects, 953, 954
  - imidapril effects on, 1249, 1250
  - and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 781
  - and long-term valproic acid effects on carnitine reabsorption, 75
  - of multiple-trauma victims, 1398
  - of NIDDM-prone subjects, and peripheral tissue glucose uptake after OGTT, 81
  - of NIDDM subjects, *see* Body weight of NIDDM subjects
  - of nondiabetic offspring of NIDDM subjects, 979
  - of PCOS women, metformin-induced resumption of normal menses and, 512, 514, 516
  - of postmenopausal women, anger, hostility and, 1147
  - of pregnant subjects, insulin resistance and, 1340
  - PV effects on, 619
  - of RA subjects, 748
  - and racial differences in PP TGs, postheparin lipase, and hepatic TG lipase, 750
  - relationship of Trp64Arg variant of  $\beta_3$ -AR gene to, 565
  - and serum 25OHD levels, 1029
  - and splanchnic utilization of enteral alanine, 916
  - of STZ-DM subjects, *see* Body weight of STZ-DM subjects
  - of transsexuals, cross-sex hormone therapy effects on, 1373
  - and troglitazone effects on AT distribution, 1103
  - and tyrosine and Phe metabolism in late pregnancy, 850
  - of uremic subjects on CAPD, long-term effects of rhEPO on, 211
  - see also* Lean subjects; Obesity
- Body weight (BW), diet effects on
- of dietary FAs in STZ-DM subjects, 456
  - effects of campestanol/sitostanol mixture with variable fat intake on, 576
  - of HF diet, 1232
  - of soy protein and very low C diet, 490
  - see also* Body weight, diet and exercise and
- Body weight (BW), diet and exercise and
- diet composition and timing of exercise effects on BW, 1597
  - in NIDDM men, 641-644
- Body weight (BW), exercise and
- insulin and exercise activation of PDH complex and, 866, 867
  - see also* Body weight, diet and exercise and; Body weight of exercising men; Body weight of exercising women
- Body weight (BW), GH secretion and
- aging-related blunting of GH secretion during exercise, SRIH tone and, 666; *see also* Body weight of GH-deficient adults
  - of older men and women, relationship between AT, serum lipids, and GH secretion, 1426
- Body weight (BW) of cirrhotic subjects
- hepatic glucose metabolism and, 1261
  - paracentesis of ascites and, 374-376
- Body weight (BW) of exercising men
- and aging-related blunting of GH secretion during exercise, SRIH tone and, 666
  - and effects of apo E genotype and exercise on plasma HDL-C and HDL<sub>2</sub>-C in obese men, 944
  - and metabolic adaptation to HF diet, 1510
  - middle-aged men, AT-LPL activity and, 185
  - see also* Body weight of older exercising men and women; Weight loss by exercising men
- Body weight (BW) of exercising women
- Mexican American and non-Hispanic, PP insulin responses and, 972
  - see also* Body weight of older exercising men and women
- Body weight (BW) of GH-deficient adults
- effects of GH therapy on, 309, 315, 1390, 1393
  - effects of GH therapy withdrawal on, 1390, 1393
- Body weight (BW) of NIDDM subjects
- with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292
  - metformin versus gliclazide effects on, 899
  - with nutritionally induced NIDDM, 1550, 1551
  - and plasma glucose response to OGTT, 479
  - SSAO activity and, 114, 115
- Body weight (BW) of older exercising men and women
- AT-LPL activity and, 185
  - chromium picolinate supplementation effects on, 549
  - and exercise effects on HDL-C, 985
- Body weight (BW) of STZ-DM subjects
- diet and exercise effects on, 641-644
  - lithium effects on, 559
  - Mg and vanadate effects on, 726, 727
- Bone loss (osteopenia), diabetic, in galactose-fed subjects, protective effects of ARI against, 904-909
- Bone metabolism, polyol pathway involvement in, protective effects of ARI against diabetic bone loss in galactose-fed subjects and, 904-909
- Bone mineral content (BMC), effects of paracentesis of ascites on DEXA of, 373-377
- Bone mineral density (BMD), effects of paracentesis of ascites on DEXA of, 373-377
- BP, *see* Blood pressure
- Bradykinin, plasma, in essential HTN, effects on long-term lisinopril therapy on, 1257
- Brain glucose GLUT1 and GLUT3 mRNA (messenger ribonucleic acid), regulation of, by O<sub>2</sub> and glucose deprivation, 422-431
- Brewer's yeast in cereal-based diet with C, 401
- Bromocriptine (BC)/SKF38393, effects of, on dyslipidemia in obesity, 1033-1040
- Brown adipose tissue (BAT), effects of high-sucrose diet with EPA-E ester and/or lard on, 1093-1094
- Brush border membranes (BBMs), small intestine, L-leucine transport in, 1432-1436
- BTS 27271, effects of amitraz and, on insulin and glucagon secretion,  $\alpha_{2D}$ -ARs and, 1461-1469
- BUN (blood urea nitrogen)
- in essential HTN, effects of long-term lisinopril therapy on, 1257
  - levels of, and F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases, 521
  - in STZ-DM, 773-774
- Butyrate, effects of soy protein/soluble fiber diet on, 813
- BW, *see* Body weight
- C, *see* Cholesterol
- C cells, thyroid, HPRL effects on CT release by, 223
- C677T genotype of MTHFR in ESRD, vitamin B<sub>12</sub> supplementation effects in relation to, 631-635

- Ca and  $\text{Ca}^{2+}$  (calcium)  
 $\text{Ca}^{2+}$  signaling in liver, effects of disruption of filamentous actin on, 1241-1247  
intracellular, *see* Intracellular Ca  
in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
plasma, in PH, 299  
serum, galactose effects on, 906  
troglitazone effects on, 125-130  
urinary excretion of, *see* Urinary excretion of Ca
- CAD, *see* Coronary artery disease
- C-AD (2-chloroadenosine), hyperglycemia-induced inhibition of phosphoinositide synthesis in RPE cells reversed by, and MNCV reduction in STZ-DM prevented by, 827-833
- Caffeine, ET production by ECs following exposure to nicotine or, 845-848
- Calciferol (vitamin D), serum, effects of campestanol/sitostanol mixture with variable fat intake on, 578
- Calcitonin (CT)  
HPRL effects on secretion of, 221-226  
*see also* Calcitonin gene-related peptide
- Calcitonin gene-related peptide (CGRP)  
in conscious subjects, effects of, independently of glucagon and insulin, 603-610  
orthotopic pancreas transplantation and, 645-650
- cAMP (cyclic adenosine monophosphate)  
accumulation of, in zona glomerulosa cells, testosterone effects on, 1108-1114  
corticosterone release and production of, in response to forskolin, 535-541  
hCG effects on secretion of, in Leydig tumor cells, 694-695, 697  
HPRL effects on accumulation of, 223  
plasma, AA effects on, 1024-1026  
in T regulation, evodiamine effects on, 1533
- Campestanol (24-methyl-5 $\alpha$ -cholestan-3 $\beta$ -ol), sitostanol and hypocholesterolemic properties of mixture of, with variable fat intake, 575-580  
sitostanol effects on campestanol absorption and distribution, 363-368
- Campesterol  
serum, effects of campestanol/sitostanol mixture on proportion of, to C, 577  
in soy protein/soluble fiber diet, 811
- Cancer  
metabolic effects of Intralipid and propranolol in malnourished older subjects with, 291-297  
recovery from TNF- $\alpha$ -induced euthyroid sick syndrome in, 324-329
- Cancer cells, ALVA-101 prostate, regulation of, by TGF- $\beta$ 1, TGF- $\beta$ 2, and their type II receptors, 1075-1081
- CAPD (continuous ambulatory peritoneal dialysis), long-term effects of rhEPO on GH release in uremic subjects on, 210-216
- Capillary angioarchitecture of islets of Langerhans, NIDDM and changes in, coinciding with impaired beta cell function but not insulin resistance in lean and obese subjects, 477-483
- Capillary density of SM in men, decrease in, related to high serum LDL-C and apo B, 1267-1271
- Carbenoxolone (CBX), effects of placental 11 $\beta$ -HSD inhibition with, on glucose metabolism and 11 $\beta$ -HSD regulation in adult offspring, 1584-1588
- Carbohydrates (CHOs)  
in C and HC diet, and  $\omega$ -3 PUFA effects on recovery of cardiac function after cold storage of heart, 1203  
in C-lowering diets, *see* Carbohydrates in C-lowering diets  
and FFA inhibition of glucose-stimulated insulin release in insulin resistance, 1315  
GH therapy effects on metabolism of, in TS girls, 7-14
- Carbohydrates (CHOs) (*Continued*)  
in HF diet, 1231, 1232  
in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
prior exercise reducing PP lipemia independently of CHO contribution to energy expenditure during exercise, 245-251  
whole-body lipolysis and utilization of, 475
- Carbohydrates (CHOs) in C-lowering diets  
in NCEP diet, 823  
in soy protein/soluble fiber diet, 810
- Carboxylase  
pyruvate, LA effects on, 508  
*see also* Phosphoenolpyruvate carboxylase
- Carcinoma, *see* Cancer
- Cardiac function, recovery of, after cold storage of heart,  $\omega$ -3 PUFA effects on, 1203-1209
- Cardiac sympathetic dysinnervation in IDDM, PET with [ $^{11}\text{C}$ ]-HED in assessment of, 92-101
- Cardiovascular (CV) disease  
atherosclerotic, fasting hyperinsulinemia and prediction of, in hyperlipidemia, 1437-1444  
*see also* Coronary artery disease; Coronary heart disease; Risk factors for CV disease
- Cardiovascular (CV) fitness, obesity, leptin and, as predictors of AT-LPL activity in sedentary and exercising middle-aged and older men, 183-189
- Cardiovascular system, *see* Heart entries beginning with terms: Arterial, Capillary, Intravascular, Vascular and elements: Card-, Vaso-
- Carnitine  
effects of long-term valproic acid therapy on reabsorption of, 74-79  
oxidation of palmitoyl, in liver and SM with HF diet, 1234  
total, LA effects on, 508  
*see also* Acylcarnitine; Free carnitine
- $\alpha$  (alpha)-Carotene, serum, effects of campestanol/sitostanol mixture with variable fat intake on level of, 578
- $\beta$  (beta)-Carotene  
effects of soy protein/soluble fiber diet on, 811, 812  
serum, *see* Serum  $\beta$ -carotene
- Carotid artery, internal, insulin-induced vasodilation of, 1470-1473
- Casein in high-sucrose diet with EPA-E ester and/or lard, 1090
- Catalase, plasma, in STZ-DM, 444, 445
- Catecholamines  
effects of local sympathetic blockade on, 1578-1579  
leptin suppression as response to hypersecretion of, in pheochromocytoma, 543-545  
*see also* Dopamine; Epinephrine; Norepinephrine
- CBX (carbenoxolone), effects of placental 11 $\beta$ -HSD inhibition with, on glucose metabolism and 11 $\beta$ -HSD regulation in adult offspring, 1584-1588
- CD (Crohn's disease), metabolic features of, 952-956
- CD4 cell count in AIDS, plasma PAF-AH and, 1527, 1528
- CD26 (dipeptidyl peptidase IV), long-lasting hypoglycemic effects of, in NIDDM, 252-258
- CD26 (dipeptidyl peptidase IV) inhibitor, effects of, on glucose tolerance, 385-389
- CD36 LIMP-II analogous-1 (CLA-1), as source of CE necessary to steroidogenesis in adrenocortical cells, 627-630
- CDCA (chenodeoxycholic acid), simvastatin with, for CTX, 233-238
- CE, *see* Cholesterol ester
- Cell death, programmed, in beta cells, TNF- $\alpha$  in, 1485-1492
- Cell proliferation  
ALVA-101 prostate cancer, TGF- $\beta$ 1 effects on, 1077  
lymphocyte, effects of LDL receptor mutations on LDL ability to support, 834-839
- Cellular processing of insulin analogs and native insulin, compared, 611-617

- Cellulose in high-sucrose diet with EPA-E ester and/or lard, 1090
- Cereal-based diet with C, effects of, on biliary C and fecal bile acid excretion, 400-405
- Cerebrotendinous xanthomatosis (CTX), simvastatin with CDCA for, 233-238
- Cessation of smoking, effects of, on BW and plasma leptin levels, 804-808
- CETPs, *see* Cholesteryl ester transfer proteins
- cGMP (cyclic guanosine monophosphate)  
in essential HTN, effects of long-term lisinopril therapy on, 1257  
hCG effects on secretion of, in Leydig tumor cells, 694-695
- CGRP, *see* Calcitonin gene-related peptide
- CHD, *see* Coronary heart disease
- Chemotactic activation of PMNs in NIDDM, filtration parameter and membrane fluidity and, 30-33
- Chenodeoxycholate, effects of soy protein/soluble fiber diet on, 813
- Chenodeoxycholic acid (CDCA), simvastatin with, for CTX, 233-238
- Childhood-onset growth hormone (GH) deficiency in adults, metabolic effects of individualized GH therapy of, 1003-1010
- Childhood-onset insulin-dependent diabetes mellitus (IDDM), LDL particle size and CAD in, 531-534
- Children  
adult, effects of placental 11 $\beta$ -HSD inhibition on glucose metabolism and 11 $\beta$ -HSD regulation in, 1584-1588  
HCL, stiffness of aortic wall in, 55-59  
nondiabetic, of NIDDM subjects, S<sub>i</sub>, glucose effectiveness, and insulin secretion in, 978-983  
on prednisone therapy, preservation of GH secretion in response to GHRP-2 in, 585-589  
temporal association between obesity and hyperinsulinemia in, 928-934  
*see also entries beginning with terms:* Childhood-onset
- D-Chiroinositol in NIDDM, differential effects of troglitazone and, on glucosamine-induced insulin resistance, 1418-1423
- Chloride, *see* Cl
- Chlorine in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- 2-Chloroadenosine (C-AD), hyperglycemia-induced inhibition of phosphoinositide synthesis in RPE cells reversed by, and reduction of MNCV in STZ-DM prevented by, 827-833
- CHO(s), *see* Carbohydrates
- Cholate, effects of soy protein/soluble fiber diet on, 813
- Cholesterol  
in CTX, 234, 236  
serum, *see* Serum cholesterol
- $\Delta^8$  (delta<sup>8</sup>)-Cholesterol, serum, effects of campestanol/sitostanol mixture on proportion of, to C, 577
- Cholesterol (C)  
in AIDS, 1526  
biliary, *see* Biliary cholesterol  
in CHD, Trp64Arg variant of  $\beta_3$ -AR gene, 653  
in Cr-deficient diet, 1064  
dietary, *see* Dietary cholesterol  
in dyslipidemia, BC/SKF38393 effects on, 1035  
effects of, on hepatic sterol 27-hydroxylase and hepatic cholesterol 7 $\alpha$ -hydroxylase regulation, 1542-1548  
free, *see* Free cholesterol  
in GH-deficient adults, effects GH therapy and its withdrawal on, 1390, 1393  
in gout, 132  
HDL glycation effects on C efflux capacity of HDLs, 139-143  
in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438  
in IDDM, *see* Cholesterol in IDDM  
LDL apheresis and concentrations of, 883  
in NIDDM, total depletion of antioxidant capacity and, 1415
- Cholesterol (C) (*Continued*)  
in older and middle-aged exercising men, AT-LPL activity and, 185  
in PCOS, metformin-induced resumption of normal menses and, 512, 516  
plasma, *see* Plasma cholesterol  
in premenopausal women, and association of plasma leptin with plasma PAI-1, 961, 962  
serum, *see* Serum cholesterol  
and SM capillary density decrease in men, 1268  
total, *see* Total cholesterol  
in uremic subjects on CAPD, long-term effects of rhEPO on, 211  
VAT, LDL particle size and, 1324, 1325  
*see also* Cholesterol ester; Cholesterol-lowering diet; High-density lipoprotein-cholesterol; Hypercholesterolemia; Low-density lipoprotein-cholesterol
- Cholesterol acyltransferase, lecithin:, FC deposition in cornea of human apo A-II transgenic mice with functional deficiency of, 415-421
- Cholesterol ester (CE)  
CLA-1 as source of needed, for steroidogenesis in adrenocortical cells, 627-630  
effects of triphasic OCs with desogestrel or LN on, 661  
*see also* Esterification of C; Esterified cholesterol
- Cholesterol 7 $\alpha$ -hydroxylase, hepatic, regulation of hepatic sterol 27-hydroxylase and, compared, 1542-1548
- Cholesterol (C) in IDDM  
in childhood-onset IDDM with CAD, 532, 533  
and urinary excretion of apo A fragments, 370
- Cholesterol (C)-lowering diet  
of campestanol/sitostanol mixture with variable dietary fat intake, 475-480  
NCEP, Lp response to, 822-826  
soy protein and soluble fiber added to, 809-816  
unsaturated fat in, hepatic Fe levels and, 200-204
- Cholesteryl ester transfer proteins (CETPs)  
in MHL, 64  
net mass transfer of plasma, in normolipidemic subjects with peripheral vascular disease, 1361-1366
- Cholic acid in C and HC diet, and  $\omega$ -3 PUFA effect on recovery of cardiac function after cold storage of heart, 1203
- Choline in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Chorionic gonadotropin, *see* Human chorionic gonadotropin
- Chromium, *see* Cr
- Chronic alcohol intake, effects of, on hepatic  $\beta$ -galactoside 2,6-ST mRNA, 797-803
- Chronic hyperchloremic acidosis (CMA), renal N wasting, renal phosphate depletion, and renal Mg wasting due to, GH therapy effects on, 763-770
- Chronic leptin administration, effects of, on insulin-stimulated SM glucose, 671-676
- Chronic physiologic hyperinsulinemia, plasma FFAs, de novo lipogenesis, and dyslipidemia in conscious subjects, 330-337
- Chronic smoking, S<sub>i</sub>, SM BF and glucose uptake and, 239-244
- Chylomicron remnants, PP VLDL-C and, in NTG and HTG men with and without CHD, 301-307
- Cigarette smoking, *see* Smoking
- Circadian variations  
in plasma and erythrocyte glutamate, glutamine, and alanine in men on diet with and without added MSG, 1455-1460  
in serum leptin in older men, 1011-1014
- Circulating tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), concentrations of, in peripheral versus abdominal obesity, 1332-1335
- Cirrhosis  
effects of paracentesis of ascites on DEXA measurements of BMD and BMC in, 373-377

- Cirrhosis (*Continued*)  
 nonoxidative hepatic glucose metabolism in, 1260-1266  
 vitamin E in, 86-91
- Cl (chloride)  
 effects of inorganic nitrate and, on hCG-stimulated steroidogenesis in Leydig tumor cells, 693-700  
 xylitol and F effects on, 523
- CLA-1 (CD36 LIMPII analogous-1), as source of CE necessary to steroidogenesis in adrenocortical cells, 627-630
- Clonidine, GH responses to, in uremic subjects on CAPD, long-term effects of rhEPO on, 213-214
- CMA (chronic hyperchloremic acidosis), GH effects on renal N wasting, renal phosphate depletion, and renal Mg wasting induced by, 763-770
- Coagulation  
 in glucose-treated erythrocytes, effects of vitamin E and NAC on PS externalization and induction of, 957-959  
 intravascular, effects of reduced NO production due to L-arginine deficiency in LPI on, 1136-1140
- Cochlear dysfunction in NIDDM independently of neuropathy and acute hyperglycemia, 1346-1350
- Codon 64, *see entries beginning with terms:* Trp64Arg variant
- Coenzyme A, *see* Acetyl coenzyme A; Palmitoyl coenzyme A
- Coenzyme A dehydrogenase, *see* Acyl-coenzyme A dehydrogenase
- Coenzyme A reductase, inhibitors of HMG-, *see* Lovastatin; Pravastatin; Simvastatin
- Cold storage of heart,  $\omega$ -3 PUFA effects on recovery of cardiac function after, 1203-1209
- Colitis, ulcerative, metabolic features of, 952-956
- Colonic bacteria, serum lipids and, as risk factors for CV disease, 264-268
- Combined hyperlipidemia  
 associated with muscle protein release in exercise, effects of TG-lowering intervention on, 1518-1523  
 familial, effects of gemfibrozil with lovastatin on, 47-54
- Combined radionuclide and magnetic resonance imaging (MRI), role of diagnosis of minimal or localized osteomyelitis of foot in IDDM and NIDDM with, in conservative management, 922-927
- Congenital hypothyroidism in infants, effects of L-T<sub>4</sub> for, on apo concentrations, 1343-1345
- Connecting peptides, *see* C-peptide(s); C-peptide minimal model
- Conscious subjects  
 CGRP effects in, independently of glucagon and insulin, 603-610  
 with chronic physiologic hyperinsulinemia, plasma FFAs, de novo lipogenesis, and dyslipidemia, 330-337  
 dose-response relationships of insulin to glucose fluxes in, 965-970  
 E in, *see* Epinephrine in conscious subjects  
 gut clearance of NE by, 259-263  
 immunoblockade of GLP-1 by MoAbs in, insulin response to intragastric glucose and, 41-46
- Conservative management of localized or minimal osteomyelitis of foot in IDDM and NIDDM, role of combined RI and MRI diagnosis in, 922-927
- Continuous ambulatory peritoneal dialysis (CAPD), long-term effects of rhEPO on GH release in uremic subjects on, 210-216
- Contraceptives, triphasic oral, with desogestrel or LN, effects of, on apo A-I-containing HDL particles, 658-664
- Copper, *see* Cu
- Coprostan in soy protein/soluble fiber diet, 811
- Corn starch in high-sucrose diet with EPA-E ester and/or lard, 1090
- Cornea of human apo A-II transgenic mice with functional LCAT deficiency, FC deposition in, 415-421
- Cornmeal in cereal-based diet with C, 401
- Coronary artery disease (CAD) (*Continued*)  
 and MI in young adults, 1159  
 NIDDM with, *see* Non-insulin-dependent diabetes mellitus, CAD and
- Coronary heart disease (CHD)  
 FCHL and, 47  
 hyperinsulinemia in normal subjects as predictor of NIDDM, HTN and, 989-994  
 PP VLDL-C and chylomicron remnants in HTG and NTG men with and without, 301-307  
 VAT and metabolic risk factors for, 355-362  
*see also* Glucose in CHD; Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance, CHD and
- Corticosteroids, *see* Steroid(s) and specific corticosteroids
- Corticosterone, aging-related changes in secretion of, in female subjects, 535-541
- Corticotropin (ACTH; adrenocorticotropin hormone)  
 corticosterone release induced by, in female subjects, aging and, 535-541  
 exercise-induced increase in, in trained and untrained men, cortisol effects on, 390-394  
 plasma, and activities of HPA axis and SNS, 396, 398  
 plasma Lp(a) reduction induced by, in normal subjects and in HD patients, 342-346
- Cortisol (hydrocortisone)  
 CGRP effects on, in conscious subjects, 605  
 in eating disorders, 218  
 exercise and, *see* Cortisol, exercise and  
 influence of, on Trp binding to hepatic nuclei, 144-152  
 in PCOS, 169  
 plasma, in NIDDM with CAD, nicorandil effects on, 435  
 serum, effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1007  
 in stress hormone infusion, impact of acute epinephrine discontinuation of hepatic glucose metabolism during, 910-914  
 in TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients, 325
- Cortisol (hydrocortisone), exercise and  
 cortisol effects on exercise-induced ACTH increase, 390-394  
 effects of long-term exercise-induced weight loss in young identical male twins on, 1120-1127
- Counterregulatory hormones  
 effects of individualized GH therapy of childhood-onset GH deficiency in adults, 1006  
 effects of insulin, on neonatal hyperinsulinemic hypoglycemia, 568-574  
*see also* Corticotropin; Cortisol; Epinephrine; Norepinephrine
- C-peptide(s) (connecting peptide)  
 and decrease in SM capillary density in men, 1268  
 effects of chromium picolinate supplementation on, in older exercising men and women, 550  
 fasting, *see* Fasting C-peptides  
 incretin effects on, following orthotopic pancreas transplantation, 645-650  
 plasma, *see* Plasma C-peptides  
 PP, in exercising Mexican American and non-Hispanic women, 973  
 urinary, effects of soy protein/soluble fiber diet on, 812  
 in whole-body lipolysis, hypoosmolality effects on, 474, 475
- C-peptide (connecting peptide) minimal model, beta cell function during IM-IVGTT assessed with, 1162-1166
- Cr (chromium)  
 diet deficient in, insulin secretion in, 1063-1068  
 in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Cr (chromium) picolinate supplementation, effects of glucose metabolism in older exercising men and women, 546-553

- Creatinine**  
 CMA and GH effects on, 765  
 in ESRD subjects on HD, 632  
 in essential HTN, 888  
 F and xylitol effects on, 521, 523  
 in gout, 132  
 and long-term effects of valproic acid therapy on carnitine reabsorption, 75  
 in NIDDM, *see* Creatinine in NIDDM  
 in PH, 299  
 serum, *see* Serum creatinine  
 urinary excretion of, *see* Urinary excretion of creatinine
- Creatinine in NIDDM**  
 gliclazide versus metformin effects on, 898  
 with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 nephropathy and, 1098, 1099  
 SSAO activity and, 114, 115
- Critically ill multiple-trauma victims, cytokine release by mitogen-stimulated PBMCs from, 1397-1401**
- Crohn's disease (CD), metabolic features of, 952-956**
- Cross-sex hormone therapy in transsexuals, effects of, on size of adipocytes and lipolytic activity of abdominal and gluteal adipocytes, 1371-1377**
- Cryptogenic cirrhosis, vitamin E in, 87**
- CT, *see* Calcitonin**
- CTX (cerebrotendinous xanthomatosis), simvastatin with CDCA for, 233-238**
- Cu (copper)**  
 hepatic, effects of unsaturated fat on, 201  
 in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- CV disease, *see* Cardiovascular disease**
- CV (cardiovascular) fitness, obesity, leptin and, as predictors of AT-LPL activity in sedentary and exercising middle-aged and older men, 183-189**
- CV system, *see* Heart *entries beginning with term*: Arterial, Capillary, Intravascular, Vascular *and elements*: Card-, Vaso-**
- Cyanocobalamin, *see* Vitamin B<sub>12</sub>**
- Cyclase, effects of inhibitors of guanylate, on hCG-stimulated androgen production in Leydig tumor cells, 695**
- Cyclic adenosine monophosphate, *see* cAMP**
- Cyclic guanosine monophosphate, *see* cGMP**
- Cyst(s), ovarian, insulin biphasic effect on ability of hCG to induce, 995-1002**
- Cystathionine**  
 in ESRD patients on HD, 632  
 and nephropathy in NIDDM, 1096-1101
- Cysteine, effects of, on plasma and urinary concentrations of uric acid and uridine, 1024**
- L-Cystine, and leucine kinetics, 1379**
- Cytochrome P-450 1A1, 3-MC-induced, retinoids inhibiting metabolism of benzo(a)pyrene catalyzed by, 689-692**
- Cytokines**  
 release of, by mitogen-stimulated PBMCs from critically ill multiple-trauma victims, 1397-1401  
 in TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients, 325  
*see also specific cytokines*
- Deaminase, adenosine, BMI and, in NIDDM, 949-951**
- Dehydroepiandrosterone sulfate (DHEAS;  $\beta$ -hydroxy-5-androsten-17-one) in PCOS**  
 effects of long-term exercise-induced weight loss in young identical male twins on, 1120-1127  
 insulin and obesity effects on, 169  
 metformin-induced resumption of normal menses and, 512  
 in normoponderal subjects, 440
- Dehydrogenase**  
 hydroxysteroid, *see*  $\beta$ -Hydroxysteroid dehydrogenase;  $11\beta$ -Hydroxysteroid dehydrogenase  
 medium-chain acyl-coenzyme A, 2-octynoic acid simulating deficiency of, 685-688  
*see also* Pyruvate dehydrogenase complex; Pyruvate dehydrogenase kinase
- Delta<sup>8</sup> ( $\Delta^8$ )-cholesterol, serum, effects of campestanol/sitostanol mixture on proportion of, to C, 577**
- Delta<sup>6</sup> ( $\Delta^6$ )-desaturases, effects of dietary FAs on activity of, in STZ-DM, 455-460**
- Delta<sup>9</sup> ( $\Delta^9$ )-desaturases, effects of dietary FAs on activity of, in STZ-DM, 455-460**
- Delta<sub>4</sub>-DIONE, *see* Androstenedione in PCOS**
- De novo lipogenesis, chronic physiologic hyperinsulinemia and, 330-337**
- Deoxycholate, effects of soy protein/soluble fiber diet on, 813**
- 15-Deoxy- $\Delta^{12,14}$  prostaglandin J<sub>2</sub> (15d-PGJ<sub>2</sub>), *ob* gene suppressed by, 786-791**
- Deoxypyridinoline (DPYR), galactose effects on urinary excretion of, 905-906**
- Deoxyribonucleic acid (DNA), pancreatic, acarbose effects on, 350, 351**
- Depancreatized diabetic subjects, glucose production dependent on peripheral insulin in, 153-160**
- $\Delta^6$  (delta<sup>6</sup>)-Desaturases, effects of dietary FAs on activity of, in STZ-DM, 455-460**
- $\gamma^9$  (delta<sup>9</sup>)-Desaturases, effects of dietary FAs on activity of, in STZ-DM, 455-460**
- Desialylation of apo E, effects of, on its binding to HDL and its ability to deliver esterified C to liver, 1184-1192**
- Desmosterol, serum, effects of campestanol/sitostanol mixture on proportion of, to C, 577**
- Desogestrel (DG), effects of triphasic OCs with LN or, on apo A-I-containing HDL particles, 658-664**
- DEXA, *see* Dual-energy x-ray absorptiometry**
- Dexamethasone (DEX)**  
 effects of, on intracellular SM glucose in normoglycemic first-degree relatives of NIDDM subjects, 1128-1135  
 effects of insulin and, on renal G6Pase mRNA levels, 1052-1056  
 effects of short-term administration of, on hypothalamic and pituitary galanin synthesis, 792-796
- DG (desogestrel), effects of triphasic OCs with LN or, on apo A-I-containing HDL particles, 658-664**
- DHEAS, *see* Dehydroepiandrosterone sulfate in PCOS**
- DHPG (dihydroxyphenylglycol), plasma, and activities of HPA axis and SNS, 396**
- DHT, *see* Dihydrotestosterone**
- Diabetes mellitus (DM)**  
 blood vessels in, 406-409  
 effects of starvation and, on [2,3-<sup>13</sup>C]-SAD hepatocyte metabolism, 102-106  
 with obesity, *see* Diabetes mellitus with obesity  
 pancreas in, *see* Pancreas in DM  
*see also* Diabetic neuropathy; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus
- Diabetes mellitus (DM) with obesity**  
 acarbose preventing and reversing metabolic abnormalities in, 347-354  
 association of serum leptin and serum uric acid concentrations in, 678  
*see also* Obesity, NIDDM with
- Diabetic neuropathy**  
 autonomic, 92-101  
 in NIDDM, cochlear dysfunction independently of acute hyperglycemia, 1346-1350  
 oxidative stress and, 442-447

- Diabetic osteopenia (bone loss) in galactose-fed subjects, protective effects of ARI against, 904-909
- Diabetic retinopathy (DR), regulation of TGF- $\beta$ , bFGF, and VEGF mRNA in peripheral blood leukocytes in, 1172-1178
- Dialysis, *see* Continuous ambulatory peritoneal dialysis; End-stage renal disease, HD for
- Diastolic pressure, *see* Blood pressure
- 2,2-Dichloro-12-(*p*-chlorophenyl)-dodecanoic acid (BM 17.0744), as insulin sensitizer and antihyperlipidemic, 34-40
- Diet
- NIDDM induced by, insulin resistance in, 1549-1554
  - see also* Energy intake; Exercise, diet and; Fasting; Food intake; Malnutrition; Meal-induced oxidative stress; Meal tolerance test; Starvation; Supplementation *entries beginning with terms:* Dietary, Postprandial *specific food groups, food substances, and diets; for example:* Cholesterol-lowering diet
- Dietary cholesterol (C)
- effects of cereal-based diet with, on biliary C and fecal excretion of bile acids, 400-405
  - and  $\omega$ -3 PUFA effect on cardiac function recovery after cold storage of heart, 1203
  - soy protein and, *see* Dietary cholesterol, soy protein and
- Dietary cholesterol (C), soy protein and
- in C-lowering diet with soluble fiber and soy protein, 810
  - effects of, on serum lipids, biliary lipids, and fecal sterol excretion, 489-494
- Dietary fat
- in C and HC diet, and  $\omega$ -3 PUFA effects on cardiac function recovery after cold storage of heart, 1203
  - in cereal-based diet with C, 401
  - and FFA inhibition of glucose-stimulated insulin release in insulin resistance, 1315
  - in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
  - and prior exercise effects on PP lipemia, 250
  - saturation of, modulating rates of C esterification in normolipidemic men, 1210-1215
  - see also* Dietary fat in C-lowering diet; High-fat diet
- Dietary fat in C-lowering diet
- C-lowering properties of unsaturated fat, hepatic Fe levels and, 200-204
  - hypcholesterolemic properties of campestanol/sitostanol mixture with variable dietary fat intake, 575-580
  - total dietary fat in soy protein/soluble fiber diet, 810
- Dietary fatty acids (FAs)
- effects of, on lipid metabolism in STZ-DM, 455-460
  - see also specific fatty acids*
- Dietary fiber
- in C and HC diet, and  $\omega$ -3 PUFA effects on recovery of cardiac function recovery after cold storage of heart, 1203
  - and FFA inhibition of glucose-stimulated insulin release in insulin resistance, 1315
  - in high-sucrose diet with EPA-E ester and/or lard, 1090
  - see also* Dietary fiber in C-lowering diets
- Dietary fiber in C-lowering diets
- in NCEP diet, 823
  - in soluble fiber/soy protein diet, 809-816
- Dietary protein
- in C and HC diet, and  $\omega$ -3 PUFA effects on recovery of cardiac function after cold storage of heart, 1203
  - and FFA inhibition of glucose-stimulated insulin release in insulin resistance, 1315
  - in HF diet, 1231, 1232
  - in high-sucrose diet with EPA-E ester and/or lard, 1090
  - in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
  - in NCEP C-lowering diet, 823
- Dietary protein (*Continued*)
- and prior exercise effects on PP lipemia, 250
  - soy, *see* Soy protein
- Dietary sitostanol, effects of, on campestanol absorption and distribution, 363-368
- Digestibility, starch, effects of red wine, tannic acid, and ethanol on, in NIDDM, 1179-1183
- Dihydrotestosterone (DHT)
- effects of long-term exercise induced weight loss in young identical male twins on, 1120-1127
  - in hypogonadal men, T substitution and, 592
- Dihydroxyphenyl acetic acid (DOPAC), plasma, and activities of HPA axis and SNS, 396
- Dihydroxyphenylalanine (DOPA), plasma, and activities of HPA axis and SNS, 396
- Dihydroxyphenylglycol (DHPG), plasma, and activities of HPA axis and SNS, 396
- N*'-[2,4-Dimethyl]-*N*-[(2,4-dimethylphenyl)imino]-*N*-methylmethanimidamide (amitraz), effects of BTS 27271 and, on insulin and glucagon secretion,  $\alpha$ <sub>2D</sub>-ARs and, 1461-1469
- Dimorphism of NIDDM phenotype, age and, 477-483
- 17 $\beta$ -Diol-glucuronide (3 $\alpha$ DIOL-G), effects of long-term exercise induced-weight loss in young identical male twins on, 1120-1127
- $\Delta$ <sub>4</sub>-DIONE, *see* Androstenedione in PCOS
- Dipeptidyl peptidase IV [DPPIV; CD26], long-lasting hypoglycemic effects of, in NIDDM, 252-258
- Dipeptidyl peptidase IV [DPPIV; CD26] inhibitor, effects of, on glucose tolerance, 385-389
- Diphosphoglucose, hepatic uridyldiphosphoglucose and hepatic nonoxidative glucose metabolism, 1260-1266
- Discontinuation
- of epinephrine, impact of acute, on hepatic glucose metabolism during stress hormone infusion, 910-914
  - smoking, effects of, on BW and plasma leptin levels, 804-808
- Dismutase, *see* Superoxide dismutase in STZ-DM
- Diurnal variations, *see* Circadian variations
- DM, *see* Diabetes mellitus
- DNA (deoxyribonucleic acid), pancreatic, acarbose effects on, 350, 351
- Docosahexaenoic acid, TFAs and, 873
- Docosapentaenoic acid, TFAs and, 873
- DOPA (dihydroxyphenylalanine), plasma, and activities of HPA axis and SNS, 396
- DOPAC (dihydroxyphenyl acetic acid), plasma, and activities of HPA axis and SNS, 396
- Dopamine, urinary excretion of, high-sucrose diet and EPA-E ester effects on, 1092
- Dose
- dose-response relationships of insulin to glucose fluxes in conscious subjects, 965-970
  - individualized low-dose GH therapy of childhood-onset adult GH deficiency, metabolic effects of, 1003-1010
- DPPIV, *see entries beginning with terms:* Dipeptidyl peptidase IV
- DPYR (deoxyypyridinoline), galactose effects on urinary excretion of, 905-906
- DR (diabetic retinopathy), regulation of TGF- $\beta$ , bFGF, and VEGF mRNA in peripheral blood leukocytes in, 1172-1178
- Dried brewer's yeast in cereal-based diet with C, 401
- Dried skim milk in cereal-based diet with C, 401
- Dual-energy x-ray absorptiometry (DEXA)
- of AT, serum lipids, and GH secretion in older men and women, 1424-1431
  - of BMD or BMC, effects of paracentesis of ascites on, 373-377
- Dysinnervation, cardiac sympathetic, in IDDM, PET with [<sup>11</sup>C]-HED in assessment of, 92-101

- Dyslipidemia  
 in conscious subjects, chronic physiologic hyperinsulinemia and, 330-337  
 and MI in young adults, 1159  
 in obesity, BC/SKF38393 effects on, 1033-1040  
*see also* Hyperlipidemia
- E (EPI), *see* Epinephrine
- E<sub>2</sub>, *see* Estradiol
- Eating disorders, leptin in women with, 217-220
- EC(s), *see* Endothelial cells
- Echocardiography in STZ-DM, 774, 775
- Eicosapentaenoic acid (EPA), TFAs and, 873
- Eicosapentaenoic acid ethyl (EPA-E) ester, effects of, on insulin resistance and HTN, 1089-1095
- Elaidic acid, TFAs and, 873
- Elderly subjects, *see* Older subjects
- Enalapril, effects of losartan and, on insulin resistance in adipocytes in essential HTN, 1041-1046
- Endocrine variables in PCOS, impact of BMI and insulin on metabolic and, 167-172
- Endothelial cells (ECs)  
 ET production by, following exposure to nicotine or caffeine, 845-848  
 umbilical cord, IDDM plasma inducing functional modification in, 554-557
- Endothelial dysfunction in IDDM, octreotide effects on, 1236-1240
- Endothelial growth factor mRNA (messenger ribonucleic acid), vascular, regulation of, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178
- Endothelin (ET)  
 EC production of, following exposure to nicotine or caffeine, 845-848  
 insulin resistance, hyperendothelinemia, and HTN due to exogenous hyperinsulinemia, 465-471
- Endothelin-1, *see* Plasma endothelin-1 in hyperinsulinemia
- Endotoxemia, L-NAME-NO pathway in muscular hypercatabolism induced by, 190-193
- End-stage renal disease (ESRD)  
 long-term effects of rhEPO on GH release in patients on CAPD for, 210-216  
*see also* End-stage renal disease, HD for
- End-stage renal disease (ESRD), HD for  
 ACTH-induced plasma Lp(a) reduction in subjects with, 342-346  
 and vitamin B<sub>12</sub> supplementation effects on Hcy, MMA, and serum folate in subjects on HD, 631-635
- Endurance exercise, *see* Exercise
- Energy expenditure  
 and determination of AT and plasma leptin in male subjects, 1272-1277  
 HF diet and, 1232  
 prior exercise reducing PP lipemia independently of AT and CHO contributions to, during exercise, 245-251
- Energy intake  
 with C and HC diet, and  $\omega$ -3 PUFA effects on recovery of cardiac function recovery after cold storage of heart, 1203  
 metabolizable, *see* Metabolizable energy intake  
*see also* Fasting; Food intake; Malnutrition; Meal-induced oxidative stress; Meal tolerance test; Starvation; Supplementation *entries beginning with terms:* Dietary, Postprandial *specific food groups, food substances, and diets; for example:* Cholesterol-lowering diet
- Enteral alanine (Ala), splanchnic utilization of, 915-921
- EPA (eicosapentaenoic acid), TFAs and, 873
- EPA-E (eicosapentaenoic acid ethyl) ester, effects of, on insulin resistance and HTN, 1089-1095
- Epalrestat, protective effects of, against diabetic bone loss in galactose-fed subjects, polyol pathway involvement in bone metabolism and, 904-909
- EPI (E), *see* Epinephrine
- Epilepsy, hyperhomocysteinemia, MTHFR genotype, and anticonvulsant therapy of, 1047-1051
- Epinephrine (E; EPI)  
 in conscious subjects, *see* Epinephrine in conscious subjects  
 effects of, on LPL activity in SM, 461-464  
 fasting, in malnourished older cancer subjects, Intralipid and propranolol effects on, 295  
 hypersecretion of, in pheochromocytoma, leptin suppression in response to, 543-545  
 plasma, *see* Plasma epinephrine  
 urinary excretion of, high-sucrose diet and EPA-E ester effects on, 1092
- Epinephrine (E; EPI) in conscious subjects  
 CGRP effects on, 605  
 gut clearance of, 259-263  
 impact of acute discontinuation of, on hepatic glucose metabolism during stress hormone infusion, 910-914
- Epithelial cells, retinal pigment, C-AD reversing hyperglycemia-induced phosphoinositide synthesis inhibition in, and preventing reduction of MNCV in STZ-DM, 827-833
- EPOC (excess postexercise oxygen consumption), menstrual cycle effects on, in young women, 275-277
- ERT (estrogen replacement therapy), *see* Hormone replacement therapy
- Erythrityl tetranitrate, effects of, on GH-releasing activity of Hexarelin, 177, 178
- Erythrocyte(s) (red blood cell; RBC)  
 glucose-treated, effects of vitamin E and NAC on PS externalization and induction of coagulation in, 957-959  
 in NIDDM, *see* Erythrocyte(s) in NIDDM  
*see also* Erythrocyte folate; Erythrocyte membrane
- Erythrocyte(s) (red blood cell; RBC) in NIDDM  
 with angiopathy, RBC susceptibility to oxidation in, 1481-1484  
 glycated Hb and lipid peroxidation in, 205-209
- Erythrocyte (red blood cell; RBC) alanine (Ala), circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460
- Erythrocyte (red blood cell; RBC) folate in ESRD patients on HD, 632
- Erythrocyte (red blood cell; RBC) glutamate (Glu), circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460
- Erythrocyte (red blood cell; RBC) glutamine (Gln), circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460
- Erythrocyte (red blood cell; RBC) glutathione (GSH) in NIDDM with angiopathy, 1483
- Erythrocyte (red blood cell; RBC) malondialdehyde (MDA)  
 in glucose-treated RBCs, 957-959  
 in NIDDM with angiopathy, 1483
- Erythrocyte (red blood cell; RBC) membrane  
 glycohydrolase activity in, in NIDDM, 817-821  
 TBARS in, in STZ-DM, AMGN effects on, 1142
- ESRD, *see* End-stage renal disease
- Essential hypertension (HTN)  
 ACE inhibitors for, *see* Angiotensin-converting enzyme inhibitor(s) in essential HTN  
 acute hyperinsulinemia effects on urinary nitrite/nitrate excretion and plasma ET-1 levels in men with, 887-891  
*see also* Hypertension

- Esterification of C, dietary fat saturation modulating rates of, in normolipidemic men, 1210-1215
- Esterified cholesterol (C), effects of apo E desialylation on its binding to HDL and its ability to deliver, to liver, 1184-1192
- Estradiol (E<sub>2</sub>)  
   in hyperinsulinemia, 109, 110  
   in hypogonadal men, T substitution and, 592  
   in PCOS, *see* Estradiol in PCOS  
   plasma, effects of E<sub>2</sub> replacement on aging-related changes in, 535-541
- Estradiol (E<sub>2</sub>) in PCOS  
   insulin and obesity effects on, 169  
   metformin-induced resumption of normal menses and, 512, 516  
   and PAI as risk factor for miscarriage, 1590
- Estrogen replacement therapy, *see* Hormone replacement therapy
- Estrone  
   effects of aging-related changes in, on sex difference in serum leptin independently of changes in AT, 378-384  
   in PCOS, insulin and obesity effects on, 169
- ET, *see* Endothelin
- ET-1 (endothelin-1), *see* Plasma endothelin-1 in hyperinsulinemia
- Ethanol  
   effects of red wine, tannic acid and, on starch digestibility and glucose tolerance in NIDDM, 1179-1183  
   *see also* Alcohol intake
- Ethnicity, *see* Race and ethnicity
- 7-Ethoxyresorufin catalyzed by 3-MC-induced cytochrome P-450 1A1, retinoids inhibiting metabolism of, 689-692
- Euthyroid sick syndrome, TNF- $\alpha$ -induced recovery from, by cancer patients, 324-329
- Evodiamine, effects of, on T secretion in testicular interstitial cells, 1532-1535
- Excess postexercise oxygen consumption (EPOC), menstrual cycle effects on, in young women, 275-277
- Excretion, *see* Fecal excretion; Urinary excretion
- Exendin(9-39), glycosylated, properties of, 716-724
- Exercise  
   and altered purine and glycogen metabolism in heart failure subjects, 484-488  
   diet and, *see* Exercise, diet and  
   effects of TG-lowering intervention on combined hyperlipidemia associated with muscle protein release in, 1518-1523  
   FES, effects of, on GLUT1 and GLUT4 in paralyzed SM, 1409-1413  
   in NIDDM, *see* Exercise in NIDDM  
   PP lipemia reduced by prior running, independently of AT and CHO contributions to energy expenditure during, 245-251  
   response of total body fat and abdominal AT to, HERITAGE Family Study of, 1278-1286  
   testosterone and, *see* Testosterone, exercise and  
   *see also* Glucose, exercise and; Insulin, exercise effects on; Men, exercising; Women, exercising
- Exercise, diet and  
   adaptation to HF diet and, 1509-1517  
   effects of diet composition and timing of exercise on substrate utilization and sympathoadrenal function, 1596-1602  
   *see also* Exercise, diet and, in NIDDM
- Exercise, diet and, in NIDDM  
   diet and exercise effects on LDL subfractions in NIDDM men, 641-644  
   effects of fish diet and exercise on urinary F<sub>2</sub>-isoprostane excretion, 1402-1408
- Exercise in NIDDM  
   alcohol intake and metabolic responses following, 597-602  
   *see also* Exercise, diet and, in NIDDM
- Exogenous hyperinsulinemia, insulin resistance, hyperendothelinemia, and HTN due to, 465-471
- Experimental diabetes mellitus, *see* Streptozotocin-induced diabetes mellitus
- Ex vivo blood, leukocyte glycolysis and lactate output in sepsis and in, 779-785
- F, *see* Fructose
- FA(s), *see* Fatty acid(s)
- FABP2 gene, polymorphism of, in obese and insulin-resistant Japanese subjects, 655-657
- Factor VII:C, TFAs and, in young women, 873-874
- Familial combined hyperlipidemia (FCHL), gemfibrozil with lovastatin effects on, 47-54
- Familial hypercholesterolemia (FH), heterozygous, LDL oxidizability before and after LDL apheresis in, 881-886
- Family  
   HERITAGE Family study of total body fat and abdominal AT response to exercise, 1278-1286  
   *see also* Family of NIDDM subjects; Twins and entries beginning with term: Familial
- Family of NIDDM subjects  
   effects of dexamethasone on intracellular SM glucose in normoglycemic first-degree relatives of NIDDM subjects, 1128-1135  
   S<sub>1</sub>, glucose effectiveness, and insulin secretion in nondiabetic offspring, 978-983
- Fasting  
   arterial glucose concentrations with aortopulmonary shunts after, in CHD, 1082-1088  
   functional and molecular expression of Pept-1 after brief, 681-684  
   LA-induced hypoglycemia in fasting nondiabetic and STZ-DM subjects, 504-510  
   metabolic effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults during, 1003-1010  
   *see also* entries beginning with term: Fasting
- Fasting blood glucose (FBG)  
   and activity of RBC membrane glycohydrolases, 818  
   and dose-response relationships of insulin to glucose fluxes, 966  
   and individualized GH therapy of childhood-onset GH deficiency in adults, 1005-1006  
   and PAI as risk factor for miscarriage, 1590  
   in premenopausal women, and association of plasma leptin with plasma PAI-1, 961, 962  
   in STZ-DM, lithium effects on, 559  
   *see also* Fasting blood glucose in NIDDM
- Fasting blood glucose (FBG) in NIDDM  
   GLP-1-Gly8 effects on, 257  
   LDL composition and metabolism and, 121
- Fasting blood lipids, effects of soy protein/soluble fiber diet on, 811-812
- Fasting C-peptides (connecting peptides)  
   effects of chromium picolinate supplementation on, in exercising older men and women, 550  
   in GH-deficient adults, effects of GH therapy and its withdrawal on, 1391, 1393  
   in NIDDM-prone subjects, 81
- Fasting epinephrine (E) in malnourished older cancer subjects, Intralipid and propranolol effects on, 295
- Fasting free fatty acids (FFAs)  
   in malnourished older cancer subjects, Intralipid and propranolol effects on, 295  
   plasma, in NIDDM-prone subjects, 81  
   total depletion of antioxidant capacity and, 1415
- Fasting glucose  
   age and, *see* Fasting glucose, age and  
   blood, *see* Fasting blood glucose  
   in essential HTN, 888



- Fasting glucose (*Continued*)  
 exercise, *see* Fasting glucose, exercise and  
 in GH-deficient adults, effects of GH therapy and its withdrawal on, 1390, 1393  
 HPA axis and SNS activities and, 396  
 in PCOS, 169  
 plasma, *see* Fasting plasma glucose  
 in postmenopausal women, VAT and, 1147  
 Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and, 1368, 1369  
 in TS, GH therapy effects on, 9, 11
- Fasting glucose, age and  
 aging-related changes in sex hormones and, 380  
 in middle-aged exercising men, AT-LPL activity and, 185  
*see also* Fasting glucose in older subjects
- Fasting glucose, exercise and  
 effects of chromium picolinate supplementation on fasting glucose in older exercising men and women, 550  
 in middle-aged exercising men, AT-LPL activity and, 185
- Fasting glucose in older subjects  
 in malnourished older cancer subjects, Intralipid and propranolol effects on, 295  
 in older exercising men, AT-LPL activity and, 185
- Fasting hyperinsulinemia, and prediction of atherosclerotic CV disease in hyperlipidemia, 1437-1444
- Fasting insulin  
 age and, *see* Fasting insulin, age and  
 and dose-response relationships of insulin to glucose fluxes in, 966  
 in essential HTN, 888  
 exercise and, *see* Fasting insulin, exercise and  
 HPA axis, SNS activities and, 396  
 and individualized GH therapy of childhood-onset GH deficiency in adults, 1005-1006  
 in NIDDM, total depletion of antioxidant capacity and, 1415  
 in PCOS, 169  
 in postmenopausal women, VAT and, 1147  
*see also* Fasting hyperinsulinemia; Fasting plasma insulin; Fasting serum insulin
- Fasting insulin, age and  
 aging-related changes in sex hormones and, 380  
 in middle-aged exercising men, AT-LPL activity and, 185  
*see also* Fasting insulin in older subjects
- Fasting insulin, exercise and  
 AT-LPL activity in middle-aged exercising men and, 185  
*see also* Fasting insulin in older exercising subjects
- Fasting insulin in older exercising subjects  
 AT-LPL activity and, 185  
 chromium picolinate supplementation effects, on fasting insulin in exercising older men and women, 550
- Fasting insulin in older subjects  
 in malnourished older cancer subjects, Intralipid and propranolol effects on, 295  
*see also* Fasting insulin in older exercising subjects
- Fasting norepinephrine (NE) in malnourished older cancer subjects, Intralipid and propranolol effects on, 295
- Fasting plasma C-peptide (connecting peptide) in NIDDM-prone subjects, 81
- Fasting plasma free fatty acids (FFAs)  
 in NIDDM-prone subjects, 81  
 in obese and lean subjects, HR variability and, 756
- Fasting plasma glucagon in NIDDM-prone subjects, 81
- Fasting plasma glucose (FPG)  
 in CHD, 854, 855  
 chronic smoking effects on, 240  
 of lean subjects, HR variability and, 756  
 in NIDDM, *see* Fasting plasma glucose in NIDDM
- Fasting plasma glucose (FPG) (*Continued*)  
 in NIDDM-prone subjects, 81  
 in nondiabetics with MI, 1199  
 in obesity, *see* Fasting plasma glucose in obesity
- Fasting plasma glucose (FPG) in NIDDM  
 and changes in islet capillary angioarchitecture, 479, 482  
 in Japanese NIDDM subjects with insulin resistance, *FABP2* gene polymorphism and, 656  
 LDL composition and metabolism and, 119  
 SSAO activity and, 114, 115  
 total depletion of antioxidant capacity and, 1415  
 and troglitazone effects on AT distribution in men, 1103, 1104
- Fasting plasma glucose (FPG) in obesity  
 HR variability in, 756  
 Japanese men with Trp64Arg variant of  $\beta_3$ -AR gene and *UCP1* gene mutation, 637, 638
- Fasting plasma insulin (FPI)  
 in CHD, 854, 855  
 of lean subjects, 756  
 in NIDDM, *see* Fasting plasma insulin in NIDDM  
 in NIDDM-prone subjects, 81  
 in obesity, *see* Fasting plasma insulin in obesity
- Fasting plasma insulin (FPI) in NIDDM  
 in Japanese subjects with insulin resistance and *FABP2* gene polymorphism, 656  
 LDL composition and metabolism and, 119
- Fasting plasma insulin (FPI) in obesity  
 HR variability and, 756  
 in obese Japanese men, Trp64Arg variant of  $\beta_3$ -AR gene and *UCP1* gene mutation, 637, 638
- Fasting plasma lipids in NTG and HTG men, 302-303
- Fasting plasma lipoproteins (Lps) in NTG and HTG men, 302-303
- Fasting serum cholesterol (C)  
 acarbose effects on, 349  
 chronic smoking effects on, 240
- Fasting serum high-density lipoproteins (HDLs), chronic smoking effects on, 240
- Fasting serum insulin  
 metformin therapy effects on, 514, 516  
 and PAI as risk factor for miscarriage, 1590
- Fasting serum triglycerides (TGs)  
 acarbose effects on, 349  
 chronic smoking effects on, 240
- Fasting total cholesterol (TC) in NIDDM, NE-mediated vasoconstriction and, 1538
- Fasting triglycerides (TGs)  
 in malnourished older cancer subjects, Intralipid and propranolol effects on, 295  
 serum, *see* Fasting serum triglycerides
- Fat, *see* Dietary fat entries beginning with terms: Fat, Fatty elements: Adip-, Lip- and specific fats
- Fat-free mass (FFM)  
 in cirrhotic subjects, *see* Fat-free mass in cirrhotic subjects  
 exercise and, *see* Fat-free mass, exercise effects on  
 in GH-deficient adults, GH therapy effects on, 309, 310  
 HPA axis and SNS activities and, 396  
 in hyperinsulinemia, 110  
 in IBD subjects, 953, 954  
 in malnourished older cancer subjects, 292, 294  
 plasma leptin and, *see* Fat-free mass, plasma leptin and
- Fat-free mass (FFM), exercise effects on  
 and age-related blunting of GH secretion during exercise by men, 666  
 in Mexican American and non-Hispanic women, PP insulin responses and, 972  
*see also* Fat-free mass, exercise effects on, in older men and women

- Fat-free mass (FFM), exercise effects on, in older men and women  
chromium picolinate supplementation and, 549  
differential effects of exercise and body composition on, 1476
- Fat-free mass (FFM), plasma leptin and  
in plasma leptin determination, 1274  
in premenopausal women, plasma leptin and plasma PAI-1 association in, 961, 962
- Fat-free mass (FFM) in cirrhotic subjects  
effects of paracentesis of ascites on DEXA measurements and, 374  
in GH-deficient adults, effects of GH therapy and its withdrawal on, 1390  
hepatic glucose metabolism and, 1261
- Fat mass (FM)  
in cirrhosis, and effects of paracentesis of ascites on DEXA measurements, 374  
eating disorders and, 218  
in GH-deficient adults, *see* Fat mass in GH-deficient adults, GH therapy effects on  
HPA axis and SNS activities and, 396  
in IBD subjects, 953  
in obese subjects, serum leptin and serum uric acid concentrations and, 678-680  
in postmenopausal women, anger, hostility and, 1147  
in premenopausal women, plasma leptin associated with plasma PAI-1 irrespective of BMI, plasma insulin, metabolic parameters and, 960-964  
and toxin-induced infections, 946-948  
Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and, 1368, 1369  
VAT, LDL particle size and, 1323  
*see also* Fat mass in exercising men
- Fat mass (FM) in exercising men  
middle-aged men, AT-LPL activity and, 185  
older, AT-LPL activity and, 185; *see also* Fat mass in older exercising men and women  
in weight-reduced men, 17-19
- Fat mass (FM) in GH-deficient adults, GH therapy effects on  
effects of GH therapy and its withdrawal, 1390, 1393  
individualized low-dose GH effects on FM, 1005  
sex and response to, 315
- Fat mass (FM) in older exercising men and women  
chromium picolinate supplementation effects on, 549  
differential effects of exercise and body composition on, 1476
- Fatty acid(s) (FAs)  
dietary, effects of, on lipid metabolism in STZ-DM, 455-460  
and *FABP2* gene polymorphism in obese and insulin-resistant Japanese subjects, 655-657  
free, *see* Free fatty acids  
hepatic, sesamin effects on oxidation of, 1303-1313  
in high-sucrose diet with EPA-E ester and/or lard, 1090, 1094  
monounsaturated, *see* Monounsaturated fatty acids  
polyunsaturated, *see* Polyunsaturated fatty acids  
renal, and long- and short-term renal glucose oxidation regulation, 707-715  
saturated, *see* Saturated fatty acids  
short-chain, effects of soy protein/soluble fiber diet on, 812, 813  
synthesis of, following PV blockade of hepatic HMG-CoA reductase, 618-626  
*see also: cis* Fatty acid(s); *trans* Fatty acid(s)
- cis* Fatty acid(s) (FAs), effects of, on insulin release, 22-29
- trans* Fatty acid(s) (TFAs)  
effects of, on insulin release, 22-29  
 $S_i$  in young women and diet high in, 870-875
- FBG, *see* Fasting blood glucose
- FC, *see* Free cholesterol
- FNHL (familial combined hyperlipidemia), effects of combined gemfibrozil and lovastatin on, 47-54
- Fe, *see* Iron
- Fecal excretion  
of bile acids, effects of cereal-based diet with C on, 400-405  
[ $^3$ H]riboflavin, during respiratory infection, 1610  
starch, colonic bacterial activity and, 264-269  
of sterols, soy protein with very low dietary C effects on, 489-494
- Fecal output, effects of soy protein/soluble fiber diet on, 812, 813
- Fecal pH, effects of soy protein/soluble fiber diet on, 813
- Fecal short-chain fatty acids (SCFAs), effects of soy protein/soluble fiber diet on, 812, 813
- Female subjects  
aging-related changes in corticosterone secretion in, 535-541  
*see also* Girls; Women
- Ferritin in uremic subjects on CAPD, long-term effects of rEPO on, 211
- FES (functional electrical stimulation) exercise, effects of, on paralyzed SM GLUT1 and GLUT4, 1409-1413
- Fetal growth, effects of reduced  $FiO_2$  on, 738-744
- FFAs, *see* Free fatty acids
- FFM, *see* Fat-free mass
- FH (familial hypercholesterolemia), heterozygous, LDL oxidizability before and after LDL apheresis in, 881-886
- Fiber, *see* Dietary fiber
- Fibrinogen  
in childhood-onset IDDM with CAD, 532, 533  
TFAs and, in young women, 873-874
- Fibroblast growth factor mRNA (messenger ribonucleic acid), basic, regulation of, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178
- Filamentous actin, effects of disruption of, on  $Ca^{2+}$  signaling in liver, 1241-1247
- Filtration parameter, fluidity and, of PMN membrane after chemotactic activation of PMNs in NIDDM, 30-33
- $FiO_2$  (fraction of inspired oxygen), effects of reduced, on fetal growth and maternal glucose metabolism in pregnancy, 738-744
- First-degree relatives of NIDDM subjects, normoglycemic, effects of dexamethasone on intracellular SM glucose in, 1128-1135
- Fish, effects of exercise and, on urinary  $F_2$ -isoprostane excretion in NIDDM, 1402-1408
- Fish meal in cereal-based diet with C, 401
- FM, *see* Fat mass
- Folate  
in NIDDM, 1097-1099  
*see also* Folate, Hcy and, and MTHFR genotype
- Folate, Hcy and, and MTHFR genotype  
in epileptic subjects on anticonvulsant therapy, hyperhomocysteinuria and, 1047-1051  
in ESRD, effects of vitamin  $B_{12}$  supplementation on Hcy, MMA, and serum folate in relation to C677T MTHFR genotype, 631-635  
in South African black women with history of pregnancy complicated by NTDs, 269-274
- Folic acid in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Follicle-stimulating hormone (FSH)  
in eating disorders, 218  
in PCOS, metformin-induced resumption of normal menses and, 512, 516
- Food intake  
acarbose effects on, 348-349  
chronic leptin administration effects on, 672  
in dyslipidemia, BC/SKF38393 effects on, 1035  
galactose effects on, 905  
hyperinsulinemia and, 333

- Food intake (*Continued*)  
 and prior exercise effects on PP lipemia, 248, 250  
*see also* Diet
- Foot, localized or minimal osteomyelitis of, in IDDM and NIDDM, role of combined RI and MRI diagnosis of, in conservative management, 922-927
- Formate, effects of soy protein/soluble fiber diet on, 813
- Forskolin, corticosterone release and cAMP production in response to, 535-541
- FPG, *see* Fasting plasma glucose
- FPI, *see* Fasting plasma insulin
- Fraction of inspired oxygen (FiO<sub>2</sub>), effects of reduced, on fetal growth and maternal glucose metabolism in pregnancy, 738-744
- Free carnitine  
 LA effects on, 508  
 renal, renal glucose oxidation and, 709-710
- Free cholesterol (FC)  
 deposition of, in cornea of human apo A-II transgenic mice with functional LCAT deficiency, 415-421  
 in normolipidemic men, 1212
- Free fatty acids (FFAs; nonesterified fatty acids), 1314-1321  
 in adult hypopituitarism, 1059  
 diet and exercise effects on, in obese NIDDM men, 642  
 in dyslipidemia, BC/SKF38393 effects on, 1035  
 effects of high-sucrose diet with EPA-E ester and/or lard on, 1093  
 effects of local sympathetic blockade on, 1579  
 in exercising Mexican American and non-Hispanic women, 973-974  
 fasting, *see* Fasting free fatty acids  
 imidapril effects on, 1250  
 inhibition of glucose-stimulated insulin secretion by, enhanced in pancreatic islets of insulin-resistant subjects, 1314-1317  
 and metabolic adaptations to HF diet, 1513  
 metabolic effects of acipimox decrease of, in hyperthyroidism, 1318-1321  
 in PCOS, 171  
 plasma, *see* Plasma free fatty acids  
 serum, *see* Serum free fatty acids  
 VAT accumulation and, 357
- Free testosterone (T)  
 in hyperinsulinemia, 109, 110  
 in hypogonadal men, T substitution and, 592
- Free thyroxine (T<sub>4</sub>)  
 eating disorders and, 218  
 in GH-deficient adults, effects of GH therapy and its withdrawal on, 1390  
 T<sub>3</sub> effects on, 1605  
 in uremic subjects on CAPD, long-term effects of rhEPO on, 211
- Free triiodothyronine (T<sub>3</sub>), serum, HF diet and, 1233
- Frequently sampled intravenous glucose tolerance test (FSIGT)  
 in NIDDM, NE-mediated vasoconstriction and, 1538  
 TFAs and, in young women, 873
- Fructosamine  
 and activity of glycohydrolases in RBC membrane and, 818  
 in NIDDM, *see* Fructosamine in NIDDM  
 serum, galactose effects on, 906
- Fructosamine in NIDDM  
 diet and exercise effects on, in obese NIDDM men, 642  
 metformin versus gliclazide effects on, 899  
 total depletion of antioxidant capacity and, 1415
- Fructose (F)  
 effects of xylitol and, on urinary excretion and plasma concentrations of adenosine, uridine, and purine bases, 520-524  
 and FFA inhibition of glucose-stimulated insulin release in insulin resistance, 1315
- FSH, *see* Follicle-stimulating hormone
- FSIGT, *see* Frequently sampled intravenous glucose tolerance test
- $\alpha$  (alpha)-L-Fucosidase, activity RBC membrane, in NIDDM, 817-821
- [2,3-<sup>13</sup>C]Fumarate, [2,3-<sup>13</sup>C]-SAD effects on hepatocyte output of, 103
- Functional electrical stimulation (FES) exercise, effects of, on paralyzed SM GLUT1 and GLUT4, 1409-1413
- Functional lecithin:cholesterol acyltransferase (LCAT) deficiency, and FC deposition in cornea of human apo A-II transgenic mice, 415-421
- GAL (galanin), pituitary and hypothalamic, effects of short-term glucocorticoid administration on synthesis of, 792-796
- Galactitol, plasma and urinary excretion of, in galactosemia due to GALT deficiency, 1294-1302
- Galactose-fed subjects, protective effects of ARI against diabetic bone loss in, 904-909
- Galactosemia due to GALT deficiency, plasma and urinary excretion of galactitol in, 1294-1302
- Galactose-1-phosphate uridylyltransferase (GALT), galactosemia due to deficiency in, plasma and urinary excretion of galactitol in, 1294-1302
- $\alpha$  (alpha)-D-Galactosidase, activity RBC membrane, in NIDDM, 817-821
- $\beta$  (beta)-D-Galactosidase, activity RBC membrane, in NIDDM, 817-821
- $\beta$  (beta)-Galactoside  $\alpha$ (alpha)2,6-sialyltransferase (2,6-ST) mRNA (messenger ribonucleic acid), hepatic, effects of chronic alcohol intake on, 797-803
- Galanin (GAL), pituitary and hypothalamic, effects of short-term glucocorticoid administration on synthesis of, 792-796
- GALT (galactose-1-phosphate uridylyltransferase), galactosemia due to deficiency in, plasma and urinary excretion of galactitol in, 1294-1302
- Gamma ( $\gamma$ )-globulin (immunoglobulin G), and prediction of atherosclerotic CV disease, 1438
- GC (guanylate cyclase) inhibitors, effects of, on hCG-stimulated androgen production in Leydig tumor cells, 695
- Gemfibrozil, effects of lovastatin combined with, on FCHL, 47-54
- Gender, *see* Sex
- Genetics, *see* Apolipoprotein E genotype; Calcitonin gene-related peptide; Dimorphism; DNA; Family; Folate, Hcy and, and MTHFR genotype; mRNA; Mutation; Phenotype; Polymorphism; Transgenic mice *and specific genes; for example: ob gene*
- GH, *see* Growth hormone
- GHBP (growth hormone-binding protein), BMI, IGFBP-3, and high-affinity, as predictors of GHBP response to GH therapy of adult GH deficiency, 314-318
- GHRH, *see* Growth hormone-releasing hormone, GH response to
- GHRP-2 (growth hormone-releasing peptide-2), preservation of GH secretion in response to, in children on prednisone therapy, 585-589
- GHRP-6 (growth hormone-releasing peptide-6), GH response to, in normoponderal and overweight NIDDM subjects, 525-530
- Girls  
 adolescent, apo E polymorphism and changes in TC and LDL-C in, 285-290  
 with TS, GH therapy effects on lipid and CHO metabolism in, 7-14  
*see also* Sex
- $\beta$  (beta)-GlcA-ase ( $\beta$ -D-glucuronidase), activity of RBC membrane, in NIDDM, 817-821
- $\alpha$  (alpha)-D-Glc-ase ( $\alpha$ -D-glucosidase), activity of RBC membrane, in NIDDM, 817-821
- $\beta$  (beta)-D-Glc-ase ( $\beta$ -D-glucosidase), activity of RBC membrane, in NIDDM, 817-821

- $\beta$  (beta)-GlcNAx-ase (*N*-Acetyl- $\beta$ -L-glucuronidase), activity of RBC membrane, in NIDDM, 817-821
- Gliclazide, effects of metformin versus, on clinical profile and lipid peroxidation markers in NIDDM, 897-903
- Gln, *see* Glutamine
- Globulin  
F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases and, 521  
thyroxine-binding, in TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients, 325-326  
*see* IgG; IgM
- Glomerular filtration rate, effects of long-term valproic acid therapy on, 75
- GLP-1, *see* Glucagon-like peptide-1
- Glu (glutamic acid), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- Glucagon (hyperglycemic factor; hyperglycemic-glycogenolytic factor) amitrax and BTS 27271 effects on secretion on,  $\alpha_{2D}$ -ARs and, 1461-1469  
CGRP effects on, independently of insulin and, 603-610  
in IDDM, pramlintide effects on glycemic control and PP, 935-941  
LA preventing hyperglycemic response to, in fasted nondiabetic and STZ-DM subjects, 505-506  
plasma, *see* Plasma glucagon  
serum, effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1007  
in stress hormone infusion, impact of acute epinephrine discontinuation on hepatic glucose metabolism during, 910-914  
in whole-body lipolysis, hypoosmolality effects on, 474, 475  
*see also* Glucagon-like peptide-1
- Glucagon-like peptide-1 (GLP-1)  
in IDDM, 134-137  
immunoblockade of, with MoAbs in conscious subjects, insulin response to intragastric glucose and, 41-46  
*see also* Glucagon-like peptide-1 antagonist; Glucagon-like peptide-1-Gly8 and entries beginning with terms: Dipeptidyl peptidase IV
- Glucagon-like peptide-1 (GLP-1) antagonist, glycosylated exendin(9-39) as, properties of, 716-724
- Glucagon-like peptide-1 (GLP-1)-Gly8, long-lasting hypoglycemic effects of, in NIDDM, 252-258
- Glucocorticoids, effects of short-term administration of, on hypothalamic and pituitary galanin synthesis, 792-796
- Glucokinase mRNA (messenger ribonucleic acid), glucose exposure effects on, 320-321
- Gluconate, effects of, on hCG-stimulated androgen secretion and cAMP levels in Leydig tumor cells, 697
- Gluconeogenesis  
aortopulmonary shunts and, 1085  
LA effects on, in fasting nondiabetic and STZ-DM subjects, 504-510
- Glucosamine, insulin resistance in NIDDM induced by, differential effects of troglitazone and D-chiroinositol on, 1418-1423
- Glucose  
arterial contractions and PKC-induced intracellular Ca release and, 1015-1022  
BM 17.0744 effects on adipocyte uptake and consumption of, 36  
in CHD, *see* Glucose in CHD  
in conscious subjects, *see* Glucose in conscious subjects  
in Cr-deficient diet, 1064  
in diabetic depancreatized subjects, production of, dependent on peripheral insulin 153-160  
effects of, on plasma concentrations and urinary excretion of uridine and purine bases, 338-341  
effects of local sympathetic blockade on, 1573-1583
- Glucose (*Continued*)  
effects of long-term exposure of islets of Langerhans to supraphysiologic concentrations of, on insulin mRNA, 319-323  
effects of placental 11 $\beta$ -HSD inhibition on metabolism of, and on 11 $\beta$ -HSD regulation in adult offspring, 1584-1588  
erythrocytes treated with, effects of vitamin E and NAC on PS externalization and induction of coagulation in, 957-959  
exercise and, *see* Glucose, exercise and  
fasting, *see* Fasting glucose  
in GH-deficient adults, GH therapy effects on, 310, 311  
hepatic, *see* Hepatic glucose metabolism  
and insulin-induced internal carotid artery vasodilation, 1472  
insulin release and secretion and, *see* Glucose, and insulin release and secretion  
KRP-297 effects on impaired uptake of, in SM of obese insulin-resistant subjects, 1450-1454  
oxidation of, *see* Oxidation, glucose  
in PCOS, metformin-induced resumption of normal menses and, 512, 516  
plasma, *see* Plasma glucose  
reduced FiO<sub>2</sub> effects on metabolism of maternal, in pregnancy, 738-744  
and relationship between serum leptin, IGF-I, IGFBP-1, and IGF-BP-3, 841  
role of Ca and, in troglitazone effects on vascular reactivity, 125-130  
serum, *see* Serum glucose  
SM, *see* Skeletal muscle glucose  
in STZ-DM, Mg and vanadate effects on metabolism of, 725-731  
tissue-specific, aging-related changes in metabolism of, 1445-1449  
urinary excretion of, imidapril effects on, 1250  
in vascular smooth muscle, metformin and insulin effects on metabolism of, 1357-1360  
VAT accumulation and, 357  
*see also* Diabetes mellitus; Glucose-6-phosphatase; Glucose tolerance; Glucose transport; Hyperglycemia; Hypoglycemia; Intragastric glucose; Normoglycemia; Uridyldiphosphoglucose and entries beginning with elements: Gluc-, Glyc-
- Glucose, exercise and  
AA and glucose effects on exercise-induced gut and SM proteolysis, 161-166  
effects of chromium picolinate supplementation on glucose metabolism in exercising older men and women, 546-553  
and metabolic adaptations to HF diet, 1513, 1515  
PP glucose in exercising Mexican and non-Hispanic women, 973
- Glucose, and insulin release and secretion  
FA-stimulated insulin secretion and, 25  
glucose stimulation of FFA inhibition of insulin release in insulin resistance, 1314-1317  
S<sub>1</sub> and, and glucose effectiveness in nondiabetic offspring of NIDDM subjects, 978-983
- Glucose in CHD  
and arterial glucose concentrations with aortopulmonary shunts after fast, 1082-1088  
Trp64Arg variant of  $\beta_3$ -AR gene and, 653  
whole-body uptake of, 855
- Glucose in conscious subjects  
CGRP effects on, 605-606  
dose-response relationships of insulin to fluxes in, 965-970
- Glucose-6-phosphatase (G6Pase) mRNA (messenger ribonucleic acid), renal, effects of dexamethasone and insulin on levels of, 1052-1056
- Glucose-6-phosphate (G6P) in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1130, 1131
- Glucose tolerance  
high-sucrose diet with EPA-E ester and/or lard effects on, 1092

Glucose tolerance (*Continued*)

- Ile-thiazolidide effects on, 385-389
- metformin effects on insulin resistance and, in obesity, 701-706
- in NIDDM, effects of red wine, tannic acid, and ethanol on, 1179-1183
- see also* Impaired glucose tolerance; Intraperitoneal glucose tolerance test; Intravenous glucose tolerance test; Meal tolerance test; Oral glucose tolerance test

## Glucose transport

- in adipocytes, *see* Glucose transport in adipocytes
- insulin-mediated, in NIDDM with CAD, ATP-sensitive K channels in, 432-436
- see also* GLUT1; GLUT1 mRNA; GLUT2 mRNA; GLUT3 mRNA; GLUT3 protein; GLUT4; GLUT4 mRNA

## Glucose transport in adipocytes

- in exogenous hyperinsulinemia, 468
- masoprocol effects on, 411-414

 $\alpha$  (alpha)-D-Glucosidase ( $\alpha$ -D-Glc-ase), activity of RBC membrane, in NIDDM, 817-821 $\beta$  (beta)-D-Glucosidase ( $\beta$ -D-Glc-ase), activity of RBC membrane, in NIDDM, 817-821 $\alpha$  (alpha)-Glucosidase inhibitor preventing and reversing metabolic abnormalities in obese diabetic subjects, 347-354 $\beta$  (beta)-D-Glucuronidase ( $\beta$ -GlcA-ase), activity of RBC membrane, in NIDDM, 817-821Glucuronide, androsterone and 17 $\beta$ -diol-, effects of long-term exercise induced-weight loss in young identical male twins on, 1120-1127

## GLUT1, paralyzed SM, FES exercise effects on, 1409-1413

## GLUT1 mRNA (messenger ribonucleic acid)

- in placenta, hypoxemia effects on abundance of, 743
- regulation of brain glucose, by O<sub>2</sub> and glucose deprivation, 422-431
- GLUT2 mRNA (messenger ribonucleic acid), effects of exposure to supraphysiologic glucose concentrations on, 320-321

## GLUT3 mRNA (messenger ribonucleic acid)

- loss of, in skeletal muscle, 876-880
- in placenta, hypoxemia effects on abundance of, 743
- regulation of brain glucose, by O<sub>2</sub> and glucose deprivation, 422-431

## GLUT3 protein, loss of, in SM, 876-880

## GLUT4

- dexamethasone effects on, 1131-1132
- paralyzed SM, FES exercise effects on, 1409-1413

GLUT4 mRNA (messenger ribonucleic acid), effects of PPAR $\gamma$  on, 788

## Glutamate, plasma and erythrocyte, circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460

## Glutamic acid (Glu), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024

## L-Glutamic acid, and leucine kinetics, 1379

## Glutamine (Gln)

- and L-NAME-NO pathway in endotoxemia-induced muscular hypercatabolism, 190-193
- plasma and erythrocyte, circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460

## Glutathione (GSH)

- RBC, NIDDM with angiopathy, 1483
- see also* Glutathione in STZ-DM

## Glutathione peroxidase (GSH-Px) in STZ-DM, lithium effects on, 561

## Glutathione (GSH) in STZ-DM

- lithium effects on, 561
- plasma nerve, 444, 445

## Gluteal adipocytes in transsexuals, effects of cross-sex hormone therapy on lipolytic activity of, 1371-1377

Gly, *see* Glycine

## Glycated Hb (hemoglobin)

- narrow therapeutic window of, 1498-1502
- and RBC lipid peroxidation in NIDDM, 205-209

## Glycation

- effects of HDL, on HDL oxidation susceptibility and its C efflux capacity, 139-143

*see also* Glycated HbGlycemic control, *see specific antiglycemic agents*Glycerides, *see* Triglyceride(s)

## Glycerol

- blood, CGRP effects on, 605, 607
- effects of acute epinephrine discontinuation on hepatic uptake of, 913
- TG incorporation of, in obesity, BC/SKF38393 effects on, 1035
- see also* Plasma glycerol

## Glycine (Gly)

- effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- and leucine kinetics, 1379
- long-lasting hypoglycemic effects of GLP-1-Gly8 in NIDDM, 252-258

## Glycogen

- hepatic, in nutritionally induced NIDDM, 1550
- in hyperinsulinemia, 335
- SM, *see* Skeletal muscle glycogen
- in STZ-DM, effects of Mg and vanadate on, 729

## Glycogen synthase, SM, in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1131

## Glycogenolysis, aortopulmonary shunts and, 1085

## Glycohydrolases, activity of erythrocyte membrane, in NIDDM, 817-821

## Glycolysis

- leukocyte lactate output and, in sepsis and ex vivo blood, 779-785
- in STZ-DM, effects of Mg and vanadate on, 729

## Glycosyl phosphatidylinositol (GPI), HS and, 1223-1224

## Glycosylated exendin(9-39), properties of, 716-724

## Glycosylated Hb (hemoglobin) in NIDDM

- acute effects of adrenergic-mediated ischemia on, 496
- with angiopathy, 1482
- NE-mediated vasoconstriction and, 1538
- with nephropathy, 1098

## Glypican mRNA (messenger ribonucleic acid), northern blot of, HS and, 1224

GMP (guanosine monophosphate), *see* cGMPGonadotropin, *see* Human chorionic gonadotropin

## Gout, lipids in Taiwanese aborigines with, 131-133

## G6P (glucose-6-phosphate) in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1130, 1131

## G6Pase (glucose-6-phosphatase) mRNA (messenger ribonucleic acid), renal, effects of dexamethasone and insulin on levels of, 1052-1056

## GPI (glycosyl phosphatidylinositol), HS and, 1223-1224

Growth, fetal, effects of reduced FiO<sub>2</sub> on, 738-744Growth factors, *see specific growth factors*

## Growth hormone (GH)

- NO modulating GH-releasing activity of Hexarelin in young and old subjects, 176-182
- response of, to GHRP-6 by normoponderal and overweight NIDDM subjects, 525-530
- see also* Growth hormone, release and secretion of; Growth hormone, therapy with; Growth hormone-releasing hormone, GH response to

## Growth hormone (GH), release and secretion of

- in elderly women, relationship between AT, serum lipids and, 1424-1431
- in older men, *see* Older men, GH secretion in

- Growth hormone (GH), release and secretion of (*Continued*)  
 preservation of, in response to GHRP-2 in children on prednisone therapy, 585-589  
 in uremic subjects on CAPD, long-term effects of rhEPO on, 210-216
- Growth hormone (GH), therapy with  
 effects of, on CMA-induced renal N wasting, renal phosphate depletion, and renal Mg wasting, 763-770  
 in girls with TS, effects of, on lipid and CHO metabolism in, 7-14  
*see also* Growth hormone, therapy of adult GH deficiency with
- Growth hormone (GH), therapy of adult GH deficiency with, 308-318  
 effects of GH withdrawal and, on insulin secretion, 1387-1396  
 individualized low-dose, of childhood-onset deficiency, 1003-1010  
 predictors of GHBP response to, 314-318  
 sex and response to, 308-313
- Growth hormone-binding protein, *see entries beginning with terms:*  
 Insulin-like growth factor-binding protein
- Growth hormone deficiency, *see* Growth hormone, therapy of adult GH deficiency with; Hypopituitarism
- Growth hormone-releasing hormone (GHRH), GH response to  
 in normoponderal and overweight NIDDM subjects, 525-530  
 in obesity, 1152-1156  
 in uremic subjects on CAPD, long-term effects of rhEPO on, 210-216
- Growth hormone-releasing peptide-2 (GHRP-2), preservation of GH secretion in response to, in children on prednisone therapy, 585-589
- Growth hormone-releasing peptide-6 (GHRP-6), GH response to, in normoponderal and overweight NIDDM subjects, 525-530
- GSH, *see* Glutathione
- GSH-Px (glutathione peroxidase) in STZ-DM, lithium effects on, 561
- Guanosine monophosphate, *see* cGMP
- Guanylate cyclase (GC) inhibitors, effects of, on hCG-stimulated androgen production in Leydig tumor cells, 695
- Gut  
 E and NE clearance by, in conscious subjects, 259-263  
 effects of AAs and glucose on exercise-induced gut muscle proteolysis, 161-166
- Hb (hemoglobin)  
 glyated, *see* Glycated Hb  
 and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 782  
 in uremic subjects on CAPD, long-term rhEPO effects on, 211  
*see also* Hb in NIDDM
- Hb (hemoglobin) in NIDDM  
 glyated, and erythrocyte lipid peroxidation, 205-209  
 glycosylated, *see* Glycosylated Hb in NIDDM
- HbA<sub>1</sub> (hemoglobin A<sub>1</sub>)  
 in childhood-onset IDDM with CAD, 532, 533  
 in STZ-DM, 444
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>)  
 in diabetic retinopathy, 1173, 1176  
 and F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases, 521  
 GH therapy effects on, *see* HbA<sub>1c</sub>, GH therapy effects on  
 in obesity, association of serum leptin and serum uric acid concentrations in, 678  
*see also* HbA<sub>1c</sub> in IDDM; HbA<sub>1c</sub> in NIDDM; HbA<sub>1c</sub> in PCOS
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>), GH therapy effects on  
 and effects of GH therapy withdrawal on, 1390  
 in GH-deficient adults, 310, 311, 1390  
 in TS, 9-11
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>) in IDDM  
 and octreotide effects on endothelial dysfunction in IDDM, 1237  
 and urinary excretion of apo A fragments, 370
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>) in NIDDM  
 and activity of RBC membrane glycohydrolases, 818  
 cochlear dysfunction and, 1347, 1348  
 LDL composition and metabolism and, 119, 121  
 with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 metformin versus gliclazide effects on, 899  
*rad* gene polymorphism and, 174  
 serum SSAO activity and, 114, 115  
 and troglitazone effects on AT distribution, 1103, 1104
- HbA<sub>1c</sub> (hemoglobin A<sub>1c</sub>) in PCOS  
 metformin-induced resumption of normal menses and, 512  
 and PAI as risk factor for miscarriage, 1590
- HBF, *see* Hepatic blood flow
- HBV (hepatitis B virus) infection, vitamin E in, 87
- HC (high-cholesterol) diet, and  $\omega$ -3 PUFA effects on cardiac function recovery after cold storage of heart, 1203
- hCG, *see* Human chorionic gonadotropin
- HCL, *see* Hypercholesterolemia
- HCO<sub>3</sub> (bicarbonate), aortopulmonary shunts and, 1084
- Hct, *see* Hematocrit
- HCV (hepatitis C virus) infection, vitamin E in, 87
- Hcy, *see* Homocysteine
- HD (hemodialysis) *see* End-stage renal disease, HD for
- HDL(s), *see* High-density lipoprotein(s)
- HDL-C, *see* High-density lipoprotein-cholesterol
- HDL<sub>1</sub>, *see* Lipoprotein(a)
- HDL<sub>2</sub>, *see* High-density lipoprotein<sub>2</sub>
- HDL<sub>2</sub>-C, *see* High-density lipoprotein<sub>2</sub>-cholesterol
- HDL<sub>3</sub>, *see* High-density lipoprotein<sub>3</sub>
- HDL<sub>3</sub>-C, *see* High-density lipoprotein<sub>3</sub>-cholesterol
- Heart  
 C-lowering effects of unsaturated fat on, 201  
*see also* Coronary heart disease; Heart failure; Heart rate; Left ventricular mass; Myocardial infarction and *entries beginning with element:* Card-
- Heart failure, and altered SM purine and glycogen metabolism during exercise, 484-488
- Heart rate (HR)  
 aortopulmonary shunts and, 1084  
 BC/SKF38393 effects on LPL activity and TGs in, 1036  
 CGRP effects on, in conscious subjects, 607  
 chronic smoking effects on, 240  
 effects of gut and hepatic clearance of E and NE on, 261  
 effects of local sympathetic blockade on, 1573  
 in exercise, *see* Heart rate in exercise  
 and HTN, *see* Heart rate, and HTN  
 imidapril effects on, 1250  
 and insulin-induced internal carotid artery vasodilation, 1472  
 in malnourished older cancer subjects, 292, 294, 295  
 T<sub>3</sub> effects on, 1605  
 variability of, in lean and obese subjects, effects of different insulin infusion rates on, 755-762
- Heart rate (HR), and HTN  
 in acute hyperinsulinemia, 888  
 essential HTN, effects of long-term lisinopril therapy on, 1257
- Heart rate (HR) in exercise  
 acipimox and exercise effects on HR, 247  
 and age-related blunting of GH secretion, SRIH tone and, 667  
 heart failure and, 485
- [11<sup>c</sup>]-HED ([11<sup>c</sup>]-*meta*-hydroxyephedrine), PET with, in assessment of cardiac sympathetic dysinnervation in IDDM, 92-101
- Height  
 of cirrhotic subjects, 374  
 of exercising subjects, *see* Height of exercising subjects

- Height (*Continued*)  
 of HCL subjects, 57, 59  
 and HPA axis and SNS activities, 396  
 of hyperinsulinic subjects, sex hormones and, 108, 110  
 of NIDDM-prone subjects, and peripheral tissue glucose uptake after OGTT, 81  
 of NIDDM subjects, with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 of nondiabetic offspring of NIDDM subjects, 979  
 race and, *see* Height, race and ethnicity and  
 and splanchnic utilization of enteral alanine, 916  
 and Trp64Arg variant of  $\beta_3$ -AR gene, 565
- Height, race and ethnicity and  
 low serum insulin and, 1217  
 and racial differences in PP TGs, postheparin lipase, and hepatic TG lipase, 750
- Height of exercising subjects  
 and age-related blunting of GH secretion during exercise, 666  
 and metabolic adaptation to HF diet, 1510  
 of older exercising men and women, 549, 1476  
 of weight-reduced men, 17  
 young women, timing of exercise and diet composition effects on substrate utilization and, 1597
- Hematocrit (Hct)  
 C-lowering effects of unsaturated fat on, 201  
 in STZ-DM, 774  
 in uremic subjects on CAPD, long-term effects of rhEPO on, 211
- Hemochromatosis, vitamin E in, 87
- Hemodialysis, *see* End-stage renal disease, HD for
- Hemodynamic function  
 in STZ-DM, echocardiography of, 775  
*see also* Blood flow; Blood pressure; Heart rate
- Hemoglobin, *see entries beginning with acronym: Hb*
- Heparan sulfate (HS), antimutagenic, arising from mesangial cell-surface proteoglycans, 1220-1229
- Heparin, *see* Postheparin lipase
- Hepatic alanine (Ala), CGRP effects on, in conscious subjects, 605
- Hepatic blood flow (HBF)  
 CGRP effects on, in conscious subjects, 605  
 hepatic clearance of E and NE and, 261  
 imidapril effects on, 1249
- Hepatic cholesterol (C), PV effects on, 619, 622
- Hepatic cholesterol (C) 7 $\alpha$ -hydroxylase, regulation of hepatic sterol 27-hydroxylase and, compared, 1542-1548
- Hepatic clearance of E and NE in conscious subjects, 259-263
- Hepatic Cu (copper), effects of unsaturated fat on, 201
- Hepatic fatty acids (FAs), sesamin effects on oxidation of, 1303-1313
- Hepatic Fe (iron), C-lowering properties of unsaturated fat and levels of, 200-204
- Hepatic free fatty acids (nonesterified fatty acids; FFAs), CGRP effects on, in conscious subjects, 605
- Hepatic  $\beta$ -galactoside  $\alpha$ (alpha)2,6-sialyltransferase (2,6-ST) mRNA (messenger ribonucleic acid), effects of chronic alcohol intake on, 797-803
- Hepatic glucose metabolism  
 nonoxidative, in cirrhosis, 1260-1266  
 during stress hormone infusion, effects of acute epinephrine discontinuation on, 910-914
- Hepatic glutathione (GSH), lithium effects on, in STZ-DM, 561
- Hepatic glutathione peroxidase (GSH-Px), lithium effects on, in STZ-DM, 561
- Hepatic glycogen in nutritionally induced NIDDM, 1550
- Hepatic insulin  
 in diabetic depancreatized subjects, 156  
 incretin effects on, following orthotopic pancreas transplantation, 645-650
- Hepatic lactate  
 CGRP effects on, in conscious subjects, 605  
 effects of acute E discontinuation on uptake of, 913
- Hepatic lipid(s)  
 PV effects on, 619-621  
 sesamin effects on, 1309
- Hepatic lipid peroxide (LPO) in STZ-DM, lithium effects on, 561
- Hepatic nuclei, influence of cortisol, T<sub>3</sub>, and insulin on Trp binding to, 144-152
- Hepatic phosphoenolpyruvate carboxylase (PEPCK) in nutritionally induced NIDDM, 1550
- Hepatic phospholipids (PLs), sesamin effects on, 1309
- Hepatic sterol 27-hydroxylase, regulation of hepatic cholesterol 7 $\alpha$ -hydroxylase and, compared, 1542-1548
- Hepatic superoxide dismutase (SOD) in STZ-DM, lithium effects on, 561
- Hepatic triacylglycerol (TAG), sesamin effects on, 1309
- Hepatic triglyceride(s) (TGs) in dyslipidemia, BC/SKF38393 effects on, 1035
- Hepatic triglyceride lipase, PP, in young men, racial differences in, 749-757
- Hepatic uridyldiphosphoglucose (UDPG), and hepatic nonoxidative glucose metabolism, 1260-1266
- Hepatitis B virus (HBV) infection, vitamin E in, 87
- Hepatitis C virus (HCV) infection, vitamin E in, 87
- Hepatocytes, DM and starvation effects on metabolism of [2,3-<sup>13</sup>C]-SAD in, 102-106
- HERITAGE Family Study of total body fat and abdominal AT response to exercise, 1278-1286
- Heterozygous familial hypercholesterolemia (FH), LDL oxidizability before and after LDL apheresis in, 881-886
- Hexanoate, oxidation of, in liver and SM with HF diet, 1234
- Hexarelin, NO modulating GH-releasing activity of, in young and old subjects, 176-182
- HF diet, *see* High-fat diet
- High-affinity growth hormone-binding protein (GHBP), BMI, IGFBP-3 and, as predictors of GHBP response to GH therapy of GH-deficient adults, 314-318
- High-cholesterol (HC) diet, and  $\omega$ -3 PUFA effects on cardiac function recovery after cold storage of heart, 1203
- High-density lipoprotein(s) (HDL;  $\alpha$ -lipoprotein)  
 in adult hypopituitarism, 1059  
 apo E desialylation effects on its binding to, 1184-1192  
 and decrease in SM capillary density in men, 1268  
 effects of triphasic OCs with desogestrel or LN on apo A-I-containing particles of, 658-664  
 ERT effects on, 228  
 in GH-deficient adults, effects of GH therapy and its withdrawal on, 1390  
 glycation effects on oxidation or C efflux capacity of, 139-143  
 in HCL, simvastatin effects on, 69, 70  
 in HTN, 888  
 in hyperinsulinemia, 110  
 in MHL, relationship between PP LpB:CIII particle changes and subpopulation of, 60-67  
 in obesity with hyperuricemia, 678, 679  
 plasma, in human apo A-II transgenic mice, 416  
*see also* High-density lipoprotein-cholesterol
- High-density lipoprotein-cholesterol (HDL-C)  
 in AIDS, 1526-1528  
 diet effects on, *see* High-density lipoprotein cholesterol, C-lowering diet effects on  
 effects of testosterone and exercise on concentrations of, 1493-1497  
 effects of triphasic OCs with desogestrel or LN on, 659  
 in essential HTN, 888

- High-density lipoprotein-cholesterol (HDL-C) (*Continued*)  
 exercise and, *see* High-density lipoprotein-cholesterol, exercise and  
 in FCHL, gemfibrozil and lovastatin effects on, 48, 49, 51  
 GH therapy effects on, in TS, 10, 11; *see also* High-density lipoprotein-cholesterol in GH-deficient adults  
 in gout, 132  
 in HCL, simvastatin effects on, 70  
 in HTG and NTG, CAD and, 303  
 in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438  
 in hypogonadal men, T substitution and, 592, 594  
 in IDDM, *see* High-density lipoprotein-cholesterol in IDDM  
 LDL apheresis and concentrations of, 883  
 in MHL, 62, 63, 65  
 in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM  
 in normolipidemia with peripheral vascular resistance, 1363-1365  
 in older women, *see* High-density lipoprotein-cholesterol in older women  
 in PCOS, *see* High-density lipoprotein-cholesterol in PCOS  
 plasma, *see* Plasma high-density lipoprotein-cholesterol  
 PP, *see* Postprandial high-density lipoprotein-cholesterol  
 in premenopausal women, and association of plasma leptin with plasma PAI-1, 961, 962  
 SSAO activity and, 114, 115  
 TFAs and, in young women, 873  
 Trp64Arg variant of  $\beta_3$ -AR gene and, *see* High-density lipoprotein-cholesterol, Trp64Arg variant of  $\beta_3$ -AR gene and  
 VAT and, *see* High-density lipoprotein-cholesterol, VAT and  
 in young adults with MI, 1158, 1159  
*see also* High-density lipoprotein<sub>2</sub>-cholesterol; High-density lipoprotein<sub>3</sub>-cholesterol
- High-density lipoprotein cholesterol (HDL-C), C-lowering diets effects on  
 of campestanol/sitostanol mixture diet with variable fat intake, 577  
 of NCEP diet, 824  
 of soy protein with very low dietary C, 490-491
- High-density lipoprotein-cholesterol (HDL-C), exercise and  
 combined hyperlipidemia associated with muscle protein release and, 1520, 1521  
 and testosterone effects on HDL-C concentrations, 1493-1497  
*see also* High-density lipoprotein-cholesterol in exercising men; High-density lipoprotein-cholesterol in older exercising men and women
- High-density lipoprotein-cholesterol (HDL-C), Trp64Arg variant of  $\beta_3$ -AR gene and  
 in CHD, 653  
 in insulin resistance, 1363
- High-density lipoprotein-cholesterol (HDL-C), VAT and  
 age and, and LDL particle size and, 1324, 1325  
 VAT accumulation and, 357
- High-density lipoprotein-cholesterol (HDL-C) in exercising men  
 middle-aged exercising men, AT-LPL activity and, 185  
 obese men, apo E genotype and exercise inducing increases in plasma HDL-C, 943-945  
 in weight-reduced men, 19  
*see also* High-density lipoprotein-cholesterol in older exercising men and women
- High-density lipoprotein-cholesterol (HDL-C) in GH-deficient adults  
 effects of GH therapy on, 310, 1393  
 effects of GH therapy withdrawal on, 1393
- High-density lipoprotein-cholesterol (HDL-C) in IDDM  
 childhood-onset IDDM with CAD, 532, 533  
 and urinary excretion of apo A fragments, 370
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM  
 glycosylated Hb and lipid peroxidation in NIDDM erythrocytes, 206
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM (*Continued*)  
 with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 metformin versus gliclazide effects on, 900  
 troglitazone effects on, 1104  
*see also* High-density lipoprotein-cholesterol in obese Japanese men with NIDDM
- High-density lipoprotein-cholesterol (HDL-C) in obese Japanese men with NIDDM  
 diet and exercise effects on, 643  
 with insulin resistance, *FABP2* gene polymorphism and, 656
- High-density lipoprotein-cholesterol (HDL-C) in obesity  
 insulin and obesity effects on HDL-C in PCOS, 171  
 in obese Japanese men with Trp64Arg variant of  $\beta_3$ -AR gene and *UCPI* gene mutation, 637, 638; *see also* High-density lipoprotein-cholesterol in obese Japanese men with NIDDM  
 serum leptin and serum uric acid concentrations and, 678
- High-density lipoprotein-cholesterol (HDL-C) in older exercising men and women  
 AT-LPL activity and, 185  
 differential effects of exercise and body composition on, 1477  
 exercise effects on concentration of HDL-C, 984-988
- High-density lipoprotein cholesterol (HDL-C) in older women  
 AT, GH secretion and, 1426, 1428  
*see also* High-density lipoprotein-cholesterol in older exercising men and women
- High-density lipoprotein-cholesterol (HDL-C) in PCOS  
 insulin and obesity effects on, 171  
 metformin-induced resumption of normal menses and, 512, 516
- High-density lipoprotein<sub>1</sub>, *see* Lipoprotein(a)
- High-density lipoprotein<sub>2</sub> (HDL<sub>2</sub>)  
 and decrease in SM capillary density in men, 1268  
 effects of triphasic OCs with desogestrel or LN on, 659  
*see also* High-density lipoprotein<sub>2</sub>-cholesterol
- High-density lipoprotein<sub>2</sub>-cholesterol (HDL<sub>2</sub>-C)  
 in FCHL, gemfibrozil and lovastatin effects on, 48, 49, 51  
 NCEP C-lowering diet effects on, 824  
 in young adults with MI, 1159  
*see also* High-density lipoprotein<sub>2</sub>-cholesterol in exercising men
- High-density lipoprotein<sub>2</sub>-cholesterol (HDL<sub>2</sub>-C) in exercising men  
 middle-aged men, AT-LPL activity and, 185  
*see also* High-density lipoprotein<sub>2</sub>-cholesterol in obese exercising men; High-density lipoprotein<sub>2</sub>-cholesterol in older exercising men
- High-density lipoprotein<sub>2</sub>-cholesterol (HDL<sub>2</sub>-C) in obese exercising men  
 diet and exercise effects on, 643  
 plasma, apo E genotype and exercise inducing increases in, 943-945
- High-density lipoprotein<sub>2</sub>-cholesterol (HDL<sub>2</sub>-C) in older exercising men  
 AT-LPL activity and, 185  
 exercise effects on, 985
- High-density lipoprotein<sub>3</sub> (HDL<sub>3</sub>)  
 and decrease in SM capillary density in men, 1268  
 effects of triphasic OCs with desogestrel or LN on, 659  
*see also* High-density lipoprotein<sub>3</sub>-cholesterol
- High-density lipoprotein<sub>3</sub>-cholesterol (HDL<sub>3</sub>-C)  
 in FCHL, gemfibrozil and lovastatin effects on, 48, 49, 51  
 NCEP C-lowering diet effects on, 824  
 in older exercising women, 985  
 in young adults with MI, 1159  
*see also* High-density lipoprotein<sub>3</sub>-cholesterol in exercising men
- High-density lipoprotein<sub>3</sub>-cholesterol (HDL<sub>3</sub>-C) in exercising men  
 obese men, 643, 944  
 older men, exercise effects on, 985



- High-fat diet (HF)  
 adaptation to, in endurance exercise, 1509-1517  
 simulation of O<sub>2</sub> consumption following addition of lipid substrates to liver and SM of subjects on, 1230-1235
- High-sucrose diet with EPA ester and/or lard, effects of, on insulin resistance and HTN, 1089-1095
- HindIII* gene, LPL, polymorphism of, in young MI adults, 1157-1161
- Hispanic Americans, *see* Race and ethnicity
- Histidine (His), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- L-Histidine (His), and leucine kinetics, 1379
- Histology, pancreas, in DM with obesity, acarbose effects on, 347-354
- HIV (human immunodeficiency virus) infection, plasma PAF-AH in, 1524-1531
- HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, *see* Lovastatin; Pravastatin; Simvastatin
- Homocysteine (Hcy)  
 in hyperlipidemia, and prediction of atherosclerotic CV disease, 1438 total, and nephropathy in NIDDM, 1096-1101  
*see also* Folate, Hcy and, and MTHFR genotype
- Hormone replacement therapy (HRT)  
 effects of gender and, on vascular reactivity, 227-232  
*see also* Hormone replacement therapy in postmenopausal women
- Hormone replacement therapy (HRT) in postmenopausal women  
 effects of, on vascular reactivity, 227-232  
 PP lipid metabolism enhanced by, 1193-1196  
 short-term HRT with MPA effects on LVM, IGF-I and, 1328-1331  
 VAT and, 1157
- Hostility, anger and, and VAT in postmenopausal women, 1146-1151
- HPA axis, *see* Hypothalamic-pituitary-adrenal axis
- HPRL, *see* Hyperprolactinemia
- HR, *see* Heart rate
- HRT, *see* Hormone replacement therapy
- HS (heparan sulfate), antimitogenic, arising from mesangial cell-surface proteoglycans, 1220-1229
- HSD, *see* 3 $\beta$ -Hydroxysteroid dehydrogenase; 11 $\beta$ -Hydroxysteroid dehydrogenase
- 5-HT (serotonin), long-term infusion of NE and, into VMH, effects of, on pancreatic islet function, 1287-1289
- HTG (hypertriglyceridemia), PP VLDL-C and chylomicron remnants in HTG men with and without CHD, 301-307
- HTN, *see* Hypertension
- Human chorionic gonadotropin (hCG)  
 insulin biphasic effect on ability of, to induce ovarian cysts, 995-1002  
 steroidogenesis in Leydig tumor cells stimulated by, effects of Cl and inorganic nitrate on, 693-700
- Human immunodeficiency virus (HIV) infection, plasma PAF-AH in, 1524-1531
- Human islet amyloid polypeptide (IAPP; amylin), expression of amyloid deposition in transgenic mice islets and in nude mice transplanted with human islets, compared, 448-454
- HX (hypoxanthine), *see* Plasma hypoxanthine
- Hydrocortisone, *see* Cortisol
- Hydroperoxides, plasma lipid, in STZ-DM, AMGN effects on, 1142
- $\beta$  (beta)-Hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone sulfate in PCOS
- $\beta$  (beta)-Hydroxybutyrate ( $\beta$ -OHB)  
 blood, CGRP effects on, in conscious subjects, 607  
 LA effects on, 508  
 and metabolic adaptation to HF diet in exercise, 1513  
 in whole-body lipolysis, hypoosmolality effects on, 474, 475
- 7 $\alpha$  (alpha)-Hydroxycholesterol, serum vitamin E and, in liver cirrhosis, 89
- [<sup>11</sup>C]-*meta*-Hydroxyephedrine ([<sup>11</sup>C]-HED), PET with, in assessment of cardiac sympathetic dysinnervation in IDDM, 92-101
- N*-[2-Hydroxyethyl]nicotinamide nitrate [ester] (nicorandil), effects of, on insulin-mediated glucose transport in NIDDM with CAD, 432-436
- 7 $\alpha$  (alpha)-Hydroxylase, hepatic cholesterol, regulation of hepatic sterol 27-hydroxylase and, compared, 1542-1548
- 11 $\beta$  (beta)-Hydroxylase, aging and activity of, 535-541
- 21 $\beta$  (beta)-Hydroxylase, aging and activity of, 535-541
- 27-Hydroxylase, hepatic sterol, regulation of hepatic cholesterol 7 $\alpha$ -hydroxylase and, compared, 1542-1548
- 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, *see* Lovastatin; Pravastatin; Simvastatin
- 17-Hydroxyprogesterone (17-OHP) in PCOS, 169
- 3 $\beta$  (beta)-Hydroxysteroid dehydrogenase (HSD), aging effects on activity of, 535-541
- 11 $\beta$  (beta)-Hydroxysteroid dehydrogenase (11 $\beta$ -HSD), placental, effects of inhibition of, on glucose metabolism and 11 $\beta$ -HSD regulation in adult offspring, 1584-1588
- 25-Hydroxyvitamin D (25OHD), serum, in older subjects, longitudinal changes in, 1028-1032
- Hypercatabolism, endotoxemia-induced muscular, L-NAME-NO pathway in, 190-193
- Hyperchloremic acidosis, chronic, renal N wasting, renal phosphate depletion, and renal Mg wasting induced by, GH therapy effects on, 763-770
- Hypercholesterolemia (HCL), 55-73  
 heterozygous familial, LDL oxidizability before and after LDL apheresis in, 881-886  
 relationship between PP LpB:CIII particles changes and HDL subpopulation in, 60-67  
 simvastatin effects on sterol absorption in, 68-73  
 stiffness of aortic wall in children with, 55-59
- Hyperendotelinemia, exogenous hyperinsulinemia and, 465-471
- Hyperglycemia  
 C-AD reversing inhibition of phosphoinositide synthesis in RPE cells induced by, and preventing reduction of MNCV in STZ-DM, 827-833  
 LA preventing hyperglycemic response to glucagon in fasting nondiabetic and STZ-DM subjects, 505-506  
 in NIDDM, *see* Hyperglycemia in NIDDM  
 thermogenic effect of, during lipid infusion, 278-284
- Hyperglycemia in NIDDM  
 acute, cochlear dysfunction in NIDDM independently of neuropathy and, 1346-1350  
 LDL oxidation, meal-induced oxidative stress and, 1503-1508
- Hyperglycemic factor, *see* Glucagon
- Hyperhomocysteinemia in epileptic subjects on anticonvulsant therapy, MTHFR genotype and, 1047-1051
- Hyperinsulinemia  
 chronic physiologic, in conscious subjects, plasma FFAs, de novo lipogenesis, dyslipidemia and, 330-337  
 fasting, and prediction of atherosclerotic CV disease in hyperlipidemia, 1437-1444  
 HTN and, *see* Hypertension, hyperinsulinemia and  
 temporal association between obesity and, in children, adolescents, and young adults, 928-934  
*see also* Insulin resistance; Plasma endothelin-1 in hyperinsulinemia
- Hyperinsulinemic hypoglycemia, neonatal, effects of insulin counter-regulatory hormones on, 568-574
- Hyperinsulinism, sex hormones and, in young African American adults, 107-112
- Hyperlipidemia  
 BM 17.0744 effects on, 34-40  
 combined, *see* Combined hyperlipidemia  
 fasting hyperinsulinemia and prediction of atherosclerotic CV disease in, 1437-1444

- Hyperlipidemia (*Continued*)  
*see also* Hypercholesterolemia; Hyperlipoproteinemia; Hypertriglyceridemia
- Hyperlipoproteinemia, mixed, relationship between PP LpB:CIII particles changes and HDL subpopulation in, 60-67
- Hyperparathyroidism, primary, RAA in, before and after surgery, 298-300
- Hyperprolactinemia (HPRL)  
 effects of, on CT secretion, 221-226  
 verapamil for, 1351-1356
- Hypertension (HTN), 1-6  
 in childhood-onset IDDM with CAD, 532  
 EPA-E ester effects on, 1089-1095  
 essential, *see* Essential hypertension  
 in FCHL, 47  
 hyperinsulinemia, *see* Hypertension, hyperinsulinemia and  
 in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438  
 insulin release and secretion in, 3-6  
 insulin resistance in pregnancy and, 1339-1342  
 and MI in young adults, 1159  
 in NIDDM with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 relationship between apo A phenotype and troglitazone-induced Lp(a) increase in, 1-2
- Hypertension (HTN), hyperinsulinemia and  
 effects of acute hyperinsulinemia on urinary nitrite/nitrate excretion and plasma ET-1 levels in essentially hypertensive men, 887-891  
 exogenous hyperinsulinemia, 465-471  
 in normal subjects, as predictor of NIDDM, CHD, and HTN, 989-994
- Hyperthyroidism, metabolic effects of FFA decrease with acipimox in, 1318-1321
- Hypertriglyceridemia (HTG) in men with and without CHD, PP VLDL-C and chylomicron remnants in, 301-307
- Hypertrophy of subcutaneous adipocytes, CHD and, 355-362
- Hyperuricemia  
 lipid abnormalities in Taiwanese aborigines with, 131-133  
 in obesity, serum leptin associated with serum uric acid concentrations in, 677-680
- Hypocholesterolemic properties, *see* Cholesterol-lowering diet and specific hypocholesterolemic agents
- Hypocortisolemia, effects of, on work capacity, 392
- Hypoglycemia  
 and effects of local sympathetic blockade on BF and glucose uptake, 1575-1583  
 GH responses to, in uremic subjects on CAPD, long-term effects of rhEPO on, 213  
 LA-induced, in fasting STZ-DM and nondiabetic subjects, 504-510  
 metabolic effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults during, 1003-1010  
 neonatal hyperinsulinemic, effects of insulin counterregulatory hormones on, 568-574
- Hypoglycemic agents, *see specific hypoglycemic agents*
- Hypogonadal men, effects T substitution modes on serum lipids and Lps in, 590-596
- Hypoosmolality, effects of, on whole-body lipolysis, 472-476
- Hypopituitarism  
 adult, VLDL apo B-100 kinetics in, 1057-1062  
*see also* Growth hormone, therapy of adult GH deficiency with
- Hypothalamic galanin (GAL), effects of short-term glucocorticoid administration on synthesis of, 792-796
- Hypothalamic-pituitary-adrenal (HPA) axis, 390-399  
 activities of SNS and, in Pima Indians, 395-399  
 exercise and reduced cortisol effects on, 390-394
- Hypothalamus  
 ventromedial, effects of long-term infusion of NE and 5-HT into, on pancreatic islet function, 1287-1289  
*see also entries beginning with term:* Hypothalamic
- Hypothyroidism, congenital, effects of L-T<sub>4</sub> for, on apo concentrations in infants with, 1343-1345
- Hypoxanthine, *see* Plasma hypoxanthine
- Hypoxemia, *see* Placenta, hypoxemia effects on
- Hypoxia, effects of, on brain glucose GLUT1 and GLUT3 mRNA, 422-431
- IAPP (islet amyloid polypeptide), *see* Amylin
- IBD (inflammatory bowel disease), metabolic features of, 952-956
- IDDM, *see* Insulin-dependent diabetes mellitus
- Identical male twins, young, effects of long-term exercise-induced weight loss in, on sex hormones, 1120-1127
- IDL, *see* Intermediate-density lipoprotein
- IGF-I, *see* Insulin-like growth factor-I
- IGFBP, *see entries beginning with terms:* Insulin-like growth factor-binding protein
- IgG (immunoglobulin G;  $\gamma$ -globulin), prediction of atherosclerotic CV disease and, 1438
- IgM (immunoglobulin M) in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438, 1440, 1442
- IGT, *see* Impaired glucose tolerance
- IL-1 $\beta$  (interleukin-1 $\beta$ ), release of, by mitogen-stimulated PBMCs of critically ill multiple-trauma victims, 1397-1401
- IL-6 (interleukin-6), release of, by mitogen-stimulated PBMCs of critically ill multiple-trauma victims, 1397-1401
- Ile, *see* Isoleucine
- Imidapril, S<sub>1</sub> improvement by, through enhancement of signal transduction via IRS proteins and improvement of vascular resistance, 1248-1255
- IM-IVGTT (insulin-modified intravenous glucose tolerance test), beta cell function during, C-peptide minimal model in assessment of, 1162-1166
- Immunoblockade of GLP-1 by MoAbs in conscious subjects, insulin response to intragastric glucose and, 41-46
- Immunoglobulin G (IgG; gamma-globulin), and prediction of atherosclerotic CV disease, 1438
- Immunoglobulin M (IgM), and prediction of atherosclerotic CV disease, 1438, 1440, 1442
- Impaired glucose tolerance (IGT)  
 hyperinsulinemia and, 989-994  
 in PCOS, 169  
 in TS, GH therapy effects on, 9, 11
- Incretin, preserving effects of, after orthotopic pancreas transplantation, 645-650
- Individualized low-dose growth hormone (GH) therapy of childhood-onset GH deficiency in adults, metabolic effects of, 1003-1010
- Indomethacin  
 effects of, on GH-releasing activity of Hexarelin, 178  
*ob* gene suppressed by, 786-791
- INF- $\alpha$  (interferon- $\alpha$ ) in AIDS, 1527
- Infants, congenital hypothyroidism in, effects of L-T<sub>4</sub> for, on apo concentrations, 1343-1345
- Infarction, *see* Myocardial infarction
- Infections  
 HIV, plasma PAF-AH in, 1524-1531  
 respiratory, tissue distribution and turnover of [<sup>3</sup>H]riboflavin during, 1608-1611  
*see also* Sepsis
- Inflammatory bowel disease (IBD), metabolic features of, 952-956
- Inorganic nitrate, effects CI and, on hCG-stimulated steroidogenesis in Leydig tumor cells, 693-700

- Inorganic phosphate (orthophosphate;  $P_i$ )  
 plasma, glucose effects on, 339-341  
 urinary excretion of, AA effects on, 1024-1026  
 xylitol and F effects on, 523
- Inspired oxygen, reduced fraction of, in pregnancy, effects of, on fetal growth and maternal glucose metabolism, 738-744
- Insulin, 144-160, 603-617  
 biphasic effect of, on hCG ability to induce ovarian cysts, 995-1002  
 cellular processing of insulin analogs and, compared, 611-617  
 CGRP effects in conscious subjects independently of glucagon and, 603-610  
 and chronic leptin administration effects on insulin-stimulated SM glucose, 671-676  
 and decrease in SM capillary density in men, 1268  
 dose-response relationships of, to glucose fluxes in conscious subjects, 965-970  
 and eating disorders, 218  
 effects of dexamethasone and, on renal G6Pase mRNA levels, 1052-1056  
 effects of different infusion rates of, on HR variability in lean and obese subjects, 755-762  
 effects of metformin and, on glucose metabolism in vascular smooth muscle, 1357-1360  
 exercise and, *see* Insulin, exercise and  
 GH and, *see* Insulin, GH and  
 hepatic, *see* Hepatic insulin  
 incretin effects on, following orthotopic pancreas transplantation, 645-650  
 internal carotid artery vasodilation induced by, 1472  
 in obesity, reduced GH response to GHRH and elevated, 1152-1156  
 in PCOS, *see* Insulin in PCOS  
 peripheral, in diabetic depancreatized subjects, glucose production dependent on, 153-160  
 plasma, *see* Plasma insulin  
 relationship of Trp64Arg variant of  $\beta_3$ -AR gene to total body fat but not to percent body fat and, in Thai subjects, 564-567  
 response of, to intragastric glucose, effects of immunoblockade of GLP-1 by MoAbs on, 41-46  
 serum, *see* Serum insulin  
 and Trp binding to hepatic nuclei, 144-152  
 VAT and, *see* Insulin, VAT and  
 in whole-body lipolysis, hypoosmolality effects on, 474, 475  
*see also* Hepatic insulin; Hyperinsulinemia; Hyperinsulinism; Insulin counterregulatory hormones; Insulin-dependent diabetes mellitus; Insulin-modified intravenous glucose tolerance test; Insulin mRNA; Insulin release and secretion; Insulin resistance; Insulin sensitivity; Non-insulin-dependent diabetes mellitus *and entries beginning with terms:* Insulin-like growth factor
- Insulin, exercise and  
 and metabolic adaptations to HF diet, 1513  
 PDH complex activation by exercise and, 865-869  
 PP insulin response to exercise by Mexican American and non-Hispanic women, 971-977
- Insulin, GH and  
 in obesity, reduced GH response to GHRH and elevated insulin, 1152-1156  
 in TS, GH therapy effects on insulin, 9, 11
- Insulin, VAT and  
 in postmenopausal women, 1147  
 and VAT accumulation, 357
- Insulin counterregulatory hormones, effects of, on neonatal hyperinsulinemic hypoglycemia, 568-574
- Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)  
 cardiac sympathetic dysinnervation in, PET with [ $^{11}C$ ]-HED in assessment of, 92-101
- Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus) (*Continued*)  
 childhood-onset, with CAD, LDL particle size and, 531-534  
 functional modification in umbilical cord ECs induced by IDDM plasma, 554-557  
 GLP-1 in, 134-137  
 leukocyte growth factor mRNA in DR of, 1174-1175  
 localized or minimal osteomyelitis of foot in, role of combined RI and MRI diagnosis of, in conservative management, 922-927  
 octreotide effects on endothelial dysfunction in, 1236-1240  
 pramlintide effects on glycemic control and PP glucagon concentrations in, 935-941  
 urinary excretion of apo A fragments in, 369-372
- Insulin-like growth factor-I (IGF-I)  
 AT, serum lipids, GH secretion and, in older men and women, 1426  
 in GH-deficient adults, GH therapy effects, 309, 315; *see also* Serum insulin-like growth factor-I in GH-deficient adults  
 octreotide effects on endothelial dysfunction in IDDM and, 1237  
 relationship between serum leptin and, 840-844  
 short-term MPA therapy effects on LVM and, 1328-1331  
 in uremic subjects on CAPD, long-term effects of rhEPO on, 211
- Insulin-like growth factor-binding protein-1 (IGFBP-1)  
 relationship between serum leptin and, 840-844  
 serum, effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1006, 1007
- Insulin-like growth factor-binding protein-3 (IGFBP-3)  
 AT, serum lipids, GH secretion and, in older men and women, 1426  
 BMI, high-affinity GHBP and, as predictors of GHBP response to GH therapy of GH-deficient adults, 314-318  
 MPA and, 1329, 1330  
 relationship between serum leptin and, 840-844
- Insulin-modified intravenous glucose tolerance test (IM-IVGTT), beta cell function during, C-peptide minimal model in assessment of, 1162-1166
- Insulin mRNA (messenger ribonucleic acid), effects of long-term exposure of islets of Langerhans to supraphysiologic glucose concentrations on, 319-323
- Insulin in PCOS  
 effects of BMI and, on metabolic and endocrine variables in PCOS, 167-172  
 metformin-induced resumption of normal menses and, 512, 516
- Insulin receptor substrate (IRS) proteins, imidapril improving  $S_i$  by improving vascular resistance and enhancing signal transduction via, 1248-1255
- Insulin release and secretion  
 amitraz and BTS 27271 effects on,  $\alpha_{2D}$ -ARs and, 1461-1469  
 in Cr-deficient diet, 1063-1068  
 effects of *cis* and *trans* FAs on, 22-29  
 in GH-deficient adults, effects of GH therapy and its withdrawal on, 1387-1396  
 glucose and, *see* Glucose, and insulin release and secretion  
 in HTN, 3-6  
 Ile-thiazolidine effects on, 387-388  
 insulin hypersecretion in obesity and NIDDM, beta cell function and, 857-864
- Insulin resistance  
 in adipocytes of essential HTN subjects, effects of enalapril and losartan on, 1041-1046  
 EPA-E ester effects on, 1089-1095  
 hyperendothelinemia, HTN and, due to exogenous hyperinsulinemia, 465-471  
 islets of Langerhans in, *see* Islets of Langerhans in insulin resistance in pregnancy, *see* Insulin resistance in pregnancy  
 Trp64Arg variant of  $\beta_3$ -AR gene and, *see* Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and

- Insulin resistance (*Continued*)  
*see also* Hyperinsulinemia; Insulin resistance in NIDDM; Insulin resistance in obesity
- Insulin resistance in NIDDM  
 glucosamine-induced, differential effects of troglitazone and D-chiroinositol on, 1418-1423  
 in lean NIDDM subjects, changes in capillary angioarchitecture of islets of Langerhans coinciding with impaired beta cell function but not, 477-483  
 in nutritionally induced NIDDM, 1549-1554  
 Trp64Arg variant of  $\beta_3$ -AR gene not associated with CHD or, 853-856  
*see also* Insulin resistance in NIDDM with obesity
- Insulin resistance in NIDDM with obesity  
 in obese Japanese subjects, *FABP2* gene polymorphism and, 655-657  
*see also* Insulin resistance in NIDDM with obesity, beta cell function and
- Insulin resistance in NIDDM with obesity, beta cell function and changes in capillary angioarchitecture of islets of Langerhans coinciding with impaired function of, but not insulin resistance, 477-483  
 insulin hypersecretion and, 857-864
- Insulin resistance in obesity  
 glucose tolerance and, miglitol effects on, 701-706  
 KRP effects on impaired glucose uptake in SM of subjects with, 1450-1454  
*see also* Insulin resistance in NIDDM with obesity
- Insulin resistance in pregnancy  
 HTN and, 1339-1342  
 preeclampsia with, 892-896
- Insulin sensitivity ( $S_i$ )  
 BM 17.0744 effects on, 34-40  
 and chronic smoking effects on skeletal BF and glucose uptake, 239-244  
 glucose effectiveness, insulin secretion and, in nondiabetic offspring of NIDDM subjects, 978-983  
 in HTN, 888  
 imidapril improving, by enhancing signal transduction via IRS proteins and improving vascular resistance, 1248-1255  
 and serum TGs in obese white and black women, visceral and truncal SC AT and, 194-199  
 in young women, diet high in TFAs and, 870-875  
*see also* Insulin resistance
- Interferon- $\alpha$  (INF- $\alpha$ ) in AIDS, 1527
- Interleukin-1 $\beta$  (IL-1 $\beta$ ), release of, by mitogen-stimulated PBMCs of critically ill multiple-trauma victims, 1397-1401
- Interleukin-6 (IL-6), release of, by mitogen-stimulated PBMCs of critically ill multiple-trauma victims, 1397-1401
- Intermediate-density lipoprotein (IDL)  
 in obese NIDDM men, diet and exercise effects on, 643  
 plasma, in human apo A-II transgenic mice, 416
- Internal carotid artery, insulin-induced vasodilation of, 1470-1473
- Interstitial cells, testicular, evodiamine effects on T secretion in, 1532-1535
- Intestinal oligopeptide transporter, Pept-1 as, functional and molecular expression of, after brief fast, 681-684
- Intracellular Ca (calcium)  
 elevated glucose effects on arterial contractions and on PKC-induced release of, 1015-1022  
 in umbilical cord ECs, effects of IDDM plasma on, 554-557
- Intracellular skeletal muscle (SM) glucose in normoglycemic relatives of NIDDM subjects, effects of dexamethasone on, 1128-1135
- Intragastric glucose, effects of GLP-1 immunoblockade by MoAbs on insulin response to, in conscious subjects, 41-46
- Intralipid, metabolic effects of propranolol and, in elderly malnourished cancer subjects, 291-297
- Intraperitoneal glucose tolerance test (IPGTT), miglitol effects on, in obesity, 701-706
- Intravascular coagulation, effects of reduced NO production due to L-arginine deficiency in LPI on, 1136-1140
- Intravenous glucose tolerance test (IVGTT)  
 acarbose effects on, 349-350  
 frequently sampled, *see* Frequently sampled intravenous glucose tolerance test  
 in hypothyroidic subjects, acipimox and, 1318-1321  
 IM-, C-peptide minimal model in assessment of beta cell function during, 1162-1166  
 miglitol effects on, in obesity, 701-706  
 in NIDDM, plasma insulin response to, 480  
 after orthotopic pancreas transplantation, 646, 648
- Iodine in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- IPGTT (intraperitoneal glucose tolerance test), miglitol effects on, in obesity, 701-706
- Iron (Fe)  
 hepatic, C-lowering properties of unsaturated fat and levels of, 200-204  
 in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- IRS (insulin receptor substrate) proteins, imidapril improvement of  $S_i$  by improving vascular resistance and enhancing signal transduction via, 1248-1255
- Ischemia, acute effects of adrenergic-mediated, on MNCV in NIDDM, 495-500
- Islet amyloid polypeptide, *see* Amylin
- Islets of Langerhans  
 effects of long-term infusion of NE and 5-HT into VMH on function of, 1287-1289  
 in insulin resistance, *see* Islets of Langerhans in insulin resistance  
 long-term exposure of, to supraphysiologic glucose concentrations, effects of, on insulin mRNA, 319-323  
 transplanted human, in nude mice, amyloid deposition in human IAPP transgenic mice and in, compared, 448-454  
*see also* Beta cells
- Islets of Langerhans in insulin resistance  
 FFA inhibition of glucose-stimulated insulin release enhanced in, 1314-1317  
 NIDDM and changes in islet capillary angioarchitecture coinciding with impaired beta cell function but not insulin resistance, 477-483
- Isobutyrate, effects of soy protein/soluble fiber diet on, 813
- Isoleucine (Ile)  
 effects of, on plasma and urinary concentrations of uric acid and uridine, 1024  
 effects of Ile-thiazolidine on glucose tolerance, 385-389
- L-Isoleucine (Ile), and leucine kinetics, 1379
- F<sub>2</sub>-Isoprostane, effects of fish and exercise on urinary excretion of, in NIDDM, 1402-1408
- Isotopic enrichment of urinary AAs following infusions of L-[1-<sup>13</sup>C]Phe and L-[1-<sup>13</sup>C]lysine, 732-737
- Isovalerate, effects of soy protein/soluble fiber diet on, 813
- IVGTT, *see* Intravenous glucose tolerance test
- Japanese-American men, insulin resistance and Trp64Arg variant of  $\beta_3$ -AR gene in, 1367-1370
- Japanese subjects  
 with NIDDM, *UCP2* gene mutation in, 581-584  
*see also* Japanese subjects, obese
- Japanese subjects, obese  
 and insulin-resistant, *FABP2* gene polymorphism in, 655-657

- Japanese subjects, obese (*Continued*)  
 phenotypic characterization of Trp64Arg variant of  $\beta_3$ -AR gene and UCP1 gene mutation in, 636-640
- K (potassium)  
 in high-sucrose diet with EPA-E ester and/or lard, 1090  
 in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
 plasma, in PH, 299  
 xylitol and F effects on, 523  
*see also* K channels; Na/K-ATPase
- K (potassium) channels, ATP-sensitive, in insulin-mediated glucose transport in NIDDM with CAD, 432-436
- $\alpha$ -Ketoisocaproate ( $\alpha$ -KIC)  
 protein synthesis and, 1566  
 splanchnic utilization of, 1555-1563
- Ketones, MCAD deficiency and turnover of, 685-6881
- 6-Keto prostaglandin  $F_{1\alpha}$  ( $PGF_{1\alpha}$ ), plasma, in essential HTN, effects of long-term lisinopril therapy on, 1257
- $\alpha$ -KIC, *see*  $\alpha$ -Ketoisocaproate
- Kidney  
 [ $^3$ H]riboflavin in, during respiratory infection, 1609  
 in STZ-DM, lithium effects on, 558-563  
*see also* End-stage renal disease and entries beginning with term:  
 Renal and element: Nephro-
- Kinase  
 effects of exposure to glucose on glucokinase mRNA, 320-321  
 PDH, insulin activation of, enhanced by exercise, 865-866  
*see also* Phosphatidylinositol 3-kinase; Protein kinase; Protein kinase C
- Kinetics  
 glucose, *see* Kinetics, glucose  
 of glycerol in whole-body lipolysis, hypoosmolality effects on, 473-474  
 hepatic UDPG, 1262-1263  
 leucine, *see* Kinetics, leucine  
 NE, in NIDDM, 1538  
 Phe, and tyrosine, in late pregnancy, 849-852  
 of VLDL apo B-100 in adult hypopituitarism, 1057-1062
- Kinetics, glucose  
 in cirrhosis, 1263  
 hypoxemia effects on, in pregnancy, 741
- Kinetics, leucine  
 in late pregnancy, 849-852  
 L-leucine, in small intestine BBMs, 1433-1434  
 over three meals, 1378-1386
- Kitavans (traditional Pacific Islanders), low serum insulin in, 1216-1219
- KRP-297, effects of impaired glucose uptake in SM of obese insulin-resistant subjects, 1450-1454
- LA (lipoic acid), hypoglycemia induced by, in fasting STZ-DM and nondiabetic subjects, 504-510
- Lactate  
 blood, *see* Blood lactate  
 effects of local sympathetic blockade on, 1579  
 exercise and, *see* Lactate, exercise and  
 hepatic, *see* Hepatic lactate  
 leukocyte glycolysis and output of, in sepsis and ex vivo blood, 779-785  
 in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1129  
 plasma, in diabetic depancreatized subjects, 158  
 [ $2$ - $^{13}$ C]Lactate, [ $2$ - $^{13}$ C]-SAD effects on hepatocyte output of, 103
- Lactate, exercise and  
 and metabolic adaptation to HF diet, 1513  
 and PDH complex activation by exercise, 866, 867
- Lactic acid  
 AA effects on, 1024-1026  
 blood, glucose effects on, 339-341  
 xylitol and F effects on, 522
- Lard, high-sucrose diet with EPA-E ester and/or, effects of, on insulin resistance and HTN, 1089-1095
- Late pregnancy, Phe and tyrosine metabolism in, 849-852
- Lathosterol  
 plasma, in CTX, 236  
 serum, effects of campestanol/sitostanol mixture on proportion of, to C, 577
- LCAT (lecithin:cholesterol acyltransferase), FC deposition in cornea of human apo A-II transgenic mice with functional deficiency of, 415-421
- LDL(s), *see* Low-density lipoprotein(s)
- LDL-C, *see* Low-density lipoprotein-cholesterol
- Lean body mass, *see* Fat-free mass
- Lean subjects  
 effects of different insulin infusion rates on, HR variability in, 755-762  
 with PCOS, serum TNF- $\alpha$  in, 437-441  
*see also* Lean subjects, NIDDM
- Lean subjects, NIDDM  
 changes in capillary angioarchitecture of islets of Langerhans coinciding with impaired beta cell function but not insulin resistance in, 477-483  
 GH response to GHRH and GHRP-6 in, 525-530
- Lecithin:cholesterol acyltransferase (LCAT), FC deposition in cornea of human apo A-II transgenic mice with functional deficiency of, 415-421
- Left ventricular mass (LVM), effects of short-term MPA therapy on, IGF-I and, 1328-1331
- Leptin  
 effects of chronic administration of, on insulin-stimulated SM glucose, 671-676  
 HF diet and, 1233  
 in NIDDM, effects of troglitazone on, 1104  
 obesity and, but not CV fitness, predicting AT-LPL activity in sedentary and exercising middle-aged and older men, 183-189  
 suppression of, in response to hypersecretion of catecholamines in pheochromocytoma, 543-545  
 $T_3$  regulation of, 1603-1607  
 TSH effects on production of, in adipocytes, 1570-1574  
 in women with eating disorders, 217-220  
*see also* Leptin mRNA; Plasma leptin; Serum leptin
- Leptin mRNA (messenger ribonucleic acid), effects of 15d-PGJ $_2$ , indomethacin, and troglitazone on, 786-791
- Leu, *see* Leucine; L-Leucine
- Leucine (Leu)  
 differences in protein synthesis between Phe and, following unbalanced infusion of amino acids, 1564-1569  
 exercise-induced gut and SM proteolysis and, 163-164  
*see also* Kinetics, leucine; L-Leucine
- L-Leucine (Leu)  
 effects of FAs on insulin secretion stimulated by, 25-27  
 transport of, in small intestine BBMs, 1432-1436
- Leukocytes  
 F and xylitol effects on plasma concentrations of, 521  
 lactate output and glycolysis by, in sepsis and ex vivo blood, 779-785  
 peripheral blood, in diabetic retinopathy, regulation of TGF- $\beta$ , bFGF, and VEGF mRNA in, 1172-1178  
*see also* specific types of leukocytes
- Levonorgestrel (LN), effects of triphasic OCs with desogestrel or, on apo A-I-containing HDL particles, 658-664

- Leydig tumor cells, hCG-stimulated steroidogenesis in, effects of Cl and inorganic nitrate on, 693-700
- LH, *see* Luteinizing hormone
- Linoleic acid, TFAs and, 873
- Lipase, *see* Postheparin lipase; Triglyceride lipase *and entries beginning with terms*: Lipoprotein lipase
- Lipemia (lipidemia)  
prior exercise reducing PP, independently of AT and CHO contributions to energy expenditure during exercise, 245-251  
*see also* Hyperlipidemia
- Lipid(s)  
biliary, *see* Biliary lipids  
diet and, *see* Lipid(s), diet and  
GH therapy effects on, *see* Lipid(s), GH therapy effects on  
hepatic, PV effects on, 619-621  
in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1129  
in older men and women, differential effects of body composition and exercise on, 1474-1480  
oxidation of, *see* Oxidation, lipid  
peroxidation of, *see* Peroxidation, lipid  
plasma, *see* Plasma lipid(s)  
PP, HRT enhancing metabolism of, in postmenopausal women, 1193-1196  
serum, *see* Serum lipids  
in Taiwanese aborigines with gout, 131-133  
thermogenic effect of hyperglycemia during infusion of, 278-284  
*see also* Dyslipidemia; Hyperlipidemia; Normolipidemia; Phospholipid(s) *entries beginning with element*: Lip- and specific lipids
- Lipid(s), diet and  
fasting blood, soy protein/soluble fiber diet effects on, 811-812  
NCEP C-lowering diet effects, 823  
simulation of O<sub>2</sub> consumption following addition of lipid substrates to liver and SM of subjects on HF diet, 1230-1235  
in STZ-DM, effects of dietary FAs on, 455-460
- Lipid(s), GH therapy effects on  
in GH-deficient adults, 310  
in TS girls, 7-14
- Lipid hydroperoxides, plasma, in STZ-DM, AMGN effects on, 1142
- Lipid peroxide (LPO) in STZ-DM, lithium effects on, 561
- Lipid transfer proteins, plasma, net mass transfer of plasma CETPs and, in normolipidemic subjects with peripheral vascular disease, 1361-1366
- Lipogenesis, de novo, chronic physiologic hyperinsulinemia and, 330-337
- Lipoic acid (LA), hypoglycemia induced by, in fasting STZ-DM and nondiabetic subjects, 504-510
- Lipolysis  
by adipocytes, *see* Lipolysis by adipocytes  
AT, BC/SKF38393 effects on, 1037  
whole-body, hypoosmolality effects on, 472-476  
*see also* Lipolysis by adipocytes
- Lipolysis by adipocytes  
by abdominal and gluteal adipocytes in transsexuals, effects of cross-sex hormone therapy on, 1371-1377  
masoprocol effects on, 411-414  
TSH effects on, 1572
- Lipopolysaccharide (LPS), and leukocyte glycolysis and lactate output in sepsis and ex vivo blood, 779-785
- Lipoprotein (Lp)  
effects of triphasic OCs with desogestrel or LN on, 659  
in older men and women, differential effects of body composition and exercise on, 1474-1480  
response of, to NCEP C-lowering diet, 822-826
- Lipoprotein (Lp) (*Continued*)  
*see also* High-density lipoprotein(s); Hyperlipoproteinemia; Intermediate-density lipoprotein; Lipoprotein(a); Lipoprotein B:CIII; Low-density lipoprotein(s); Plasma lipoprotein(s); Serum lipoproteins
- Lipoprotein(a) [Lp(a); high-density lipoprotein<sub>1</sub>]  
in FCHL, gemfibrozil and lovastatin effects on, 48, 49, 51  
in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438  
in PCOS, metformin-induced resumption of normal menses and, 512, 516  
plasma, ACTH-induced reduction of, in normal and HD subjects, 342-346  
relationship between apo A phenotype and troglitazone-induced increase in, in HTN, 1-2  
TFAs and, in young women, 873
- Lipoprotein B:CIII (LpB:CIII), PP, relationship between changes in particles of, and HDL subpopulation in, 60-67
- Lipoprotein lipase (LPL) activity  
AT, *see* Adipose tissue lipoprotein lipase activity  
in heart, SM, and AT, BC/SKF38393 effects on, 1036  
SM, E effects on, 461-464
- Lipoprotein lipase (LPL) *HindIII* gene, polymorphism of, in young adults with MI, 1157-1161
- Lipoprotein lipase (LPL) mRNA (messenger ribonucleic acid), TSH effects on levels of, in adipocytes, 1572
- Lisinopril, long-term therapy of essential HTN with, plasma NO and related vasoactive factors following, 1256-1259
- Lithium, STZ-DM effects on tissue, and effects of lithium supplementation on STZ-DM, 558-563
- Liver  
apo E desialylation effects on its binding to HDL and its ability to deliver esterified C to, 1184-1192  
Ca<sup>2+</sup> distribution in, effects of disruption of filamentous actin and, 1241-1247  
cirrhotic, *see* Cirrhosis  
and HF diet, simulation of O<sub>2</sub> consumption following in addition of lipid substrates to, 1230-1235  
imidapril effects on PI 3-kinase associated with IRS proteins in, 1249-1251  
lithium effects on, in STZ-DM, 558-563  
[<sup>3</sup>H]riboflavin in, during respiratory infection, 1609  
*see also* Liver mitochondria; Organ weight, liver *and entries beginning with element*: Hepat-
- Liver mitochondria in NIDDM, bioenergetics of, 1115-1119
- LN (levonorgestrel), effects of triphasic OCs with desogestrel or, on apo A-I-containing HDL particles, 658-664
- Local sympathetic blockade, effects of, on BF and glucose uptake during hypoglycemia, 1575-1583
- Localized osteomyelitis of foot in IDDM and NIDDM, role of combined RI and MRI diagnosis of, in conservative management, 922-927
- Long-term exercise-induced weight loss in young identical male twins, effects of, on sex hormones, 1120-1127
- Long-term renal glucose oxidation regulation, substrate interactions in, 707-715
- Long-term therapy  
with lisinopril for essential HTN, plasma NO and related vasoactive factors following, 1256-1259  
with rhEPO, effects of, on GH secretion in uremic subjects on CAPD, 210-216  
with valproic acid, effects of, on carnitine reabsorption, 74-79
- Long-term weight maintenance in weight-reduced men, exercise effects on, 15-21
- Losartan, effects of enalapril and, on insulin resistance in adipocytes in essential HTN, 1041-1046

- Lovastatin, effects of gemfibrozil combined with, on FCHL, 47-54
- Low-density lipoprotein(s) (LDL;  $\beta$ -lipoprotein)
- apheresis of, LDL oxidizability before and after, 881-886
  - and decrease in SM capillary density in men, 1268
  - effects of triphasic OCs with desogestrel or LN on, 659
  - and ERT effects on vascular reactivity, 228
  - exercise effects on, in older men and women, 985
  - in HCL, simvastatin effects on, 69, 70
  - in HTN, 888
  - in hyperinsulinemia, 110
  - in hypogonadal men, T substitution and, 592, 594
  - in NIDDM, *see* Low-density lipoprotein(s) in NIDDM
  - in obesity, *see* Low-density lipoprotein(s) in obesity
  - particle size of, *see* Low-density lipoprotein(s), particle size of
  - plasma, *see* Plasma low-density lipoprotein(s)
  - serum, *see* Serum low-density lipoprotein(s)
  - see also* Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor; Low-density lipoprotein receptor protein; Very-low-density lipoprotein(s)
- Low-density lipoprotein(s) (LDL), particle size of
- in childhood-onset IDDM, CAD and, 531-534
  - in middle-aged and young men, 1322-1327
- Low-density lipoprotein(s) (LDL) in NIDDM
- composition and metabolism of, 118-124
  - in obese NIDDM men, effects of exercise and diet on subfractions of, 641-644
- Low-density lipoprotein(s) (LDL) in obesity
- association of serum leptin and serum uric acid concentrations in, 678, 679
  - in obese NIDDM men, exercise and diet effects on subfractions of, 641-644
- Low-density lipoprotein-cholesterol (LDL-C)
- in AIDS, 1526-1528
  - apo E polymorphism and changes in, in adolescent girls, 285-290
  - AT, GH secretion and, in older men and women, 1426, 1428
  - and CAD, *see* Low-density lipoprotein-cholesterol, CAD and
  - in CHD, Trp64Arg variant of  $\beta_3$ -AR gene, 653
  - diet effects on, *see* Low-density lipoprotein-cholesterol, diet effects on
  - and essential HTN, 888
  - exercise and, *see* Low-density lipoprotein-cholesterol, exercise and
  - GH therapy effects on, *see* Low-density lipoprotein-cholesterol, GH therapy effects on
  - in gout, 132
  - in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438
  - in IDDM, *see* Low-density lipoprotein-cholesterol in IDDM
  - LDL apheresis and concentrations of, 883
  - in MHL, 62
  - in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM
  - in obesity, *see* Low-density lipoprotein-cholesterol in obesity
  - in PCOS, *see* Low-density lipoprotein-cholesterol in PCOS
  - plasma, *see* Plasma low-density lipoprotein-cholesterol
  - PP, *see* Postprandial low-density lipoprotein-cholesterol
  - serum, *see* Serum low-density lipoprotein-cholesterol
  - TFAs and, in young women, 873
  - VAT, *see* Low-density lipoprotein-cholesterol, VAT and
  - in young adults with MI, 1158, 1159
  - see also* Very-low-density lipoprotein-cholesterol
- Low-density lipoprotein-cholesterol (LDL-C), CAD and
- in childhood-onset IDDM with CAD, 532, 533
  - in HTG and NTG, 303
- Low-density lipoprotein-cholesterol (LDL-C), diet effects on
- effects of campestanol/sitostanol mixture with variable fat intake on, 577
  - soy protein/soluble fiber diet effects on, 812
- Low-density lipoprotein-cholesterol (LDL-C), exercise and
- in combined hyperlipidemia, 1520, 1521
  - in middle-aged exercising men and women, AT-LPL activity and, 185
  - in obese NIDDM men, diet and exercise effects on subfractions of, 643
  - in weight-reduced men, 19
  - see also* Low-density lipoprotein-cholesterol in exercising older men and women
- Low-density lipoprotein-cholesterol (LDL-C), GH therapy effects on
- in GH-deficient adults, 310
  - in TS, 10, 11
- Low-density lipoprotein-cholesterol (LDL-C), VAT and
- age, LDL particle size and, 1324, 1325
  - VAT accumulation and, 357
- Low-density lipoprotein-cholesterol (LDL-C) in exercising older men and women
- AT-LPL activity and, 185
  - differential effects of exercise and body composition on, 1477
  - with very low dietary C, 490-491
- Low-density lipoprotein-cholesterol (LDL-C) in IDDM
- childhood-onset IDDM with CAD, 532, 533
  - and urinary excretion of apo A fragments, 370
- Low-density lipoprotein-cholesterol (LDL-C) in NIDDM
- with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292
  - and meal-induced LDL oxidative stress, 1503-1508
  - metformin versus gliclazide effects on, 900
- Low-density lipoprotein-cholesterol (LDL-C) in obesity
- association of serum leptin and serum uric acid concentrations and, 678
  - in obese NIDDM men, diet and exercise effects on subfractions of, 643
  - in PCOS, insulin and obesity effects on, 171
- Low-density lipoprotein-cholesterol (LDL-C) in PCOS
- insulin and obesity effects on, 171
  - metformin-induced resumption of normal menses and, 512, 516
- Low-density lipoprotein (LDL) receptor, impact of mutations of, on LDL ability to support lymphocyte proliferation, 834-839
- Low-density lipoprotein (LDL) receptor protein, PV effects on, 622
- Low-dose growth hormone (GH) therapy, individualized, of childhood-onset GH deficiency in adults, metabolic effects of, 1003-1010
- Lp, *see* Lipoprotein
- Lp(a), *see* Lipoprotein(a)
- LpB:CIII (lipoprotein B:CIII), relationship between changes in particles of PP, and HDL subpopulation in, 60-67
- LPI (lysine protein intolerance), effects of reduced NO production by L-arginine deficiency in, on intravascular coagulation, 1136-1140
- LPL, *see* Lipoprotein lipase activity; Lipoprotein lipase *HindIII* gene
- LPO (lipid peroxide) in STZ-DM, lithium effects on, 561
- LPS (lipopolysaccharide), and leukocyte glycolysis and lactate output in sepsis and ex vivo blood, 779-785
- Luteinizing hormone (LH)
- in eating disorders, 218
  - see also* Luteinizing hormone in PCOS
- Luteinizing hormone (LH) in PCOS
- metformin-induced resumption of normal menses and, 512, 516
  - serum, 440
- LVM (left ventricular mass), effects of short-term MPA therapy on, IGF-I and, 1328-1331
- Lymphocyte proliferation, effects of LDL receptor mutations on LDL ability to support, 834-839
- Lys<sup>B28</sup>Pro<sup>B29</sup> insulin, differences between cellular processing of Asp<sup>B10</sup> insulin, native insulin and, 611-617

- D-[<sup>13</sup>C]Lysine, renal reabsorption of, and effects of, on urinary AAs, 732-737
- L-Lysine, and leucine kinetics, 1379
- L-[1-<sup>13</sup>C]Lysine, isotopic enrichment of urinary AAs following infusions of, 732-737
- Lysinuric protein intolerance (LPI), effects of reduced NO production by L-arginine deficiency in, on intravascular coagulation, 1136-1140
- Macroalbuminuria in NIDDM, serum leptin in, 1290-1293
- Macrophages, HDL glycation effects on HDL susceptibility to oxidation and C efflux from, 142
- Magnesium, *see* Mg
- Magnetic resonance imaging (MRI)
- of AT, serum lipids, and GH secretion in older men and women, 1424-1431
  - role of diagnosis of minimal or localized osteomyelitis of foot in IDDM or NIDDM with combined RI and, in conservative management, 922-927
- [2-<sup>13</sup>C]Malate, [2-<sup>13</sup>C]-SAD effects on hepatocyte output of, 103
- [3-<sup>13</sup>C]Malate, [3-<sup>13</sup>C]-SAD effects on hepatocyte output of, 103
- Male subjects
- energy expenditure and determination of AT and plasma leptin in, 1272-1277
  - see also* Men; Sex
- Malnutrition
- in older cancer subjects, metabolic effects of Intralipid and propranolol in, 291-297
  - see also* Diet
- Malondialdehyde (MDA)
- plasma, in STZ-DM, 444
  - RBC, *see* Erythrocyte malondialdehyde
- Manganese (Mn) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- α (alpha)-D-Mannosidase, activity RBC membrane, in NIDDM, 817-821
- MAP (mean arterial pressure), *see* Blood pressure
- Masoprocil (nordihydroguaiaretic acid), effects of, on glucose transport and lipolysis in adipocytes, 411-414
- Mass transfer, net, of plasma cholesteryl esters and lipid transfer proteins in normolipidemic subjects with peripheral vascular disease, 1361-1366
- Maternal glucose metabolism, effects of reduced FiO<sub>2</sub> on, in pregnancy, 738-744
- 3-MC (methylcholanthrene)-induced cytochrome P-450 1A1, retinoids inhibiting metabolism of benzo(a)pyrene catalyzed by, 689-692
- MCAD (medium-chain acyl-coenzyme A dehydrogenase) deficiency, simulation of, with 2-octynoic acid, 685-688
- MDA, *see* Malondialdehyde
- ME, *see* Metabolizable energy intake
- Meal-induced oxidative stress, LDL oxidation and, in NIDDM, hyperglycemia and, 1503-1508
- Meal tolerance test (MTT)
- miglitol effects on, in obesity, 701-706
  - of STZ-DM subjects, 727
- Mean arterial pressure, *see* Blood pressure
- Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency, simulation of, with 2-octynoic acid, 685-688
- Medroxyprogesterone acetate (MPA), effects of short-term therapy with, on LVM, IGF-I and, 1328-1331
- Membrane fluidity, filtration parameter and, after chemotactic activation of PMNs in NIDDM, 30-33
- Men
- decrease in SM capillary density related to high serum LDL-C and apo B in, 1267-1271
  - Men (*Continued*)
    - on diet with and without added MSG, circadian variations in plasma and erythrocyte glutamate, glutamine, and alanine in, 1455-1460
    - esterification of cholesterol in normolipidemic, dietary fat saturation modulating rates of, 1210-1215
    - exercising, *see* Men, exercising
    - hypogonadal, effects of T substitution modes on serum lipids and Lps in, 590-596
    - Japanese-American, insulin resistance and Trp64Arg variant of β<sub>3</sub>-AR gene in, 1367-1370
    - normotensive or with essential HTN, effects of acute hyperinsulinemia on urinary nitrite/nitrate excretion and plasma ET-1 levels in, 887-891
    - obese, *see* Men, obese exercising
    - PP VLDL-C and chylomicron remnants in HTG and NTG, with and without CHD, 301-307
    - sedentary, *see* Sedentary men
    - see also* Middle-aged men; Normal subjects; Older men; Sex; Young men and specific conditions
  - Men, exercising
    - and age-related blunting of GH secretion during exercise, SRIH tone and, 665-670
    - cortisol effects on exercise-induced ACTH increase in, 390-394
    - see also* Exercise; Men, obese exercising; Older men and women, exercising; Young men, exercising and specific conditions
  - Men, obese exercising
    - apo E genotype and exercise inducing plasma HDL-C and HDL<sub>2</sub>-C increases in, 943-945
    - middle-aged, leptin and obesity but not CV fitness as predictors of AT-LPL activity in, 183-189
    - NIDDM men, effects of exercise and diet on LDL subfractions in, 641-644
    - see also* Older obese men, exercising; Weight loss by exercising men
  - Menses, metformin-induced resumption of normal, in amenorrheic PCOS women, 511-519
  - Menstrual cycle
    - effects of, on EPOC in young women, 275-277
    - see also* Menses; Postmenopausal women; Premenopausal women
  - Mesangial cell-surface proteoglycans, HS with antimitogenic properties arising from, 1220-1229
  - Messenger ribonucleic acid, *see* mRNA
  - Met, *see* Methionine; DL-Methionine; L-Methionine
  - Metabolic variables in PCOS, endocrine and, impact of BMI and insulin on, 167-172
  - Metabolizable energy (ME) intake
    - HF diet and, 1232
    - in high-sucrose diet with EPA-E and/or lard, 1090
  - Metformin
    - effects of gliclazide versus, on clinical profile and lipid peroxidation markers in NIDDM, 897-903
    - effects of insulin and, on glucose metabolism in vascular smooth muscle, 1357-1360
    - and resumption of normal menses in amenorrheic PCOS women, 511-519
  - Methionine (Met), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
  - DL-Methionine (Met), high-sucrose diet with EPA-E ester and/or lard and, 1090
  - L-Methionine (Met), and leucine kinetics, 1379
  - 3-Methylcholanthrene (3-MC)-induced cytochrome P-450 1A1, retinoids inhibiting metabolism of benzo(a)pyrene catalyzed by, 689-692
  - 24-Methyl-5α-cholestan-3β-ol, *see* Campestanol, sitostanol and



- Methylenetetrahydrofolate reductase, *see* Folate, Hcy and, and MTHFR genotype
- 3-Methylglutaryl coenzyme A inhibitors, 3-hydroxy-, *see* Lovastatin; Pravastatin; Simvastatin
- Methylmalonic acid (MMA)  
effects of vitamin B<sub>12</sub> supplementation on Hcy, serum folate and, in relation to C677T MTHFR genotype in ESRD, 631-635  
and nephropathy in NIDDM, 1096-1101
- 5-Methylpyrazole-3-carboxylic acid (MPCA), effects of, on renal FAs and renal glucose oxidation, 707-715
- Metirapone  
effects of, on exercise-induced ACTH increase in trained and untrained men, 390-394  
effects of, on neonatal hyperinsulinemic hypoglycemia, 568-574
- Mexican American women, response of PP insulin to exercise by, 971-977
- Mg (magnesium)  
effects of vanadate and, on glucose metabolism in STZ-DM, 725-731  
in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
renal, GH therapy effects on CMA-induced wasting of, 763-770  
serum, galactose effects on, 906
- MHL (mixed hyperlipoproteinemia), relationship between PP LpB:CIII particle changes and HDL subpopulation in, 60-67
- MI, *see* Myocardial infarction
- Microalbuminuria  
in childhood-onset IDDM with CAD, 532  
in NIDDM, *see* Microalbuminuria in NIDDM
- Microalbuminuria in NIDDM  
nephropathy and, 1098  
serum leptin in, 1290-1293
- $\beta$  (beta)<sub>2</sub>-Microglobulin in AIDS, PAF-AH and, 1527
- Middle-aged men  
sedentary and exercising, leptin and obesity but not CV fitness as predictors of AT-LPL activity in, 183-189  
VAT and LDL particle size in, 1322-1327
- Miglitol (Bay m1099), effects of, on glucose tolerance and insulin resistance in obesity, 701-706
- Milk, dried skim, in cereal-based diet with C, 401
- Mineral content of bones, effects of paracentesis of ascites on DEXA of, 373-377
- Mineral density of bones, effects of paracentesis of ascites on DEXA of, 373-377
- Minimal osteomyelitis of foot in IDDM and NIDDM, role of combined RI and MRI diagnosis of, in conservative management, 922-927
- Miscarriage by PCOS women, PAI as risk factor for, 1589-1595
- Mitochondria, liver, in NIDDM, bioenergetics of, 1115-1119
- Mitogen-stimulated peripheral blood mononuclear cells (PBMCs) from critically ill multiple-trauma victims, cytokine release by, 1397-1401
- Mixed hyperlipoproteinemia (MHL), relationship between PP Lp B:CIII particle changes and HDL subpopulation in, 60-67
- MMA, *see* Methylmalonic acid
- Mn (manganese) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- MNCV, *see* Motor nerve conduction velocity
- MoAbs (monoclonal antibodies), immunoblockade of GLP-1 by, in conscious subjects, effects of, on insulin response to intragastric glucose, 41-46
- Molasses in cereal-based diet with C, 401
- Molybdenum (Mo) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Monoclonal antibodies (MoAbs), effects of immunoblockade of GLP-1 by, on insulin response to intragastric glucose, in conscious subjects, 41-46
- Mononuclear cells, mitogen-stimulated peripheral blood, from critically ill multiple-trauma victims, cytokine release by, 1397-1401
- Monophosphate, *see* cAMP; cGMP
- Monosodium glutamate (MSG), men on diet with and without added, circadian variations in plasma and erythrocyte glutamate, glutamine, and alanine in, 1455-1460
- Monounsaturated fatty acids (MUFAs)  
in high-sucrose diet with EPA-E ester and/or lard, 1094  
*see also* Monounsaturated fatty acids in C-lowering diets
- Monounsaturated fatty acids (MUFAs) in C-lowering diets  
in NCEP diet, 82  
in soy protein/soluble fiber diet, 810, 811
- Motor nerve conduction velocity (MNCV)  
in NIDDM, acute effects of adrenergic-mediated ischemia on, 495-500  
*see also* Motor nerve conduction velocity in STZ-DM
- Motor nerve conduction velocity (MNCV) in STZ-DM  
antioxidant levels and, 442-447  
C-AD reversing hyperglycemia-induced inhibition of phosphoinositide synthesis in RPE cells and preventing reduction of, 827-833
- MPA (medroxyprogesterone acetate), effects of short-term therapy with, on LVM, IGF-I and, 1328-1331
- MPCA (5-methylpyrazole-3-carboxylic acid), effects of, on renal FAs and renal glucose oxidation, 707-715
- MRI, *see* Magnetic resonance imaging
- mRNA (messenger ribonucleic acid)  
GLUT2, effects of exposure to supraphysiologic glucose concentrations on, 320-321  
hepatic  $\beta$ -galactoside 2,6-ST, effects of chronic alcohol intake on, 797-803  
insulin, effects of long-term exposure of islets of Langerhans to supraphysiologic glucose concentrations on, 319-323  
leptin, 15d-PGJ<sub>2</sub>, indomethacin, and troglitazone effects on, 786-791  
LPL, TSH effects on levels of, in adipocytes, 1572  
Pept-1, after brief fast, 681-684  
regulation of TGF- $\beta$ , bFGF, and VEGF, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178  
renal G6Pase, effects of dexamethasone and insulin on levels of, 1052-1056  
syndican and glypican, northern blot of, HS and, 1224  
*see also* GLUT1 mRNA; GLUT3 mRNA
- MSG (monosodium glutamate), circadian variations in plasma and erythrocyte glutamate, glutamine, and alanine in men on diet with and without added, 1455-1460
- MTHFR (methylenetetrahydrofolate reductase), *see* Folate, Hcy and, and MTHFR genotype
- MTT, *see* Meal tolerance test
- MUFAs, *see* Monounsaturated fatty acids
- Multiple-trauma victims, critically ill, cytokine release by mitogen-stimulated PBMCs from, 1397-1401
- Muscle  
imidapril effects on PI 3-kinase associated with IRS proteins in, 1249-1251  
[<sup>3</sup>H]riboflavin in, during respiratory infection, 1609  
in STZ-DM, lithium effects on, 558-563  
vascular smooth, metformin and insulin effects on glucose metabolism in, 1357-1360  
*see* Muscular hypercatabolism; Skeletal muscle
- Muscle protein, combined hyperlipidemia associated with release of, in exercise, effects of TG-lowering intervention on, 1518-1523
- Muscular hypercatabolism, endotoxemia-induced, L-NAME-NO pathway in, 190-193
- Mutation  
LDL receptor, effects of, on LDL ability to support lymphocyte proliferation, 834-839

- Mutation (*Continued*)  
 of *UCP2* gene in NIDDM Japanese subjects, 581-584  
*see also* Polymorphism
- Myocardial infarction (MI)  
 acute, high concentration of proinsulin preceding, in nondiabetics, 1197-1202  
 family history of NIDDM and, and childhood-onset IDDM with CAD, 532  
 LPL *HindIII* gene polymorphism in young adults with, 1157-1161
- Myristic acid, TFAs and, 873
- N (nitrogen)  
 blood urea, *see* BUN  
 CMA-induced wasting of renal, GH therapy effects on, 763-770  
 in high-sucrose diet with EPA-E ester and/or lard, 1090
- Na (sodium)  
 in high-sucrose diet with EPA-E ester and/or lard, 1090  
 in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
 xylitol and F effects on, 523  
*see also* Na/K-ATPase; Plasma Na
- NAC (*N*-acetylcysteine), effects of vitamin E and, on PS externalization and coagulation induction in glucose-treated erythrocytes, 957-959
- Na/K ( $\text{Na}^+/\text{K}^+$ )-ATPase (sodium/potassium-adenosine triphosphatase)  
 aldosterone production and inhibition of, 1167-1171  
 umbilical cord EC, IDDM plasma effects on, 554-557
- D-NAME (*N*-nitro-D-arginine methylester), effects of, on GH-releasing activity of Hexarelin, 177-178
- L-NAME ( $\text{N}^G$ -nitro-L-arginine methylester)  
 effects of, on GH-releasing activity of Hexarelin, 177-178  
 and L-NAME-NO pathway in endotoxemia-induced muscular hypercatabolism, 190-193
- National Cholesterol Education Program (NCEP), Lp response to C-lowering diet of, 822-826
- Natriuretic peptides, atrial, and early renal failure in STZ-DM, 771-778
- NCEP (National Cholesterol Educational Program), Lp response to C-lowering diet of, 822-826
- NE, *see* Norepinephrine
- NEFAs (nonesterified fatty acids), *see* Free fatty acids
- Neonatal hyperinsulinemic hypoglycemia, effects of insulin counterregulatory hormones on, 568-574
- Nephropathy  
 in NIDDM, tHcy and, 1096-1101  
*see also* End-stage renal disease
- Nervous system, *see* Motor nerve conduction velocity; Sympathetic nervous system and *entries beginning with element: Neur-*
- Net mass transfer of plasma CETPs and lipid transfer proteins in normolipidemic subjects with peripheral vascular disease, 1361-1366
- Neural tube defects (NTDs), folate status, MTHFR genotype, and Hcy metabolism in South African black women with history of pregnancy complicated by, 269-274
- Neuropathy, *see* Diabetic neuropathy
- Neutrophils (polymorphonuclear leukocytes), chemotactic activation of, in NIDDM, filtration parameter and membrane fluidity following, 30-33
- $\text{NH}_3$  (ammonia), plasma levels of, and altered purine and glycogen metabolism in SM of heart failure subjects during exercise, 484-488
- Niacin in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Nicorandil (*N*-[2-hydroxyethyl]nicotinamide nitrate [ester]), effects of, on insulin-mediated glucose transport in NIDDM with CAD, 432-436
- Nicotine  
 ET production by ECs following exposure to caffeine or, 845-848  
*see also* Smoking
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nitrate, inorganic, effects of CI and, on hCG-stimulated steroidogenesis in Leydig tumor cells, 693-700
- Nitric oxide (NO)  
 in acute hyperinsulinemia, 887-891  
 GH-releasing activity of Hexarelin modulated by, in young and old subjects, 176-182  
 and L-NAME-NO pathway in endotoxemia-induced muscular hypercatabolism, 190-193  
 plasma, and related vasoactive factors following long-term lisinopril therapy for essential HTN, 1256-1259  
 reduced production of, due to L-arginine deficiency in LPI, effects of, on intravascular coagulation, 1136-1140
- Nitric oxide synthase (NOS), umbilical cord EC, IDDM plasma effects on, 554-557
- Nitrite/nitrate, effects of acute hyperinsulinemia on urinary excretion of, and plasma ET-1 levels in normotensive and essentially hypertensive men, 887-891
- N*-Nitro-D-arginine methylester (D-NAME), effects of, on GH-releasing activity of Hexarelin, 177-178
- $\text{N}^G$ -Nitro-L-arginine methylester, *see* L-NAME
- Nitrogen, *see* N
- Nitroglycerin, transdermal, effects of, on TAT complex in LPI, 1138
- Nitroprusside in NIDDM, and acute effects of adrenergic-mediated ischemia on nerve conduction, 497-498
- NO, *see* Nitric oxide
- Nondiabetic offspring of NIDDM subjects,  $\text{S}_i$ , glucose effectiveness, and insulin secretion in, 978-983
- Nondiabetic subjects  
 activities of HPA axis and SNS in, ethnicity and, 395-399  
 codon 64 polymorphism of  $\beta_3$ -AR gene not associated with CHD or insulin resistance in, 853-856  
 fasting, LA-induced hypoglycemia in, 504-510  
 high concentration of proinsulin preceding acute MI in, 1197-1202  
 Mg and vanadate effects on glucose metabolism of, 725-731  
*rad* gene polymorphism in, 173-175
- Nonesterified fatty acids, *see* Free fatty acids
- Non-Hispanic women, response of PP insulin to exercise by, 971-977
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), 113-124  
 activity of RBC membrane glycohydrolases in, 817-821  
 ADA and BMI in, 949-951; *see also* Body mass and body mass index of NIDDM subjects  
 alcohol intake in, *see* Alcohol intake in NIDDM  
 ATP in, *see* ATP in NIDDM  
 with CAD, *see* Non-insulin-dependent diabetes mellitus, CAD and erythrocytes in, *see* Erythrocyte(s) in NIDDM  
 exercise in, *see* Exercise in NIDDM  
 family of subjects with, *see* Family of NIDDM subjects  
 GLP-1-Gly8 for, long-lasting hypoglycemic effects of, 252-258  
 hyperglycemia in, *see* Hyperglycemia in NIDDM  
 hyperinsulinemia in normal subjects as predictor of HTN, CHD and, 989-994  
 insulin resistance in, *see* Insulin resistance in NIDDM  
 LDL composition and metabolism in, 118-124  
 lipid peroxidation in, *see* Peroxidation, lipid, in NIDDM  
 liver mitochondria bioenergetics in, 1115-1119  
 localized or minimal osteomyelitis of foot in, role of combined RI and MRI diagnosis of, in conservative management, 922-927  
 with microalbuminuria and macroalbuminuria, serum leptin in, 1290-1293  
 MNCV in, acute effects of adrenergic-mediated ischemia on, 495-500

- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus) (*Continued*)  
 nephropathy in, tHcy and, 1096-1101  
 in obese subjects, *see* Obesity, NIDDM with  
 oxidative stress in, *see* Oxidative stress in NIDDM  
 PMN filtration parameter and membrane fluidity after chemotactic activation in, 30-33  
 subjects at risk for developing, peripheral tissue glucose uptake after OGTT in, 80-85  
 trinucleotide-repeat combination polymorphism at *rad* gene in, 173-175  
 troglitazone in, *see* Troglitazone in NIDDM  
 UCP2 gene mutation in Japanese subjects with, 581-584  
*see also* Norepinephrine in NIDDM; Streptozotocin-induced diabetes mellitus; Vitamin B<sub>12</sub> in NIDDM
- Non-insulin-dependent diabetes mellitus, CAD and  
 ATP-sensitive K channels in insulin-mediated glucose transport in, 432-436  
 family history of NIDDM and childhood-onset IDDM with CAD, 532
- Nonoxidative hepatic glucose metabolism in cirrhosis, 1260-1266
- Nonsmokers  
 plasma leptin in, 804-808  
 SM glucose uptake in, 239-244
- Nordihydroguaiaretic acid (masoprocol), effects of, on glucose transport and lipolysis in adipocytes, 411-414
- Norepinephrine (NE)  
 CGRP effects on, in conscious subjects, 605  
 fasting, in malnourished older cancer subjects, Intralipid and propranolol effects on, 295  
 gut clearance of, in conscious subjects, 259-263  
 leptin suppression in response to hypersecretion of, in pheochromocytoma, 543-545  
 long-term infusion of 5-HT and, into VMH, effects of, on pancreatic islet function, 1287-1289  
 in NIDDM *see* Norepinephrine in NIDDM  
 plasma, *see* Plasma norepinephrine  
 in stress hormone infusion, impact of acute epinephrine discontinuation on hepatic glucose metabolism during, 910-914  
 urinary excretion of, high-sucrose and EPA-E diet effects on, 1092
- Norepinephrine (NE) in NIDDM  
 acute effects of, on adrenergic-mediated ischemia on nerve conduction in, 495-500  
 NE-mediated vasoconstriction in, 1536-1541
- Normal menses, metformin-induced resumption of, in amenorrheic PCOS women, 511-519
- Normal subjects, 55-67, 74-91, 205-220, 269-284, 1328-1335  
 AA effects on plasma and urinary uric acid and uridine in, 1023-1027  
 acipimox effects on FFAs in, 1318-1321  
 ACTH-induced plasma Lp(a) reduction in, 342-346  
 acute effects of adrenergic-mediated ischemia on MNCV in, 495-500  
 aortic wall in, 55-59  
 apo A excretion in, 369-372  
 ATP-sensitive K channels in insulin-mediated glucose transport in, 432-436  
 blood vessels in, 406-409  
 circulating TNF- $\alpha$  concentrations in, 1332-1335  
 cytokines from mitogen-stimulated PBMCs in, 1397-1401  
 effects of local sympathetic blockade on BF and glucose uptake during hypoglycemia in, 1575-1583  
 effects of triphasic OCs with desogestrel or LN on apo A-I-containing HDL particles, 658-664  
 exercising, *see* Exercise  
 GH in, *see* Normal subjects, GH in  
 glucose effects on plasma purines and uridine in, 338-341
- Normal subjects (*Continued*)  
 hepatic nonoxidative glucose metabolism in, 1260-1266  
 HPA axis and SNS activities in, 395-399  
 hyperinsulinemia in, as predictor of NIDDM, HTN, and CHD, 989-994  
 insulin-induced vasodilation of internal carotid artery in, 1470-1473  
 leptin in, *see* Normal subjects, leptin in  
 long-term valproic acid therapy effects on carnitine reabsorption in, 74-79  
 MTHFR genotype in, 1047-1051  
 NE-mediated vasoconstriction in, 1536-1541  
 net mass transfer of plasma CETPs and lipid transfer proteins in normolipidemic, with peripheral vascular disease, 1361-1366  
 older, *see* Normal subjects, older  
 peripheral tissue glucose uptake after OGTT in, 80-85  
 PP LpB:CIII in, 60-67  
 pregnant, *see* Normal subjects, pregnant  
 RAA system in, 298-300  
 RBCs in, *see* Normal subjects, RBCs in  
 regulation of TGF- $\beta$ , bFGF, and VEGF mRNA in peripheral blood leukocytes of, 1172-1178  
 rhEPO effects in, 210-216  
 serum SSAO activity in, 113-117  
 serum TNF- $\alpha$  in, 437-441  
 short-term MPA effects on LVM in, 1328-1331  
 splanchnic utilization of enteral alanine in, 915-921  
 splanchnic utilization of  $\alpha$ -KIC in, 1555-1563  
 TFAs and S<sub>i</sub> in, 870-875  
 thermogenic effect of hyperglycemia during lipid infusion in, 278-284  
 Trp64Arg variant of  $\beta_2$ -AR gene in, 651-654  
 vitamin E status in, 86-91  
*see also* Men; Women
- Normal subjects, GH in  
 age-related blunting of GH secretion during exercise, 665-670  
 effects of GH therapy and its withdrawal on insulin secretion in, 1387-1396  
 GH effects on acidosis-induced renal N wasting, renal Mg wasting, and renal phosphate depletion, 763-770  
 GH response to GHRH and GHRP-6 in, 525-530  
 preservation of GH secretion in response to GHRP-2 during prednisone therapy of, 585-589
- Normal subjects, leptin in, 217-220  
 in premenopausal subjects, plasma PAI-1 associated with plasma leptin in, irrespective of BMI, FM, and plasma insulin, 960-964  
 T<sub>3</sub> and leptin regulation, 1603-1607  
*see also* Normal subjects, serum leptin in
- Normal subjects, older  
 exercise effects on HDL-C concentrations in, 984-988  
 longitudinal changes in serum 25OHD in, 1028-1032  
 twenty-four hour serum leptin variation in, 1011-1014
- Normal subjects, pregnant  
 effects of plasma from, on HUVECs, 554-557  
 folate status, MTHFR genotype, and Hcy metabolism in, 269-274  
 Phe and tyrosine metabolism in late pregnancy, 849-852
- Normal subjects, RBCs in  
 glucose-treated RBCs, effects of vitamin E and NAC on PS externalization and coagulation induction by, 957-959  
 glycated Hb and RBC lipid peroxidation in, 205-209
- Normal subjects, serum leptin in, 745-748  
 associated with serum uric acid concentrations in, 677-680  
 older, twenty-four hour variation in, 1011-1014
- Normoglycemia in first-degree relatives of NIDDM subjects, effects of dexamethasone on intracellular SM glucose in, 1128-1135

- Normolipidemia  
 dietary fat saturation modulating rates of esterification of cholesterol in normolipidemic men, 1210-1215  
 with peripheral vascular disease, net mass transfer of plasma CETPs and lipid transfer proteins in, 1361-1366
- Normoponderal subjects, *see* Lean subjects
- Normotensive men, effects of acute hyperinsulinemia on urinary nitrite/nitrate excretion and plasma ET-1 levels in, 887-891
- Normotriglyceridemia (NTG), PP VLDL-C and chylomicron remnants in, 301-307
- Northern blot of syndican and glypican mRNA, HS and, 1224
- NOS (nitric oxide synthase), umbilical cord EC, IDDM plasma effects on, 554-557
- NTDs (neural tube defects), folate status, MTHFR genotype, and Hcy metabolism in South African black women with history of pregnancy complicated by, 269-274
- NTG (normotriglyceridemia), PP VLDL-C and chylomicron remnants in, 301-307
- Nutritionally induced non-insulin dependent diabetes mellitus (NIDDM), insulin resistance in, 1549-1554
- O<sub>2</sub> (oxygen)  
 effects of reduced fraction of inspired, on fetal growth and maternal glucose metabolism in pregnancy, 738-744  
 regulation of brain glucose GLUT1 and GLUT3 mRNA by deprivation of glucose and, 422-431  
*see also* O<sub>2</sub> consumption
- O<sub>2</sub> (oxygen) consumption  
 simulation of, following addition of lipid substrates to liver and SM of subjects on HF diet, 1230-1235  
*see also* Excess postexercise oxygen consumption;  $\dot{V}O_2$
- ob* gene  
 suppressed by 15d-PGJ<sub>2</sub>, 786-791  
*see also* Leptin
- Obesity  
 circulating TNF- $\alpha$  concentrations in peripheral versus abdominal, 1332-1335  
 DM with, *see* Diabetes mellitus with obesity; Obesity, NIDDM with dyslipidemia in, BC/SKF38393 effects on, 1033-1040  
 elevated insulin in, and reduced GH response to GHRH, 1152-1156  
 HR variability in, effects of different insulin infusion rates on, 755-762  
 insulin resistance in, *see* Insulin resistance in obesity  
 serum leptin associated with serum uric acid concentrations in, 677-680  
 temporal association between hyperinsulinemia and, in children, adolescents, and young adults, 928-934  
 Trp64Arg variant of  $\beta_3$ -AR gene, *see* Trp64Arg variant of  $\beta_3$ -AR gene, obesity and  
*see also* Adipose tissue; Japanese subjects, obese; Men, obese exercising; Women, obese
- Obesity, NIDDM with  
 exercise and diet effects on LDL subfractions in obese NIDDM men, 641-644  
 and GH response to GHRH and GHRP-6, 525-530
- OCs (oral contraceptives), triphasic, with desogestrel or LN, effects of, on apo A-I-containing HDL particles, 658-664
- Octreotide, effects of, on endothelial dysfunction in IDDM, 1236-1240
- 2-Octynoic acid, simulation of MCAD deficiency with, 685-688
- Offspring, *see* Children
- OGTT, *see* Oral glucose tolerance test
- $\beta$ -OHB, *see*  $\beta$ -Hydroxybutyrate
- 25OHD (25-hydroxyvitamin D), serum, in older subjects, longitudinal changes in, 1028-1032
- 17-OHP (17-hydroxyprogesterone) in PCOS, 169
- Oil, soybean, in high-sucrose diet with EPA-E ester and/or lard, 1090
- Older men  
 GH secretion in, *see* Older men, GH secretion in  
 longitudinal changes in serum 25OHD in, 1028-1032  
 twenty-four hour variation in serum leptin in, 1011-1014  
*see also* Older men and women, exercising; Older subjects
- Older men, GH secretion in  
 blunting of, during exercise, SRIH tone and, 665-670  
 relationship between AT, serum lipids and, GH secretion, 1424-1431
- Older men and women, exercising  
 blunting of GH secretion in older men, 665-670  
 effects of chromium picolinate supplementation on glucose metabolism in, 546-553  
 exercise effects on HDL-C in, 984-988  
 Lp-lipid profile of, differential effects of body composition and exercise on, 1474-1480  
*see also* Older obese men, exercising
- Older obese men, exercising  
 leptin and obesity but not CV fitness as predictors of AT-LPL activity in sedentary and exercising men, 183-189  
 with NIDDM, effects of exercise and diet on LDL subfractions in, 641-644
- Older subjects  
 malnourished cancer, metabolic effects of Intralipid and propranolol in, 291-297  
 NO modulating GH-releasing activity of Hexarelin in, 176-182  
*see also* Older men; Older women
- Older women  
 longitudinal changes in serum 25OHD in, 1028-1032  
 relationship between GH secretion, AT, and serum lipids in, 1424-1431  
*see also* Older men and women, exercising; Older subjects
- Oleic acid, TFAs and, 873
- Oligomycin, oxidation of, in liver and SM, HF diet and, 1234
- Oligopeptide transporter, intestinal, Pept-1 as, functional and molecular expression of, after brief fast, 681-684
- Omega-3 polyunsaturated fatty acids, *see*  $\omega$ -3 Polyunsaturated fatty acids
- Oral contraceptives (OCs), triphasic, with desogestrel or LN, effects of, on apo A-I-containing particles, 658-664
- Oral glucose tolerance test (OGTT)  
 in exogenous hyperinsulinemia, 466-468  
 FES exercise effects on, 1411  
 in hyperinsulinism, 107-112  
 imidapril effects on, 1249  
 lipid infusion effects on, 278-284  
 in NIDDM, plasma insulin response to, 479  
 of older exercising men and women on chromium picolinate supplementation, 550  
 after orthotopic pancreas transplantation, 646-649  
 peripheral tissue glucose uptake after, in subjects at risk for developing NIDDM, 80-85  
 in TS, 9-10
- Organ weight  
 heart, and C-lowering effects of unsaturated fat, 201  
 of placenta, hypoxemia effects on, 740  
*see also* Organ weight, liver; Organ weight, pancreas
- Organ weight, liver  
 PV effects on, 619  
*see also* Organ weight, liver, diet effects on
- Organ weight, liver, diet effects on  
 of cereal-based diet with C, 402  
 of C-lowering unsaturated fat, 201  
 of dietary FAs in STZ-DM, 456

- Organ weight, pancreas  
 acarbose effects on, 350  
 in pregnancy with insulin resistance, 1341
- Orthophosphate, *see* Inorganic phosphate
- Orthotopic pancreas transplantation, preservation of incretin effects after, 645-650
- Osteocalcin  
 serum, galactose effects on urinary excretion of, 905-906  
 T<sub>3</sub> effects on, 1605
- Osteomyelitis of foot, localized or minimal, in IDDM and NIDDM, role of combined RI and MRI diagnosis of, in conservative management, 922-927
- Osteopenia (bone loss), diabetic, in galactose-fed subjects, protective effects of ARI against, 904-909
- Ovarian cysts, insulin biphasic effect on ability of hCG to induce, 995-1002
- Oxidase, activity of serum semicarbazide-sensitive amine, in NIDDM, correlated with BMI and serum TGs, 113-117
- Oxidation  
 FA, *see* Oxidation, FA  
 glucose, *see* Oxidation, glucose  
 HDL, effects of HDL glycation on, 139-143  
 in NIDDM, *see* Oxidation in NIDDM
- Oxidation, FA  
 effects of, on renal free carnitine and acylcarnitine, 709  
 effects of, on renal PDH complex, 709-710  
 hepatic FA, sesamin effects on, 1303-1313  
 with HF diet, 1234  
 TDG or MPCA effects on, 707-715
- Oxidation, glucose  
*cis* and *trans* FA effects on, 26  
 substrate interactions in short- and long-term regulation of, 707-715
- Oxidation, lipid  
 E effects on, 462  
 T<sub>3</sub> effects on, 1605  
*see also* Peroxidation, lipid
- Oxidation in NIDDM  
 with angiopathy, RBC susceptibility to, 1481-1484  
 meal-induced LDL, hyperglycemia and, 1503-1508
- Oxidative stress  
 diabetic neuropathy and, 442-447  
 in NIDDM, *see* Oxidative stress in NIDDM  
 soy protein/soluble fiber diet effects on, 812  
 in STZ-DM, lithium effects on, 560
- Oxidative stress in NIDDM  
 LDL oxidation and meal-induced, hyperglycemia and, 1503-1508  
 and total depletion of antioxidant capacity, 1414-1417
- Oxidizability, LDL, before and after LDL apheresis, 881-886
- Oxygen, *see* O<sub>2</sub>
- P (phosphorus)  
 in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
 serum, galactose effects on, 906
- P<sub>i</sub>, *see* Inorganic phosphate
- Pacific Islanders, traditional, low serum insulin in, 1216-1219
- PAF-AH (platelet-activating factor acetylhydrolase), plasma, in HIV infection and AIDS, 1524-1531
- PAI, *see* Plasminogen activator inhibitor; Plasminogen activator inhibitor-1
- PAI-1 gene, polymorphism of, in PCOS, metformin-induced resumption of normal menses and, 512, 514
- Palmitic acid, TFAs and, 873
- Palmitoleic acid, TFAs and, 873
- Palmitoyl carnitine, oxidation of, in liver and SM, HF diet and, 1234
- Palmitoyl coenzyme A (CoA), oxidation of, in liver and SM, HF diet and, 1234
- Pancreas  
 in DM, *see* Pancreas in DM  
 orthotopic transplantation of, preservation of incretin effects after, 645-650  
 weight of, *see* Organ weight, pancreas  
*see also* Beta cells; Islets of Langerhans
- Pancreas in DM  
 in obesity, acarbose effects on, 347-354  
 peripheral insulin in diabetic depancreatized subjects, glucose production dependent on, 153-160
- Pantothenic acid in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Paracentesis of ascites, effects of, on DEXA measurements of BMD or BMC, 373-377
- Paralyzed skeletal muscle, FES exercise effects on GLUT1 and GLUT4 in, 1409-1413
- Parametrial adipose tissue (AT), BC/SKF38393 effects on lipolysis in, 1027
- Parathyroid hormone (PTH), serum, galactose effects on, 906
- PBMCs (peripheral blood mononuclear cells), mitogen-stimulated, from critically ill multiple-trauma victims, cytokine release by, 1397-1401
- PC (pyruvate carboxylase), LA effects on, 508
- PCO<sub>2</sub>, aortopulmonary shunts and, 1084
- PCOS, *see* Polycystic ovary syndrome
- PDH (pyruvate dehydrogenase) kinase, insulin activation of, enhanced by exercise, 865-866
- PDH, *see* Pyruvate dehydrogenase complex
- PEPCK, *see* Phosphoenolpyruvate carboxylase
- Pept-1 (intestinal oligopeptide transporter), functional and molecular expression of, after brief fast, 681-684
- Peptidase, *see entries beginning with terms*: Dipeptidyl peptidase IV
- Peptides  
 atrial natriuretic, and early renal failure in STZ-DM, 771-778  
*see also* Amylin; Calcitonin gene-related peptide; C-peptide(s); Glucagon-like peptide-1; Glucagon-like peptide-1 antagonist; Growth hormone-releasing peptide-2; Growth hormone-releasing peptide-6; Oligopeptide transporter
- Percent body fat, relationship of Trp64Arg variant of  $\beta_3$ -AR gene to total body fat but not to insulin level and, in Thai subjects, 564-567
- Peripheral blood leukocytes in diabetic retinopathy, regulation of TGF- $\beta$ , bFGF, and VEGF mRNA in, 1172-1178
- Peripheral blood mononuclear cells (PBMCs), mitogen-stimulated, from critically ill multiple-trauma victims, cytokine release by, 1397-1401
- Peripheral insulin in diabetic depancreatized subjects, glucose production dependent on, 153-160
- Peripheral obesity, circulating TNF- $\alpha$  concentrations in abdominal versus, 1332-1335
- Peripheral tissue, glucose uptake by, after OGTT in subjects at risk for developing NIDDM, 80-85
- Peripheral vascular disease, normolipidemia with, net mass transfer of plasma CETPs and lipid transfer proteins in, 1361-1366
- Peroxidase (Px), lipid and GSH, in STZ-DM, lithium effects on, 561
- Peroxidation, lipid  
 in STZ-DM, AMGN effects on, 1141-1145  
*see also* Peroxidation, lipid, in NIDDM
- Peroxidation, lipid, in NIDDM  
 metformin versus gliclazide effects on, 897-903  
 in NIDDM erythrocytes, glycated Hb and, 205-209
- Peroxide, blood lipid, in STZ-DM, lithium effects on, 561

- Peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ), 15-d-PGJ<sub>2</sub> as natural ligand of, *ob* gene suppressed by, 786-791
- PET (positron emission tomography) with [<sup>11</sup>C]-HED in assessment of cardiac sympathetic dysinnervation in IDDM, 92-101
- PGF<sub>1 $\alpha$</sub>  (prostaglandin F<sub>1 $\alpha$</sub> ), plasma 6-keto, in essential HTN, effects of long-term lisinopril therapy on, 1257
- 15d-PGJ<sub>2</sub> (15-deoxy- $\Delta^{12,14}$  prostaglandin J<sub>2</sub>), *ob* gene suppressed by, 786-791
- pH  
arterial, aortopulmonary shunts and, 1084  
and L-leucine transport in small intestine BBMs, 1435
- PH (primary hyperparathyroidism), RAA in, before and after surgery, 298-300
- Phe, *see* Phenylalanine
- Phenotype  
apo A, relationship between Lp(a) troglitazone-induced increase and, in HTN, 1-2  
LDL particle size, in childhood-onset IDDM with CAD, 532, 533  
NIDDM, age and dimorphism of, 477-483  
of *UCP1* gene, Trp64Arg variant of  $\beta_3$ -AR gene in obese Japanese men and, 636-640
- Phenylalanine (Phe)  
differences in protein synthesis between leucine and, following unbalanced infusion of amino acids, 1564-1569  
effects of, on plasma and urinary concentrations of uric acid and uridine, 1024  
exercise-induced gut and SM proteolysis and, 163, 164  
metabolism of, in late pregnancy, 849-852  
plasma DOPA and activities of HPA axis and SNS, 396
- D-[<sup>13</sup>C]Phenylalanine (Phe), renal reabsorption of, and effects of, on urinary AAs, 732-737
- L-Phenylalanine (Phe), and leucine kinetics, 1379
- L-[1-<sup>13</sup>C]Phenylalanine (Phe), isotopic enrichment of urinary AAs following infusions of, 732-737
- Pheochromocytoma, leptin suppression in response to hypersecretion of catecholamines in, 543-545
- Phosphatase, *see* Glucose-6-phosphatase; Na/K-ATPase
- Phosphate  
renal, GH therapy effects on CMA-induced wasting of, 763-770  
*see also* ADP; ATP; cAMP; cGMP; Galactose-1-phosphate uridyl-transferase; Glucose-6-phosphate; Inorganic phosphate; Plasma phosphate; Urinary excretion of phosphate
- Phosphatidylinositol (PI) 3-kinase associated with IRS proteins in liver and muscle, effects of imidapril on, 1250-1251
- Phosphatidylserine (PS), effects of vitamin E and NAC on induction of coagulation in glucose-treated erythrocytes and externalization of, 957-959
- Phosphoenolpyruvate carboxylase (PEPCK)  
hepatic, in nutritionally induced NIDDM, 1550  
LA effects on, 508
- Phosphoinositide, C-AD reversing hyperglycemia-induced inhibition of synthesis of, in RPE cells, and preventing reduction of MNCV in STZ-DM, 827-833
- Phospholipid(s) (PL)  
biliary, PV effects on, 618-626  
in dyslipidemia, BC/SKF38393 effects on, 1035  
effects of high-sucrose diet with EPA-E ester and/or lard on, 1093, 1094  
effects of triphasic OCs with desogestrel or LN on, 660, 661  
liver and serum, sesamin effects on, 1309  
in normolipidemia with peripheral vascular resistance, 1363, 1364  
plasma, *see* Plasma phospholipids  
platelet, effects of fish and exercise on, in NIDDM, 1404  
*see also* Phospholipid(s), diet effects on
- Phospholipid(s) (PL), diet effects on  
soy protein with very low dietary C diet, 491  
in STZ-DM, effects of dietary FAs on plasma PLs, 456
- Phospholipid transfer proteins (PLTPs), plasma, net mass transfer of plasma CETPs and, in normolipidemic subjects with peripheral vascular disease, 1361-1366
- Phosphorus, *see* P
- Phosphorylation of IRS proteins in liver and muscle, imidapril effects on, 1249-1250
- Physiologic hyperinsulinemia, chronic, plasma FFAs, de novo lipogenesis, and dyslipidemia in conscious subjects, 330-337
- Phytosterols  
total, in C-lowering diet with soy protein and soluble fiber, 811  
*see also* Campestanol, sitostanol and; Cholesterol
- PI (phosphatidylinositol) 3-kinase associated with IRS proteins in liver and muscle, effects of imidapril on, 1250-1251
- Pima Indians, activities of HPA axis and SNS in, 395-399
- Pituitary galanin (GAL), effects of short-term glucocorticoid administration on synthesis of, 792-796
- PK (protein kinase), effects of inhibitor of, on hCG-stimulated androgen production and cAMP levels in Leydig tumor cells, 695
- PKC (protein kinase C), elevated glucose effects on arterial contractions and on intracellular Ca release induced by, 1015-1022
- PL(s), *see* Phospholipid(s)
- Placenta, hypoxemia effects on  
on abundance of GLUT3 mRNA in, 743  
on placental weight, 740
- Placental 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD), effects of inhibition of, on glucose metabolism and 11 $\beta$ -HSD regulation in adult offspring, 1584-1588
- Plant stanols, *see* Phytosterols
- Plant sterols, *see* Phytosterols
- Plasma  
IDDM, inducing functional modification in umbilical cord ECs, 554-557  
*see also entries beginning with term:* Plasma
- Plasma adenosine, F and xylitol effects on, 520-524
- Plasma alanine (Ala)  
circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460  
in diabetic depancreatized subjects, 158
- Plasma aldosterone, F effects on, 523
- Plasma bradykinin in essential HTN, effects on long-term lisinopril therapy on, 1257
- Plasma Ca (calcium) in PH, 299
- Plasma cAMP (cyclic adenosine monophosphate), AA effects on, 1024-1026
- Plasma catalase in STZ-DM, 444, 445
- Plasma cholesterol in CTX, 236
- Plasma cholesterol (C)  
C-containing diet effects on, 402  
in CTX, 236  
in NIDDM, *see* Plasma cholesterol in NIDDM  
in normolipidemia with peripheral vascular resistance, 1363  
in STZ-DM, *see* Plasma cholesterol in STZ-DM  
total, in human apo A-II transgenic mice, 416
- Plasma cholesterol (C) in NIDDM  
with angiopathy, 1482  
LDL composition and metabolism and, 119, 121
- Plasma cholesterol (C) in STZ-DM  
AMGN effects on, 1142  
effects of dietary FAs on, 456
- Plasma cholesteryl ester transfer proteins (CETPs), net mass transfer of plasma lipid transfer proteins and, in normolipidemic subjects with peripheral vascular disease, 1361-1366

- Plasma corticotropin (ACTH; adrenocorticotropin hormone), and activities of HPA axis and SNS, 396
- Plasma cortisol in NIDDM with CAD, nicorandil effects on, 435
- Plasma C-peptides (connecting peptides)  
fasting, in NIDDM-prone subjects, 81  
in NIDDM with CAD, nicorandil effects on, 435
- Plasma dihydroxyphenyl acetic acid (DOPAC), and activities of HPA axis and SNS, 396
- Plasma dihydroxyphenylalanine (DOPA), and activities of HPA axis and SNS, 396
- Plasma dihydroxyphenylglycol (DHPG), and activities of HPA axis and SNS, 396
- Plasma endothelin-1 (ET-1) in hyperinsulinemia  
acute hyperinsulinemia effects on ET-1 levels in normotensive and essentially hypertensive men, 887-891  
in exogenous hyperinsulinemia, 465-471
- Plasma epinephrine (E)  
acipimox and exercise effects on, 248  
and activities of HPA axis and SNS, 396  
effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1007  
in whole-body lipolysis, hypoosmolality effects on, 474, 475
- Plasma estradiol (E<sub>2</sub>), aging and effects of E<sub>2</sub> replacement on, 535-541
- Plasma fatty acids (FAs)  
effects of MPCA or TDG on FA supply or oxidation on, 708-709  
*see also* Plasma free fatty acids
- Plasma free fatty acids (FFAs; nonesterified fatty acids)  
CGRP effects on, in conscious subjects, 605, 607  
chronic physiologic hyperinsulinemia and, 330-337  
E effects on, 462  
fasting, in NIDDM-prone subjects, 81  
LA effects on, 508  
in NIDDM with CAD, nicorandil effects on, 435  
renal glucose oxidation and, 709, 710
- Plasma galactitol in galactosemia due to GALT deficiency, 1294-1302
- Plasma glucagon  
AA effects on, 1024  
fasting, in NIDDM-prone subjects, 81  
glucose effects on, 339, 340  
in NIDDM, GLP-1-Gly8 effects on, 255
- Plasma glucose  
acipimox and exercise effects on, 247  
CGRP effects on, in conscious subjects, 605  
E effects on, 462  
fasting, *see* Fasting plasma glucose  
in hyperinsulinemia, 333, 335, 467  
in hyperinsulinism, 109  
in hyperthyroidism, 1319  
imidapril effects on, 1250  
insulin secretion and, 4  
and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 781  
lipid infusion effects on, 282  
in NIDDM, *see* Plasma glucose in NIDDM  
in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1129  
in STZ-DM, 456, 1142  
TFAs and, in young women, 873
- Plasma glucose in NIDDM  
with angiopathy, 1482  
and changes in islet capillary angioarchitecture, 479  
cochlear dysfunction and, 1348  
GLP-1-Gly8 effects on, 255
- Plasma glutamate (Glu), circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460
- Plasma glutamine (Gln), circadian variation on concentrations of, in men on diet with and without added MSG, 1455-1460
- Plasma glutathione (GSH), nerve, in STZ-DM, 444, 445
- Plasma glycerol  
in diabetic depancreatized subjects, 158  
in whole-body lipolysis, hypoosmolality effects on, 474, 475
- Plasma high-density lipoprotein (HDL) in human apo A-II transgenic mice, 416
- Plasma high-density lipoprotein-cholesterol (HDL-C)  
apo E genotype and exercise inducing increases in, in obese men, 943-945  
in CTX, 236
- Plasma high-density lipoprotein<sub>2</sub>-cholesterol (HDL<sub>2</sub>-C), apo E genotype and exercise inducing increases in, in obese men, 943-945
- Plasma hypoxanthine (HX)  
F and xylitol effects on, 520-524  
glucose effects on, 338-341  
levels of, and altered purine and glycogen metabolism in SM during exercise by heart failure subjects, 484-488  
*see also* Urinary excretion of uridine and purine bases
- Plasma insulin  
AA effects on, 1024  
E effects on, 462  
effects of local sympathetic blockade on, 1579, 1581  
exercise-induced gut and SM proteolysis and, 163  
fasting, *see* Fasting plasma insulin  
glucose effects on, 339, 340  
in hyperinsulinemia, 333, 335  
in hyperinsulinism, 109  
in hyperthyroidism, 1319  
imidapril effects on, 1250  
and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 781  
lipid infusion effects on, 282  
in NIDDM, *see* Plasma insulin in NIDDM  
in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1129  
in NTG and HTG, 304-305  
plasma leptin associated with plasma PAI-1 irrespective of BMI, metabolic parameters and, in premenopausal women, 960-964  
TFAs and, in young women, 873
- Plasma insulin in NIDDM  
GLP-1-Gly8 effects on, 255  
response of, to IVGTT, 480  
response of, to OGTT, 479
- Plasma intermediate-density lipoprotein (IDL) in human apo A-II transgenic mice, 416
- Plasma K (potassium) in PH, 299
- Plasma 6-keto prostaglandin F<sub>1α</sub> (PGF<sub>1α</sub>) in essential HTN, effects on long-term lisinopril therapy on, 1257
- Plasma lactate  
in depancreatized diabetic subjects, 158  
in hyperinsulinemia, 335
- Plasma lathosterol in CTX, 236
- Plasma leptin  
effects of smoking and its cessation on BW and, 804-808  
energy expenditure and determination of AT and, in male subjects, 1272-1277  
in premenopausal women, plasma leptin associated with plasma PAI-1 irrespective of BMI, FM, metabolic parameters and, 960-964
- Plasma leucine (Leu), exercise-induced gut and SM proteolysis and, 163
- Plasma lipid(s)  
effects of high-sucrose diet with EPA-E ester and/or lard on, 1093

- Plasma lipid(s) (*Continued*)  
 effects of triphasic OCs with desogestrel or LN on, 659, 660  
 fasting, in NTG and HTG men, 302-303  
 in NIDDM, and changes in islet capillary angioarchitecture, 479  
*see also specific lipids*
- Plasma lipid hydroperoxides in STZ-DM, AMGN effects on, 1142
- Plasma lipid transfer proteins, net mass transfer of plasma CETPs and, in normolipidemic subjects with peripheral vascular disease, 1361-1366
- Plasma lipoprotein(s) (Lp)  
 fasting, in NTG and HTG men, 302-303  
*see also specific lipoproteins*
- Plasma lipoprotein(a) [Lp(a)], ACTH-induced reduction of, in normal and HD subjects, 342-346
- Plasma low-density lipoprotein(s) (LDL)  
 in human apo A-II transgenic mice, 416  
 in hyperinsulinemia, 110
- Plasma low-density lipoprotein-cholesterol (LDL-C)  
 in CTX, 236  
 in NIDDM, LDL composition and metabolism and, 119
- Plasma malondialdehyde (MDA) in STZ-DM, 444
- Plasma monoclonal antibodies (MoAbs), immunoblockade of GLP-1 and, 43
- Plasma Na (sodium)  
 hypoosmolality and, 473  
 in PH, 299
- Plasma NH<sub>3</sub> (ammonia), levels of, and altered purine and glycogen metabolism in SM during exercise by heart failure subjects, 484-488
- Plasma nitric oxide (NO), and related vasoactive factors following long-term lisinopril therapy for essential HTN, 1256-1259
- Plasma norepinephrine (NE)  
 acipimox and exercise effects on, 248  
 and activities of HPA axis and SNS, 396  
 effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1007  
 in NIDDM, and acute effects of adrenergic-mediated ischemia on nerve conduction, 496  
 in obese and lean subjects, HR variability and, 758, 760  
 in whole-body lipolysis, hypoosmolality effects on, 474, 475
- Plasma phenylalanine (Phe), exercise-induced gut and SM proteolysis and, 163
- Plasma phosphate  
 inorganic, glucose effects on, 339-341  
 in PH, 299
- Plasma phospholipid(s) (PLs)  
 imidapril effects on, 1250  
 in normolipidemia with peripheral vascular resistance, 1363  
 in STZ-DM, effects of dietary FAs on, 456
- Plasma phospholipid transfer proteins (PLTPs), net mass transfer of plasma CETPs and, in normolipidemic subjects with peripheral vascular disease, 1361-1366
- Plasma plasminogen activator inhibitor-I (PAI-1), plasma leptin associated with, irrespective of BMI, FM, plasma insulin, and metabolic parameters in premenopausal women, 960-964
- Plasma platelet-activating factor acetylhydrolase (PAF-AH) in HIV infection and AIDS, 1524-1531
- Plasma progesterone, effects of aging on, 535-541
- Plasma prolactin (PRL), aging effects on, 535-541
- Plasma purine bases, *see* Plasma hypoxanthine; Plasma xanthine
- Plasma renin activity (PRA)  
 in essential HTN, effects of long-term lisinopril therapy on, 1257  
 F effects on, 523  
 in PH, 299
- Plasma steroids, ovarian cysts and concentrations of, 999-1000
- Plasma superoxide dismutase (SOD) in STZ-DM, 445
- Plasma triglycerides (TGs)  
 imidapril effects on, 1250  
 in NIDDM, *see* Plasma triglycerides in NIDDM  
 in normolipidemia with peripheral vascular resistance, 1363  
 in STZ-DM, AMGN effects on, 1142  
*see also* Plasma triglycerides, diet effects on
- Plasma triglycerides (TGs), diet effects on  
 of dietary FAs in STZ-DM, 456  
 high-sucrose diet with EPA-E ester and/or lard, 1093  
 of unsaturated fat, 201
- Plasma triglycerides (TGs) in NIDDM  
 with angiopathy, 1482  
 LDL composition and metabolism and, 119, 121
- Plasma urea in STZ-DM, 444
- Plasma uric acid  
 AA effects on, 1023-1027  
 F and xylitol effects on, 520-524  
 glucose effects on, 338-341  
*see also* Urinary excretion of uridine and purine bases
- Plasma uridine  
 AA effects on, 1023-1027  
*see also* Urinary excretion of uridine and purine bases
- Plasma very-low-density lipoprotein (VLDL) in human apo A-II transgenic mice, 416
- Plasma xanthine  
 F and xylitol effects on, 520-524  
 glucose effects on, 338-341  
*see also* Urinary excretion of uridine and purine bases
- Plasminogen activator inhibitor (PAI), as risk factor for miscarriage in PCOS women, 1589-1595
- Plasminogen activator inhibitor-1 (PAI-1), plasma leptin associated with, irrespective of BMI, FM, plasma insulin, and metabolic parameters in premenopausal women, 960-964
- Platelet(s), and F and xylitol effects on urinary excretion and plasma concentrations of adenosine, uridine, and purine bases, 521
- Platelet-activating factor acetylhydrolase (PAF-AH), plasma, in HIV infection and AIDS, 1524-1531
- Platelet count, and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 782
- Platelet phospholipids (PLs), effects of fish and exercise on, in NIDDM, 1404
- PLTPs (phospholipid transfer proteins), plasma, net mass transfer of plasma CETPs and, in normolipidemic subjects with peripheral vascular disease, 1361-1366
- PMNs (polymorphonuclear leukocytes; neutrophils), chemotactic activation of, in NIDDM, filtration parameter and membrane fluidity following, 30-33
- PO<sub>2</sub>, aortopulmonary shunts and, 1084
- Polycystic ovary syndrome (PCOS)  
 insulin and obesity effects on metabolic and endocrine variables in, 167-172  
 metformin-induced resumption of normal menses with, 511-519  
 in normoponderal women, serum TNF- $\alpha$  in, 437-441  
 PAI as risk factor for miscarriage by women with, 1589-1595
- Polymorphism  
 apo E, *see* Apolipoprotein E genotype  
*FABP2* gene, in obese insulin-resistant Japanese subjects, 655-657  
*LPL HindIII* gene, in young MI adults, 1157-1161  
 in NIDDM, *see* Polymorphism in NIDDM  
*PAI-1* gene, in PCOS, metformin-induced resumption of normal menses and, 512, 514  
*see also* Mutation and entries beginning with terms: Trp64 variant of  $\beta_3$ -AR gene



- Polymorphism in NIDDM  
 trinucleotide-repeat combination, at *rad* gene, 173-175  
*UCP2* gene, 583
- Polymorphonuclear leukocytes (PMNs), chemotactic activation of, in NIDDM, filtration parameter and membrane fluidity following, 30-33
- Polyol pathway, involvement of, in bone metabolism, and protective effects of ARI against diabetic bone loss in galactose-fed subjects, 904-909
- Polyunsaturated fatty acids (PUFAs)  
 in C-lowering diets, 810, 811, 923  
 in high-sucrose diet with EPA-E ester and/or lard, 1094  
*see also*  $\omega$ -3 Polyunsaturated fatty acids
- $\omega$  (omega)-3 Polyunsaturated fatty acids (PUFAs)  
 effects of, on recovery of cardiac function after cold storage of heart, 1203-1209  
 in EPA-E diet, 1094
- Positron emission tomography (PET) with [ $^{11}\text{C}$ ]-HED in assessment of cardiac sympathetic dysinnervation in IDDM, 92-101
- Postheparin lipase  
 in MHL, 63  
 PP, in young men, racial differences in, 749-754
- Postmenopausal women  
 anger, hostility, and VAT in, 1146-1151  
 ERT effects on vascular reactivity in, 227-232  
*see also* Hormone replacement therapy in postmenopausal women
- Postprandial (PP) C-peptides (connecting peptides) in exercising Mexican American and non-Hispanic women, 973
- Postprandial (PP) glucagon, pramlintide effects on glycemic control and, in IDDM, 935-941
- Postprandial (PP) glucose in exercising Mexican American and non-Hispanic women, 973
- Postprandial (PP) high-density lipoprotein-cholesterol (HDL-C)  
 HRT enhancing metabolism of, in postmenopausal women, 1194  
 in young men, racial differences in, 750
- Postprandial (PP) insulin, response of, to exercise by Mexican American and non-Hispanic women, 971-977
- Postprandial (PP) lipemia, prior exercise reducing, independently of AT and CHO contributions to energy expenditure during exercise, 245-251
- Postprandial (PP) lipids, HRT enhancing metabolism of, in postmenopausal women, 1193-1196
- Postprandial (PP) lipoprotein B:CIII (LpB:CIII), relationship between HDL subpopulation and changes in particles of, 60-67
- Postprandial (PP) low-density lipoprotein-cholesterol (LDL-C)  
 HRT enhancing metabolism of, in postmenopausal women, 1194  
 in young men, racial differences in, 750
- Postprandial (PP) triglycerides (TGs), postheparin lipase, hepatic TG lipase and, in young men, racial differences in, 749-754
- Postprandial (PP) very-low-density lipoprotein-cholesterol (VLDL-C)  
 PP chylomicron remnants and, in NTG and HTG men with and without CHD, 301-307  
 in young adults, racial differences in, 750
- Potassium, *see* K
- PP, *see* entries beginning with term: Postprandial
- PPAR $\gamma$  (peroxisome proliferator-activated receptor  $\gamma$ ), 15-d-PGJ<sub>2</sub> as natural ligand of, *ob* gene suppressed by, 786-791
- PRA, *see* Plasma renin activity
- Pramlintide, effects of, on glycemic control and PP glucagon concentrations in IDDM, 935-941
- Pravastatin (PV), enhanced FA and C synthesis but not VLDL secretion following blockade of liver HMG-CoA reductase with, 618-626
- Prealbumin, serum vitamin E and, in liver cirrhosis, 89
- Prednisone, preservation of GH secretion in response to GHRP-2 in children on, 585-589
- Preeclampsia, insulin resistance in, 892-896
- Pregnancy  
 complicated by NTDs, folate status, MTHFR genotype, and Hcy metabolism in South African black women with history of, 269-274  
 effects of plasma from pregnant IDDM subjects on umbilical cord ECs, 554-557  
 insulin resistance and, *see* Insulin resistance in pregnancy  
 late, Phe and tyrosine metabolism in, 849-852  
 PAI as risk factor for miscarriage by PCOS women, 1589-1595  
 preeclamptic, insulin resistance in, 892-896  
 reduced FiO<sub>2</sub> effects on fetal growth and maternal glucose metabolism in, 738-744
- Premenopausal women  
 ERT effects on vascular reactivity in, 227-232  
 plasma leptin associated with plasma PAI-1 irrespective of BM, FM, plasma insulin, and metabolic parameters in, 960-964
- Primary hyperparathyroidism (PH), RAA in, before and after surgery, 298-300
- PRL, *see* Prolactin
- Pro, *see* Proline
- Progesterone  
 in PCOS, 169  
 plasma, effects of aging on, 535-541
- Programmed cell death (apoptosis) of beta cells, TNF- $\alpha$  in, 1485-1492
- Proinflammatory cytokines, *see* Cytokines
- Proinsulin, high concentration of, preceding acute MI in nondiabetics, 1197-1202
- Prolactin (PRL)  
 in PCOS, 169  
 plasma, aging effects on, 535-541  
 in uremic subjects on CAPD, long-term effects of rhEPO on, 211  
*see also* Hyperprolactinemia
- Proline (Pro)  
 differences between cellular processing of Lys<sup>B28</sup>Pro<sup>B29</sup> native insulin, and Asp<sup>B10</sup> insulin, 611-617  
 effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- L-Proline (Pro), and leucine kinetics, 1379
- Propionate, effects of soy protein/soluble fiber diet on, 813
- Propranolol, metabolic effects of Intralipid and, in elderly malnourished cancer subjects, 291-297
- Prostaglandin F<sub>1 $\alpha$</sub>  (PGF<sub>1 $\alpha$</sub> ), plasma 6-keto, in essential HTN, effects of long-term lisinopril therapy on, 1257
- 15d-Prostaglandin J<sub>2</sub> (PGJ<sub>2</sub>), *ob* gene suppressed by, 786-791
- Prostate cancer cells, ALVA-101, regulation of, by TGF- $\beta$ 1, TGF-B2, and their type II receptor, 1075-1081
- Protease inhibitors, effects of, on Trp binding to hepatic nuclei, 148
- Protein(s)  
 binding, *see*: *FABP2* gene and entries beginning with terms: Insulin-like growth factor-binding protein  
 cholesteryl ester transfer, *see* Cholesteryl ester transfer proteins;  
 Lipid transfer proteins  
 dietary, *see* Dietary protein  
 differences in synthesis of, following unbalanced infusion of amino acids, 1564-1569  
 FM and toxin-induced infections and, 947  
 GLUT3, loss of, in SM, 876-880  
 IRS, imidapril improving S<sub>i</sub> by improving vascular resistance and enhancing signal transduction via, 1248-1255  
 LDL receptor, PV effects on, 622  
 and L-NAME-NO pathway in endotoxemia-induced muscular hypercatabolism of, 190-193  
 mesangial cell syndican core, HS and, 1224-1225  
 metabolism of whole-body, in late pregnancy, 849-852

Protein(s) (*Continued*)

- muscle, combined hyperlipidemia associated with release of, in exercise, effects of TG-lowering intervention on, 1518-1523
- uncoupling, *see* Uncoupling protein
- see also* Protein intolerance; Protein kinase; Protein kinase C; Proteinuria and specific proteins
- Protein intolerance, lysinuric, effects of reduced NO production by L-arginine deficiency in, on intravascular coagulation, 1136-1140
- Protein kinase (PK), effects of inhibitor of, on hCG-stimulated androgen production and cAMP levels in Leydig tumor cells, 695
- Protein kinase C (PKC), elevated glucose effects on arterial contractions and intracellular Ca release induced by, 1015-1022
- Proteinuria
  - imidapril effects on, 1250
  - see also* Albuminuria in IDDM; Macroalbuminuria; Microalbuminuria
- Proteoglycans, mesangial cell-surface, HS with antimitogenic properties arising from, 1220-1229
- Proteolysis, exercise-induced gut and SM, effects of glucose and AAs on, 161-166
- Prothrombin time (PT) in cirrhosis
  - hepatic glucose metabolism and, 1261
  - serum vitamin E and, 89
- PS (phosphatidylserine), effects of vitamin E and NAC on induction of coagulation in glucose-treated erythrocytes and externalization of, 957-959
- PT, *see* Prothrombin time in cirrhosis
- PUFAs, *see* Polyunsaturated fatty acids
- Pulse rate, *see* Heart rate
- Purine bases, *see* Hyperuricemia; Plasma hypoxanthine; Plasma uric acid; Plasma xanthine; Serum uric acid
- PV (pravastatin), enhanced FA and C synthesis but not VLDL secretion following blockade of liver HMG-CoA reductase with, 618-626
- Px (peroxidase), lipid and GSH, in STZ-DM, lithium effects on, 561
- Pyridinoline (PYR), galactose effects on urinary excretion of, 905-906
- Pyruvate, PDH complex activation by exercise and, 866, 867
- Pyruvate carboxylase (PC), LA effects on, 508
- Pyruvate dehydrogenase (PDH) complex
  - insulin activation of, enhanced by exercise, 865-869
  - renal, renal glucose oxidation and, 709-712
- Pyruvate dehydrogenase (PDH) kinase, insulin activation of, enhanced by exercise, 865-866
- Pyruvic acid
  - AA effects on, 1024-1026
  - glucose effects on, 339-341
  - xylitol and F effects on, 522
- RA (rheumatoid arthritis), disease activity and serum leptin in, 745-748
- RAA (renin-angiotensin-aldosterone) system in PH before and after surgery, 298-300
- Race and ethnicity
  - activities of HPA axis and SNS in Pima Indians, 395-399
  - folate, Hcy, and MTHFR genotype, in South African black women with history of pregnancy complicated by NTDs, 269-274
  - of hyperlipidemic subjects, prediction of atherosclerotic CV disease and, 1438
  - insulin resistance and Trp64Arg variant of  $\beta_3$ -AR gene in Japanese-American men, 1367-1370
  - lipid abnormalities in hyperuricemic Taiwanese aborigines, 131-133
  - low serum insulin in Kitavans, 1216-1219
  - of obese subjects, *see* Race and ethnicity, and obesity
  - peripheral tissue glucose uptake after OGTT in Southern Italians at risk for NIDDM, 80-85

Race and ethnicity (*Continued*)

- and PP TGs, postheparin lipase, and hepatic TG lipase in young men, 749-754
- of pregnant subjects with preeclampsia, insulin resistance and, 893
- relationship of Trp64Arg variant of  $\beta_3$ -AR gene to total body fat but not to percent body fat and insulin level in Thai subjects, 564-567
- response of PP insulin to exercise by Mexican American and non-Hispanic women, 971-977
- sex hormones and hyperinsulinism in young adults and, 107-112
- see also* Japanese subjects
- Race and ethnicity, and obesity
  - with hyperinsulinemia, 929, 930, 932
  - in women,  $S_i$ , serum TGs, visceral and truncal SC AT and, 194-199
- rad gene in NIDDM, trinucleotide-repeat combination polymorphism at, 173-175
- Radionuclide imaging (RI), role of diagnosis of minimal or localized osteomyelitis of foot in IDDM and NIDDM with combined MRI and, in conservative management, 922-927
- RBCs (red blood cells), *see* Erythrocyte(s)
- Recombinant human erythropoietin (rhEPO), long-term effects of, on GH secretion in uremic subjects on CAPD, 210-216
- Recombinant human growth hormone, *see* Growth hormone, therapy with
- Recovery
  - of cardiac function after cold storage of heart,  $\omega$ -3 PUFA effects on, 1203-1209
  - from TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients, 324-329
- Red blood cells, *see* Erythrocyte(s)
- Red wine, effects of tannic acid, ethanol and, on glucose tolerance in NIDDM and on starch digestibility, 1179-1183
- Reduced fraction of inspired oxygen (FiO<sub>2</sub>), effects of, on fetal growth and maternal glucose metabolism in pregnancy, 738-744
- Reductase, *see* Aldose reductase inhibitor; Folate, Hcy and, and MTHFR genotype and specific HMG-CoA reductase inhibitors
- Relatives, first-degree, of NIDDM subjects, normoglycemic, effects of dexamethasone on intracellular SM glucose in, 1128-1135
- Renal acylcarnitine, renal glucose oxidation and, 709-710
- Renal failure
  - early, in STZ-DM, ANPs and, 771-778
  - see also* End-stage renal disease
- Renal function
  - in STZ-DM, 773, 774
  - see also specific aspects of renal function; for example:* Creatinine
- Renal glucose, oxidation of, substrate interactions in short- and long-term regulation of, 707-715
- Renal glucose-6-phosphatase (G6Pase) mRNA (messenger ribonucleic acid), effects of dexamethasone and insulin on levels of, 1052-1056
- Renal Mg (magnesium) wasting, GH therapy effects on CMA-induced, 763-770
- Renal N (nitrogen) wasting, GH therapy effects on CMA-induced, 763-770
- Renal phosphate depletion, GH therapy effects on CMA-induced, 763-770
- Renal pyruvate dehydrogenase (PDH) complex, renal glucose oxidation and, 709-712
- Renin, *see* Plasma renin activity; Renin-angiotensin-aldosterone system
- Renin-angiotensin-aldosterone (RAA) system in PH before and after surgery, 298-300
- RER, *see* Respiratory exchange ratio, exercise and
- Resistance training, *see* Exercise
- Respiratory exchange ratio (RER), exercise and acipimox and exercise effects on, 247

- Respiratory exchange ratio (RER), exercise and (*Continued*)  
 age-related blunting of GH secretion, SRIH tone, and 667  
 menstrual cycle effects on, in exercising young women, 277
- Respiratory infection, tissue distribution and turnover of [<sup>3</sup>H]riboflavin during, 1608-1611
- Respiratory quotient (RQ) in whole-body lipolysis, 475
- Resting metabolic rate (RMR)  
 exercise and, in weight-reduced men, 18, 20  
 menstrual cycle effects on, in young women, 277
- Retinal pigment epithelial (RPE) cells, C-AD reversing hyperglycemia-induced phosphoinositide synthesis inhibition in, and preventing reduction of nerve conduction velocity in STZ-DM, 827-833
- Retinoids inhibiting metabolism of benzo(a)pyrene catalyzed by 3-MC-induced cytochrome P-450 1A1, 689-692
- Retinol, *see* Vitamin A; Vitamin A<sub>1</sub>
- Retinopathy, diabetic, regulation of TGF- $\beta$ , bFGF, and VEGF mRNA in peripheral blood leukocytes in, 1172-1178
- rhEPO (recombinant human erythropoietin), long-term effects of, on GH secretion in uremic subjects on CAPD, 210-216
- Rheumatoid arthritis (RA), disease activity and serum leptin in, 745-748
- RI (radionuclide imaging), role of diagnosis of minimal or localized osteomyelitis of foot in IDDM and NIDDM with combined MRI and, in conservative management, 922-927
- Riboflavin (vitamin B<sub>2</sub>) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- [<sup>3</sup>H]Riboflavin (vitamin B<sub>2</sub>), tissue distribution and turnover of, during respiratory infection, 1608-1611
- Ribonucleic acid, *see* mRNA
- Risk factors  
 for developing NIDDM, peripheral tissue glucose uptake after OGTT and, 80-85  
 for miscarriage by PCOS women, PAI as, 1589-1595  
*see also* Risk factors for CV disease and *specific risk factors*
- Risk factors for CV disease  
 serum lipids and colonic bacteria as, 264-268  
 VAT and metabolic risk factors for CHD, 355-362  
 in weight-reduced men, exercise effects on, 17-19
- RMR, *see* Resting metabolic rate
- RNA (ribonucleic acid), *see* mRNA
- RPE (retinal pigment epithelial) cells, C-AD reversing hyperglycemia-induced phosphoinositide synthesis inhibition in, and preventing reduction of MNCV in STZ-DM, 827-833
- RQ (respiratory quotient) in whole-body lipolysis, 475
- Running, PP lipemia reduced by prior, independently of AT and CHO contributions to energy expenditure during, 245-251
- S, *see* Sucrose
- S<sub>i</sub>, *see* Insulin sensitivity
- [2,3-<sup>13</sup>C]-SAD (succinic acid dimethylester), starvation and DM effects on metabolism of, in hepatocytes, 102-106
- Safety of gemfibrozil combined with lovastatin, 49-50
- Salsalate, effects of short-term therapy with, on serum TSH, 501-503
- SAT, *see* Subcutaneous adipose tissue
- Saturated fatty acids (SFAs)  
 in EPA-E diet, 1094  
*see also* Saturated fatty acids in C-lowering diet
- Saturated fatty acids (SFAs) in C-lowering diet  
 composed of soy protein and soluble fiber, 810, 811  
 in NCEP diet, 823
- Scavenger receptor B1 (SR-B1), CLA-1 as analog of, 627-630
- SCFAs (short-chain fatty acids), effects of soy protein/soluble fiber diet on, 812, 813
- Sedentary men  
 cortisol effects on exercise-induced ACTH increase in, 390-394
- Sedentary men (*Continued*)  
 middle-aged and older, leptin and obesity but not CV fitness as predictors of AT-LPL activity in, 183-189
- Selenium in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Semicarbazide-sensitivity amine oxidase (SSAO), serum, in NIDDM, serum TGs and BMI correlated with activity of, 113-117
- Sepsis  
 leukocyte glycolysis and lactate output in ex vivo blood and, 779-785  
 toxin-induced, FM and, 946-948
- Serine (Ser), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- L-Serine (Ser), and leucine kinetics, 1379
- Serotonin (5-HT), long-term infusion of NE and, into VMH, effects of, on pancreatic islet function, 1287-1289
- Serum albumin  
 in cirrhosis, hepatic glucose metabolism and, 1261  
 galactose effects on, 906
- Serum apolipoprotein(s) (apo)  
 effects of L-T<sub>4</sub> therapy for congenital hypothyroidism on, in infants, 1343-1345  
 TFAs and, in young women, 873
- Serum apolipoprotein A-I (apo A-I), soy protein/soluble fiber diet effects on, 812
- Serum apolipoprotein B (apo B)  
 in men, decrease in SM capillary density related to high, 1267-1271  
 soy protein/soluble fiber diet effects on, 812
- Serum Ca (calcium), galactose effects on, 906
- Serum campestanol, effects of campestanol/sitostanol mixture on proportion of, to C, 577
- Serum  $\alpha$  (alpha)-carotene, effects of campestanol/sitostanol mixture with variable fat intake on level of, 578
- Serum  $\beta$  (beta)-carotene  
 effects of campestanol/sitostanol mixture with variable fat intake on level of, 578  
 soy protein/soluble fiber diet effects on, 812
- Serum cholestanol  
 in CTX, 234  
 ratio of, to C, campestanol/sitostanol mixture effects on, 577
- Serum  $\Delta^8$  (delta<sup>8</sup>)-cholesterol, effects of campestanol/sitostanol mixture on proportion of, to C, 577
- Serum cholesterol (C)  
 fasting, *see* Fasting serum cholesterol  
 PV effects on, 619  
 serum vitamin E and, in liver cirrhosis, 87, 89  
 L-T<sub>4</sub> effects on, 1343  
*see also* Serum cholesterol, diet effects on
- Serum cholesterol (C), diet effects on  
 diet and exercise effects on, in obese NIDDM men, 642  
 effects of campestanol/sitostanol mixture with variable fat intake on, 577  
 total, effects of soy protein/soluble fiber diet on, 812
- Serum cortisol, effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1007
- Serum creatinine  
 in essential HTN, effects on long-term lisinopril therapy on, 1257  
 galactose effects on, 906, 907  
 in NIDDM, 1098, 1099
- Serum dehydroepiandrosterone sulfate (DHEAS;  $\beta$ -hydroxy-5-androsten-17-one) in normoponderal PCOS subjects, 440
- Serum desmosterol, effects of campestanol/sitostanol mixture on proportion of, to C, 577
- Serum folate  
 effects of vitamin B<sub>12</sub> supplementation on Hcy, MMA and, in relation to C677T MTHFR genotype in ESRD, 631-635

- Serum folate (*Continued*)  
 in NIDDM, 1097, 1099
- Serum free fatty acids (FFAs; nonesterified fatty acids)  
 effects of individualized GH therapy of childhood-onset GH deficiency in adults on, 1006, 1007  
 effects of PHDC activation by exercise on, 866, 867  
 in nutritionally induced NIDDM, 1550  
 sesamin effects on, 1309  
*see also* Serum free fatty acids in Japanese subjects
- Serum free fatty acids (FFAs; nonesterified fatty acids) in Japanese subjects  
 with NIDDM and insulin resistance, *FABP2* gene polymorphism and, 656  
 obese, Trp64Arg variant of  $\beta_3$ -AR gene and *UCP1* gene mutation in, 637, 638
- Serum free triiodothyronine ( $T_3$ ) with HF diet, 1233
- Serum fructosamine, galactose effects on, 906
- Serum glucagon, effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1007
- Serum glucose  
 effects of PHDC activation by exercise on, 866, 867  
 galactose effects on, 905, 906  
 in nutritionally induced NIDDM, 1550  
 sesamin effects on, 1309
- Serum high-density lipoprotein (HDLs)  
 in dyslipidemia, BC/SKF38393 effects on, 1036  
 fasting, chronic smoking effects on, 140  
 and lipid peroxidation in NIDDM, 900
- Serum high-density lipoprotein-cholesterol (HDL-C)  
 in CHD, 854, 855  
 soy protein/soluble fiber diet effects on, 812  
 L- $T_4$  effects on, 1343, 1344
- Serum 25-hydroxyvitamin D (25OHD) in older subjects, longitudinal changes in, 1028-1032
- Serum insulin  
 acarbose effects on, 349-350  
 fasting, *see* Fasting serum insulin  
 low, in Kitavans, 1216-1219  
 in nutritionally induced NIDDM, 1550, 1551
- Serum insulin-like growth factor-I (IGF-I) in GH-deficient adults  
 GH therapy effects on, 309  
 individualized low-dose GH therapy and, 1004
- Serum insulin-like growth factor-binding protein-1 (IGFBP-1), effects of individualized low-dose GH therapy of childhood-onset GH deficiency in adults on, 1006, 1007
- Serum lathosterol, effects of campestanol/sitostanol mixture on proportion of, to C, 577
- Serum leptin  
 effects of aging-related changes in sex hormones on sex difference in, independently of AT changes, 378-384  
 in NIDDM with microalbuminuria and macroalbuminuria, 1290-1293  
 in RA, disease activity and, 745-748  
 relationship between IGF-I, IGFBP-1, and IGFBP-3 and, 840-844  
 serum uric acid concentrations associated with, 677-680  
 twenty-four hour variation in, in older men, 1011-1014
- Serum lipids  
 in CT, 235-236  
 effects of T substitution modes on, in hypogonadal men, 590-596  
 in FCHL, gemfibrozil and lovastatin effects on, 49  
 hepatic, PV effects on, 619-621  
 in NIDDM with insulin resistance, *FABP2* gene polymorphism and, in Japanese subjects, 656  
 in obesity, *see* Serum lipids in obesity  
 in older men and women, *see* Serum lipids in older men and women
- Serum lipids (*Continued*)  
 as risk factors for CV disease, colonic bacteria and, 264-268  
 sesamin effects on, 1309  
 soy protein with very low dietary C effects on, 489-494  
 TFAs and, in young women, 873  
*see also specific lipids*
- Serum lipids in obesity  
 miglitol effects on, 705  
 in obese Japanese men with Trp64Arg variant of  $\beta_3$ -AR gene and *UCP1* gene mutation, 637, 638
- Serum lipids in older men and women  
 differential effects of exercise and body composition on, 1475-1476  
 relationship between GH secretion, AT and, 1424-1431
- Serum lipoproteins (Lps)  
 effects of T substitution modes on, in hypogonadal men, 590-596  
 in FCHL, gemfibrozil and lovastatin effects on, 49  
 in older men and women, differential effects of exercise and body composition on, 1475-1476  
 as risk factor for CV disease, colonic bacteria and, 266-268  
 TFAs and, in young women, 873
- Serum low-density lipoprotein(s) (LDL)  
 in dyslipidemia, BC/SKF38393 effects on, 1036  
 and lipid peroxidation in NIDDM, 900
- Serum low-density lipoprotein-cholesterol (LDL-C)  
 in men, decrease in SM capillary density related to high, 1267-1271  
 soy protein/soluble fiber diet effects on, 812  
 L- $T_4$  effects on, 1344
- Serum luteinizing hormone (LH) in PCOS, 440
- Serum Mg (magnesium), galactose effects on, 906
- Serum osteocalcin, galactose effects on, 905-906
- Serum P (phosphorus), galactose effects on, 906
- Serum parathyroid hormone (PTH), galactose effects on, 906
- Serum phospholipids (PLs), sesamin effects on, 1309
- Serum retinol (vitamin  $A_1$ ), effects of campestanol/sitostanol mixture with variable fat intake on level of, 578
- Serum semicarbazide-sensitive amine oxidase (SSAO), activity of, in NIDDM, correlated with BMI and serum TGs, 113-117
- Serum sitostanol, effects of campestanol/sitostanol mixture on proportion of, to C, 577
- Serum testosterone (T) in normoponderal PCOS subjects, 440
- Serum thyrotropin (TSH)  
 short-term salsalate therapy effects on, 501-503  
 $T_3$  effects on, 1605  
 L- $T_4$  effects on, 1343
- Serum thyroxine ( $T_4$ ), total,  $T_3$  effects on, 1605
- Serum  $\alpha$ -tocopherol, *see* Serum vitamin E
- Serum triacylglycerol (TAG), sesamin effects on, 1309
- Serum triglycerides (TGs)  
 fasting, *see* Fasting serum triglycerides  
 PV effects on, 619  
 $S_i$  and, in obese white and black women, visceral and truncal SC AT and, 194-199  
 serum SSAO activity in NIDDM correlated with, 113-117  
 L- $T_4$  effects on, 1343, 1344  
 total, in CHD, 854, 855  
*see also* Serum triglycerides, diet effects on
- Serum triglycerides (TGs), diet effects on  
 of campestanol/sitostanol mixture with variable fat intake, 577  
 diet and exercise effects on, in obese NIDDM men, 642  
 of soy protein/soluble fiber diet, 812
- Serum tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) in normoponderal PCOS women, 437-441
- Serum uric acid  
 in Japanese NIDDM subjects with insulin resistance, *FABP2* gene polymorphism and, 656

- Serum uric acid (*Continued*)  
 serum leptin associated with concentrations of, 677-680
- Serum very-low-density lipoprotein (VLDL) in dyslipidemia, BC/SKF38393 effects on, 1036
- Serum vitamin B<sub>12</sub> in NIDDM, 1097-1099
- Serum vitamin D, effects of campestanol/sitostanol mixture with variable fat intake on level of, 578
- Serum vitamin E ( $\alpha$ -tocopherol)  
 in cirrhosis, 87  
 effects of campestanol/sitostanol mixture with variable fat intake on level of, 578
- Sesamin, effects of, on hepatic FA oxidation, 1303-1313
- Sex  
 of CHD subjects, 652, 653  
 of childhood-onset GH-deficient adults, 1004  
 of cirrhotic subjects, 87  
 of CT subjects, 234  
 of diabetic retinopathy subjects, 1173  
 of epileptic subjects on anticonvulsants, 1048, 1050  
 and ERT effects on vascular reactivity, 227-232  
 of ESRD patients of HD, 632  
 of essential HTN subjects, effects of long-term lisinopril therapy and, 1257  
 of FCHL subjects, 47  
 of GH-deficient adults, *see* Sex of GH-deficient adults  
 of hyperinsulinemic subjects, *see* Sex of hyperinsulinemic subjects  
 of hyperinsulinic subjects, 110  
 of hyperthyroidic subjects, and FFA decrease with acipimox, 1319  
 of hyperuricemic Taiwanese aborigines, 132  
 of IBD subjects, 953  
 of IDDM subjects, *see* Sex of IDDM subjects  
 of lean subjects, HR variability and, 756  
 and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 781, 782  
 of malnourished older cancer subjects, 294  
 of MHL subjects, 62  
 of multiple-trauma victims, 1398  
 of NIDDM subjects, *see* Sex of NIDDM subjects  
 of nondiabetic subjects, *see* Sex of nondiabetic subjects  
 of obese subjects, *see* Sex of obese subjects  
 of PH subjects, 299  
 serum leptin and, *see* Sex, serum leptin and  
 and serum 25OHD levels, 1031  
 and splanchnic utilization of enteral alanine, 916  
*see also* Female subjects; Girls; Male subjects; Men; Women
- Sex, serum leptin and  
 and effects of aging-related changes in sex hormones on sex differences in serum leptin independently of AT changes, 378-384  
 and low serum insulin, ethnicity and, 1217  
 in NIDDM subjects with macroalbuminuria and microalbuminuria, 1291, 1292  
 and serum uric acid in obesity, 678-680  
 twenty-four hour variation in serum leptin in older men, 1011-1014
- Sex of GH-deficient adults  
 response to GH therapy and, 308-313  
 VLDL apo B-100 kinetics and, 1058
- Sex hormone(s)  
 aging-related changes in, *see* Aging-related changes in sex hormones  
 in hyperinsulinic young women, race and, 107-112  
 in young men, *see* Young men, sex hormones in  
*see also specific sex hormones*
- Sex hormone-binding globulin (SHBG)  
 effects of aging-related changes in, on sex difference in serum leptin independently of changes in AT, 378-384
- Sex hormone-binding globulin (SHBG) (*Continued*)  
 in exercising Mexican American and non-Hispanic women, 973-974  
 in hyperinsulinic young adults, race and, 107-112  
 in hypogonadal men, T substitution and, 592  
 in PCOS, metformin-induced resumption of normal menses and, 512, 516
- Sex hormone therapy  
 effects of cross-, in transsexuals on size of adipocytes and lipolytic activity of abdominal and gluteal adipocytes 1371-1377  
*see also* Hormone replacement therapy
- Sex of hyperinsulinemic subjects  
 obesity and, 929, 932  
 and prediction of NIDDM, HTN, and CHD, 990, 992, 993
- Sex of IDDM subjects  
 cardiac sympathetic dysinnervation and, 93  
 octreotide effects on endothelial dysfunction in IDDM and, 1237  
 with osteomyelitis of foot, 923  
 and urinary excretion of apo A fragments, 370
- Sex of NIDDM subjects  
 and acute effects of adrenergic-mediated ischemia on nerve conduction, 496  
 with angiopathy, 1482  
 cochlear dysfunction and, 1347  
 fish and exercise effects on urinary excretion of F<sub>2</sub>-isoprostane, 1404  
 with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 NE-mediated vasoconstriction and, 1538  
 with osteomyelitis of foot, 923  
*rad* gene polymorphism and, 174  
 total depletion of antioxidant capacity and, 1415  
*see also* Sex of NIDDM subjects, lipid peroxidation and
- Sex of NIDDM subjects, lipid peroxidation and  
 gliclazide versus metformin effects on lipid peroxidation, 898  
 glycated Hb and lipid peroxidation of erythrocytes, 206
- Sex of nondiabetic subjects  
 with MI, 1199  
 of nondiabetic offspring of NIDDM subjects, 979
- Sex of obese subjects  
 HR variability and, 756  
 serum leptin and serum uric acid association in obesity and, 678-680
- SFAs, *see* Saturated fatty acids
- SHBG, *see* Sex hormone-binding globulin
- Short-chain fatty acids (SCFAs), effects of soy protein/soluble fiber diet on, 812, 813
- Short-term regulation of renal glucose oxidation, substrate interactions in, 707-715
- Short-term therapy  
 with glucocorticoids, effects of, on hypothalamic and pituitary galanin synthesis, 792-796  
 with MPA, effects of, on LVM, IGF-I and, 1328-1331  
 with salsalate, effects of, on serum TSH, 501-503
- Shunts, aortopulmonary, arterial glucose concentrations with, after fast, 1082-1088
- $\alpha$ (alpha)2,6-Sialyltransferase (2,6-ST) mRNA (messenger ribonucleic acid), hepatic  $\beta$ -galactoside, effects of chronic alcohol intake on, 797-803
- Side effects, *see* Adverse and side effects
- Signal transduction via IRS proteins, improvement of vascular resistance and enhancement of, as imidapril mechanisms of S<sub>i</sub> improvement, 1248-1255
- Simvastatin  
 with CDCA for CTX, 233-238  
 effects of, on LDL metabolism in NIDDM, 118-124  
 sterol absorption in HCL and, 68-73
- Sitostanol, *see* Campestanol, sitostanol and

- Sitosterol in soy protein/soluble fiber diet, 811
- Skeletal muscle (SM)
- decrease in capillary density in, related to high serum LDL-C and apo B in men, 1267-1271
  - E effects on LPL activity in, 461-464
  - loss of GLUT3 mRNA and protein in, 876-880
  - LPL activity and TGs in, BC/SKF38393 effects on, 1036
  - of obese insulin-resistant subjects, KRP effects on impaired glucose uptake in, 1450-1454
  - paralyzed, FES exercise effects on GLUT1 and GLUT4 in, 1409-1413
  - purine metabolism in, during exercise by heart failure subjects, 484-488
  - see also* Skeletal muscle, diet and; Skeletal muscle glucose; Skeletal muscle glycogen
- Skeletal muscle (SM), diet and
- effects of high-sucrose diet with EPA-E ester and/or lard on SM PLs, 1094
  - HF diet, simulation of O<sub>2</sub> consumption following addition of lipid substrates and, 1230-1235
- Skeletal muscle (SM) glucose
- chronic smoking effects on S<sub>i</sub>, SM BF and, 239-244
  - effects of AAs and, on exercise-induced SM proteolysis, 161-166
  - insulin-stimulated, chronic leptin administration effects on, 671-676
  - intracellular, in normoglycemic relatives of NIDDM subjects, effects of dexamethasone on, 1128-1135
- Skeletal muscle (SM) glycogen
- metabolism of, during exercise by heart failure subjects, 484-488
  - in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1130-1132
- Skeletal muscle (SM) glycogen synthase in normoglycemic first-degree relatives of NIDDM subjects, dexamethasone effects on, 1131
- SKF38393/bromocriptine (BC), effects of, on dyslipidemia in obesity, 1033-1040
- Skim milk, dried, in cereal-based diet with C, 401
- SM, *see* Skeletal muscle
- Small intestine brush border membranes (BBMs), L-leucine transport in, 1432-1436
- Smoking
- and CHD, 854
  - and childhood-onset IDDM with CAD, 532
  - chronic, effects of, on S<sub>i</sub>, SM BF, and glucose uptake, 239-244
  - effects of, and its cessation on BW and plasma leptin levels, 804-808
  - erythrocyte lipid peroxidation in NIDDM and, 206
  - and hyperinsulinemia, 990
  - in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438
  - and MI in nondiabetic subjects, 1199
  - by postmenopausal women, VAT and, 1147
  - by young adults, MI and, 1159
  - see also* Smoking, race and ethnicity and
- Smoking, race and ethnicity and
- low serum insulin and, 1217
  - and racial differences in PP TGs, postheparin lipase, and hepatic TG lipase, 750
- Smooth muscle, vascular, metformin and insulin effects on glucose metabolism in, 1357-1360
- SNS, *see* Sympathetic nervous system
- SOD, *see* Superoxide dismutase in STZ-DM
- Sodium, *see* Na
- Soluble fiber, combined effects of soy protein and, in C-lowering diet, 809-816
- Somatostatin (SRIH)
- effects of, on neonatal hyperinsulinemic hypoglycemia, 568-574
  - octreotide as analog of, effects of, on endothelial dysfunction in IDDM, 1236-1240
- Somatostatin (SRIH) (*Continued*)
- tone of, and age-related blunting of GH secretion in exercising men, 665-670
- South African black women with history of pregnancy complicated by NTDs, folate status, MTHFR genotype, and Hcy metabolism in, 269-274
- Southern Italians at risk for NIDDM, peripheral tissue glucose uptake after OGTT in, 80-85
- Soy protein
- in cereal-based diet with C, 401
  - combined effect of soluble fiber and, 809-816
  - effects of very low dietary C with, on serum lipids, biliary lipids, and fecal sterols, 489-494
- Soybean oil in high-sucrose diet with EPA-E ester and/or lard, 1090
- Splanchnic utilization
- of enteral alanine, 915-921
  - of  $\alpha$ -KIC, 1555-1563
- SR-B1 (scavenger receptor B1), rodent, CLA-1 as analog of, 627-630
- SRIH, *see* Somatostatin
- SSAO (semicarbazide-sensitive amine oxidase), activity of serum, correlated with BMI and serum TGs in NIDDM, 113-117
- 2,6-ST ( $\alpha$ 2,6-sialyltransferase) mRNA (messenger ribonucleic acid), hepatic  $\beta$ -galactoside, effects of chronic alcohol intake on, 797-803
- Stanols, *see* Campestanol, sitostanol and; Cholestanol
- Starch
- effects of red wine, tannic acid, and ethanol on digestibility of, in NIDDM, 1179-1183
  - fecal excretion of, and colonic bacterial activity, 264-269
  - and FFA inhibition of glucose-stimulated insulin release in insulin resistance, 1315
- Starvation
- effects of DM and, on hepatocyte metabolism of [2,3-<sup>13</sup>C]-SAD, 102-106
  - see also* Fasting
- Stearic acid, TFAs and, 873
- Steroid(s)
- plasma, ovarian cysts and concentrations of, 999-1000
  - as therapy of IBD, 952-956
  - see also* Glucocorticoids; Sex hormone(s); Steroidogenesis and specific steroids
- Steroidogenesis
- in adrenocortical cells, CLA-1 as source of CE necessary to, 627-630
  - hCG-stimulated, in Leydig tumor cells, effects of Cl and inorganic nitrate on, 693-700
- Sterol(s)
- diet and, *see* Sterol(s), diet and
  - simvastatin effects on absorption of, in HCL, 68-73
  - see also* specific sterols
- Sterol(s), diet and
- fecal sterols, effects of soy protein with very low dietary C on, 489-494
  - total phytosterols in C-lowering diet with soy protein and soluble fiber, 811; *see also* Campestanol, sitostanol and; Cholestanol
- Sterol 27-hydroxylase, hepatic, regulation of hepatic cholesterol 7 $\alpha$ -hydroxylase and, compared, 1542-1548
- Stiffness of aortic wall in HCL children, 55-59
- Stigmasterol in C-lowering diet with soy protein/soluble fiber, 811
- Storage, cold heart,  $\omega$ -3 PUFA effects on recovery of cardiac function after, 1203-1209
- Streptozotocin-induced diabetes mellitus (STZ-DM)
- AMGN effects on lipid peroxidation in, 1141-1145
  - ANPs and early renal failure in, 771-778
  - effects of, on tissue lithium, and lithium supplementation effects on, 558-563

- Streptozotocin-induced diabetes mellitus (STZ-DM) (*Continued*)  
 Mg and vanadate effects on glucose metabolism in, 725-731  
 MNCV in, *see* Motor nerve conduction velocity in STZ-DM  
*see also* Streptozotocin-induced diabetes mellitus, diet effects on  
 Streptozotocin-induced diabetes mellitus (STZ-DM), diet effects on  
 dietary FA effects on lipid metabolism in, 455-460  
 LA-induced hypoglycemia in fasting subjects with, 504-510  
 Stress, *see* Oxidative stress  
 Stress hormones  
   effects of acute epinephrine discontinuation on hepatic glucose  
   metabolism during infusion of, 910-914; *see also* Epinephrine  
   *see also* Cortisol; Glucagon; Norepinephrine  
 STZ-DM, *see* Streptozotocin-induced diabetes mellitus  
 Subcutaneous adipocytes, CHD and hypertrophy of, 355-362  
 Subcutaneous adipose tissue (SAT)  
   in NIDDM subjects, 479  
   visceral and truncal, S<sub>1</sub> and serum TGs in, obesity, race and, 194-199  
 [2,3-<sup>13</sup>C]Succinate, [2,3-<sup>13</sup>C]-SAD effects on hepatocyte output of, 103  
 [2,3-<sup>13</sup>C]-Succinic acid dimethylester (SAD), starvation and DM effects  
   on metabolism of, in hepatocytes, 102-106  
 Sucrose (S)  
   effects of high-sucrose diet with EPA-E ester and/or lard on insulin  
   resistance and HTN, 1089-1095  
   in NCEP C-lowering diet, 823  
 Sulfate, effects of, on hCG-stimulated androgen secretion and cAMP  
   levels in Leydig tumor cells, 697  
 Superoxide dismutase (SOD) in STZ-DM  
   lithium effects on, 561  
   plasma, 445  
 Supplementation  
   chromium picolinate, effects of glucose metabolism in older exercis-  
   ing men and women, 546-553  
   lithium, effects of, on STZ-DM, 558-563  
   with vitamin B<sub>12</sub>, effects of, on Hcy, MMA, and serum folate in  
   relation to C677T MTHFR genotype in ESRD, 631-635  
 Supraphysiologic glucose concentrations, effects of long-term exposure  
   of islets of Langerhans to, on insulin mRNA, 319-323  
 Sympathetic blockade, local, effects of, on BF and glucose uptake  
   during hypoglycemia, 1575-1583  
 Sympathetic nervous system (SNS)  
   activities of HPA axis and, in Pima Indians, 395-399  
   dysinnervation of cardiac, PET with [<sup>11</sup>C]-HED in assessment of,  
   92-101  
 Sympathoadrenal function in young women, timing of exercise and diet  
   composition effects on substrate utilization, 1596-1602  
 Syndican, Western blot of, HS and, 1225  
 Syndican core proteins, mesangial cell, HS and, 1224-1225  
 Syndican mRNA (messenger ribonucleic acid), northern blot of, HS  
   and, 1224  
 Synthase, SM glycogen, in normoglycemic first-degree relatives of  
   NIDDM subjects, dexamethasone effects on, 1131  
 Systolic pressure, *see* Blood pressure  
 T, *see* Testosterone  
 T<sub>3</sub>, *see* Triiodothyronine  
 T<sub>4</sub>, *see* Thyroxine  
 TAG (triacylglycerol), liver and serum, sesamin effects on, 1309  
 Taiwanese aborigines with gout, lipid abnormalities in, 131-133  
 Tannic acid, effects of red wine, ethanol and, on glucose tolerance in  
   NIDDM and on starch digestibility, 1179-1183  
 TAT (thrombin-antithrombin III) complex in LPI, 1138  
 TBARS, *see* Thiobarbituric acid-reactive substances  
 TBG (thyroxine-binding globulin) in TNF- $\alpha$ -induced euthyroid sick  
   syndrome in cancer patients, 325-326  
 TC, *see* Total cholesterol  
 TDG (2-tetradecylglycidate), effects of, on renal FAs and renal glucose  
   oxidation, 707-715  
 Teenagers, *see* Adolescents  
 Temporal association between obesity and hyperinsulinemia in chil-  
   dren, adolescents, and young adults, 928-934  
 Testicular interstitial cells, evodiamine effects on T secretion in,  
   1532-1535  
 Testosterone (T)  
   aging-related changes in, effects of, on sex difference in serum leptin  
   independently of changes in AT, 378-384  
   aldosterone production inhibited by, 1108-1114  
   effects of substitution modes of, on serum lipids and Lps in  
   hypogonadal men, 590-596  
   evodiamine effects on secretion of, in testicular interstitial cells,  
   1532-1535  
   exercise and, *see* Testosterone, exercise and  
   free, in hyperinsulinemia, 109, 110  
   in Leydig tumor cells, 694  
   *see also* Testosterone in PCOS  
 Testosterone (T), exercise and  
   effects of exercise and T on HDL-C concentrations, 1493-1497  
   long-term exercise-induced weight loss effects on T in young  
   identical male twins, 1120-1127  
 Testosterone (T) in PCOS  
   metformin-induced resumption of normal menses and, 512, 516  
   and PAI as risk factor for miscarriage, 1590  
   serum, in normoponderal PCOS subjects, 440  
 2-Tetradecylglycidate (TDG), effects of, on renal FAs and renal glucose  
   oxidation, 707-715  
 TFAs, *see: trans* Fatty acids  
 TG(s), *see* Triglyceride(s)  
 TGF, *see entries beginning with terms:* Transforming growth factor  
 Thai subjects, relationship of Trp64Arg variant of  $\beta_3$ -AR gene to total  
   body fat but not to percent body fat and insulin level in, 564-567  
 tHcy (total homocysteine), and nephropathy in NIDDM, 1096-1101  
 Thermogenic effect of hyperglycemia during lipid infusion, 278-284  
 Thiamine (vitamin B<sub>1</sub>) in meal-induced oxidative stress and LDL  
   oxidation in NIDDM, 1504  
 Thiobarbituric acid-reactive substances (TBARS)  
   erythrocyte membrane, in STZ-DM, AMGN effects on, 1142  
   FM, toxin-induced infections and, 946-948  
 Threonine (Thr), effects of, on plasma and urinary concentrations of  
   uric acid and uridine, 1024  
 L-Threonine (Thr), and leucine kinetics, 1379  
 Thrombin-antithrombin III (TAT) complex in LPI, 1138  
 Thyroid C cells, HPRL effects on CT release by, 223  
 Thyroid function  
   changes in tests of, during short-term salsalate therapy, 501-503  
   *see also* Hyperthyroidism; Hypothyroidism; Thyroxine; Thyrotropin;  
   Triiodothyronine  
 Thyrotropin (TSH)  
   effects of, on leptin production in adipocytes, 1570-1574  
   in hyperthyroidism, and FFA decrease with acipimox, 1319  
   serum, *see* Serum thyrotropin  
   in TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients,  
   325-326  
   in uremic subjects on CAPD, long-term effects of rhEPO on, 211  
 Thyroxine (T<sub>4</sub>)  
   free, *see* Free thyroxine  
   in hyperthyroidism, and FFA decrease with acipimox, 1319  
   in TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients,  
   325-326  
   total, *see* Total thyroxine  
 L-Thyroxine (T<sub>4</sub>) for congenital hypothyroidism in infants, effects of, on  
   apo concentrations, 1343-1345

- Thyroxine-binding globulin (TBG) in TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients, 325-326
- Timing of exercise by young women, effects of diet composition and, on substrate utilization and sympathoadrenal function in, 1596-1602
- Tissue lithium, STZ-DM effects on, 558-563
- Tissue-specific glucose metabolism, aging-related changes in, 1445-1449
- TNF- $\alpha$ , *see* Tumor necrosis factor- $\alpha$
- $\alpha$ -Tocopherol, *see* Vitamin E
- Tomography, positron emission, sympathetic cardiac dysinnervation in IDDM assessed with [ $^{11}$ C]-HED and, 93-101
- Total antioxidant capacity, depletion of, in NIDDM, 1414-1417
- Total bile acids, effects of soy protein/soluble fiber diet on, 813
- Total body fat (total adipose tissue)  
relationship of Trp64Arg variant of  $\beta_3$ -AR gene to, but not to percent AT and insulin level in Thai subjects, 564-567  
response of, to exercise, HERITAGE Family Study of, 1278-1286
- Total body glucose, *see* Whole-body glucose
- Total body protein, *see* Whole-body protein
- Total carnitine, LA effects on, 508
- Total cholesterol (TC)  
in adult hypopituitarism, 1059  
in AIDS, 1526  
apo E polymorphism and changes in, in adolescent girls, 285-290  
AT, GH secretion and, in older men and women, 1426, 1428  
and decrease in SM capillary density in men, 1268  
diet effects on, *see* Total cholesterol, diet effects on  
exercise effects on, in weight-reduced men, 19  
GH therapy effects on, *see* Total cholesterol, GH therapy effects on  
in HCL, *see* Total cholesterol in HCL  
HRT enhancing PP metabolism of, in postmenopausal women, 1194  
in HTG and NTG, CHD and, 303  
in HTN, 888  
in human apo A-II transgenic mice, 416, 417  
in hyperinsulinemia, 110  
in hypogonadal men, T substitution and, 592, 594  
imidapril effects on, 1250  
in MHL, 62  
and MI, *see* Total cholesterol, MI and  
in NIDDM, *see* Total cholesterol in NIDDM  
in obesity, *see* Total cholesterol in obesity  
plasma, in human apo A-II transgenic mice, 416  
PP, in young men, racial differences in, 750  
serum, *see* Total serum cholesterol  
serum vitamin E and, in cirrhosis, 89  
TFAs and, in young women, 873  
Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and, 1368
- Total cholesterol (TC), diet effects on  
of high-sucrose diet with EPA-E ester and/or lard, 1093  
of soy protein with very low dietary C, 490-491
- Total cholesterol (TC), GH therapy effects on  
in GH-deficient adults, 310  
in TS, 10, 11
- Total cholesterol (C), MI and  
in nondiabetics, 1199  
in young adults, 1158, 1159
- Total cholesterol (TC) in HCL  
in familial combined HCL, gemfibrozil and lovastatin effects on, 48, 49, 51  
simvastatin effects on, 69, 70
- Total cholesterol (TC) in NIDDM  
and changes in islet capillary angioarchitecture, 479  
fasting, NE-mediated vasoconstriction and, 1538
- Total cholesterol (TC) in NIDDM (*Continued*)  
glycated Hb and lipid peroxidation in NIDDM erythrocytes and, 206  
with insulin resistance, *FABP2* gene polymorphism and, in Japanese subjects, 656  
with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
metformin versus gliclazide effects on, 900  
serum SSAO activity and, 114, 115  
troglitazone effects on, 1104
- Total cholesterol (TC) in obesity  
and association of serum leptin and serum uric acid concentrations, 678, 679  
in obese Japanese men with Trp64Arg variant of  $\beta_3$ -AR gene and *UCP1* gene mutation, 637, 638
- Total dietary fat in soy protein/soluble fiber diet, 810
- Total dietary fiber in soy protein/soluble fiber diet, 810
- Total homocysteine (tHcy), and nephropathy in NIDDM, 1096-1101
- Total phytosterols in soy protein/soluble fiber diet, 811
- Total serum cholesterol (C)  
in CHD, 854, 855  
soy protein/soluble fiber diet effects on, 812  
L-T $_4$  effects on, 1344
- Total serum triglycerides (TGs) in CHD, 854, 855
- Total thyroxine (T $_4$ )  
serum, T $_3$  effects on, 1605  
short-term salsalate therapy effects on, 501-503
- Total triiodothyronine (T $_3$ ), short-term salsalate therapy effects on, 501-503
- Toxin-induced infections, FM and, 946-948
- Traditional Pacific Islanders (Kitavans), low serum insulin in, 1216-1219
- Training, *see* Exercise
- Transaminase, alanine and aspartate, and F and xylitol effects on plasma concentrations and urinary excretion of adenosine, uridine, and purine bases, 521
- Transdermal nitroglycerin, effects of, on TAT complex in LPI, 1138
- Transfer proteins, *see* Cholesteryl ester transfer proteins; Lipid transfer proteins
- Transferase  
chronic alcohol intake effects on hepatic  $\beta$ -galactoside 2,6-ST mRNA, 797-803  
FC deposition in cornea of human apo A-II transgenic mice with functional LCAT deficiency, 415-421  
galactosemia due to GALT deficiency, 1294-1302
- Transferrin in uremic subjects on CAPD, long-term effects of rhEPO on, 211
- Transforming growth factor- $\beta$  (TGF- $\beta$ ) mRNA (messenger ribonucleic acid), regulation of, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178
- Transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1), regulation of ALVA-101 prostate cancer cells by, 1075-1081
- Transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) type II receptor, regulation of ALVA-101 prostate cancer cells by, 1075-1081
- Transforming growth factor- $\beta$ 2 (TGF- $\beta$ 2), regulation of ALVA-101 prostate cancer cells by, 1075-1081
- Transforming growth factor- $\beta$ 2 (TGF- $\beta$ 2) type II receptor, regulation of ALVA-101 prostate cancer cells by, 1075-1081
- Transgenic mice  
expressing human IAPP, amyloid deposition in islets of Langerhans of, and in human islets transplanted in nude mice, compared, 448-454  
human apo A-II, with functional LCAT deficiency, FC deposition in cornea of, 415-421



- Transplantation  
 of human islets of Langerhans in nude mice, amyloid deposition in islets of human IAPP transgenic mice and in, compared, 448-454  
 orthotopic pancreas, preservation of incretin effects after, 645-650
- Transsexuals, effects of cross-sex hormone therapy on size of adipocytes and lipolytic activity of abdominal and gluteal adipocytes in, 1371-1377
- Trauma, critically ill victims of, cytokine release by mitogen-stimulated PBMCs from, 1397-1401
- Triacylglycerol (TAG), liver and serum, sesamin effects on, 1309
- Triglyceride(s) (TG)  
 in adult hypopituitarism, 1059  
 in AIDS, 1526-1528  
 apo E polymorphism and changes in, 286  
 AT, GH secretion and, in older men and women, 1426, 1428  
 in CHD, Trp64Arg variant of  $\beta_3$ -AR gene, 653  
 in Cr-deficient diet, 1064  
 diet effects on, *see* Triglyceride(s), diet effects on  
 in dyslipidemia, BC/SKF38393 effects on, 1035, 1036  
 effects of TG-lowering intervention on combined hyperlipidemia associated with muscle protein release in exercise, 1518-1523  
 effects of triphasic OCs with desogestrel or LN on, 660, 661 and ERT effects on vascular reactivity, 228  
 exercise and, *see* Triglycerides(s) in exercising men  
 fasting, *see* Fasting triglycerides  
 GH therapy effects on, *see* Triglyceride(s), GH therapy effects on  
 in gout, 132  
 in HCL, *see* Triglyceride(s) in HCL  
 in hyperinsulinemia, 110  
 in hyperlipidemia, prediction of atherosclerotic CV disease and, 1438  
 in hypogonadal men, T substitution and, 592, 594  
 in IDDM, *see* Triglyceride(s) in IDDM  
 LDL apheresis and concentrations of, 883  
 in MHL, 62, 63  
 in NIDDM, *see* Triglyceride(s) in NIDDM  
 in normolipidemia with peripheral vascular resistance, 1363-1365  
 in obesity, *see* Triglyceride(s) in obesity  
 in PCOS, *see* Triglyceride(s) in PCOS  
 plasma, *see* Plasma triglycerides  
 PP, HRT enhancing metabolism of, in postmenopausal women, 1194  
 in premenopausal women, and association of plasma leptin with plasma PAI-1, 961, 962  
 race and, *see* Triglyceride(s), race and ethnicity and  
 serum, *see* Serum triglycerides  
 TFAs and, in young women, 873  
 Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and, 1368  
 in uremic subjects on CAPD, long-term effects of rhEPO on, 211  
 VAT and, *see* Triglyceride(s), VAT and  
 in young adults with MI, 1158, 1159  
*see also* Hypertriglyceridemia; Normotriglyceridemia
- Triglyceride(s) (TG), diet effects on  
 of NCEP C-lowering diet, 824  
 of soy protein with very low dietary C, 490-491  
*see also* Serum triglycerides, diet effects on
- Triglyceride(s) (TG), GH therapy effects on  
 effects of GH therapy, 310, 1390, 1393  
 effects of GH therapy withdrawal on, 1390, 1393  
 in TS, 10, 11
- Triglyceride(s) (TG), race and ethnicity and  
 PP, in young men, racial differences in, 749-754  
*see also* Triglyceride(s) in Japanese subjects
- Triglyceride(s) (TG), VAT and  
 age and, and LDL particle size and, 1324, 1325  
 VAT accumulation and, 357
- Triglyceride(s) (TG) in exercising men  
 apo E genotype and exercise effects on, 944  
 middle-aged men, AT-LPL activity and, 185  
 older, AT-LPL activity and, 185; *see also* Triglyceride(s) in older exercising men and women  
 in weight-reduced men, 19
- Triglyceride(s) (TG) in HCL  
 in children, stiffness of aortic wall and, 57  
 in familial combined HCL, gemfibrozil and lovastatin effects on, 48, 49, 51  
 simvastatin effects on, 69, 70
- Triglyceride(s) (TG) in IDDM  
 in childhood-onset IDDM with CAD, 532, 533  
 and urinary excretion of apo A fragments, 370
- Triglyceride(s) (TG) in Japanese subjects  
 and changes in islet capillary angioarchitecture, 479  
*see also* Triglyceride(s) in NIDDM Japanese subjects
- Triglyceride (TG) lipase, PP hepatic, in young men, racial differences in, 749-757
- Triglyceride(s) (TG) in NIDDM  
 glycated Hb and lipid peroxidation in NIDDM erythrocytes and, 206  
 and insulin resistance, *FABP2* gene polymorphism and, 656  
 with macroalbuminuria and microalbuminuria, serum leptin and, 1291, 1292  
 metformin versus gliclazide effects on, 900  
 total depletion of antioxidant capacity and, 1415  
 troglitazone effects on, 1104  
*see also* Triglyceride(s) in NIDDM Japanese subjects
- Triglyceride(s) (TG) in NIDDM Japanese subjects  
 glycated Hb and lipid peroxidation in NIDDM erythrocytes and, 206  
 with insulin resistance, *FABP2* gene polymorphism and, 656
- Triglyceride(s) (TG) in obesity  
 and association of serum leptin and serum uric acid concentrations, 678, 679  
 in obese Japanese subjects with Trp64Arg variant of  $\beta_3$ -AR gene and *UCPI* gene mutation, 637, 638
- Triglyceride(s) (TG) in older exercising men and women  
 differential effects of exercise and body composition on, 985  
 exercise effects on, 1477
- Triglyceride(s) (TG) in PCOS  
 insulin, obesity and, 171  
 metformin-induced resumption of normal menses and, 512, 514, 516
- Triiodothyronine ( $T_3$ )  
 in eating disorders, 218  
 in hyperthyroidism, and FFA decrease with acipimox, 1319  
 influence of, on Trp binding to hepatic nuclei, 144-152  
 leptin regulation by, 1603-1607  
 serum free, with HF diet, 1233  
 in TNF- $\alpha$ -induced euthyroid sick syndrome in cancer patients, 325-326  
 total, short-term salsalate therapy effects on, 501-503
- Trinucleotide-repeat combination polymorphism at *rad* gene in NIDDM, 173-175
- Triphasic oral contraceptives (OCs) with desogestrel or LN, effects of, on apo A-I-containing HDL particles, 658-664
- Triphosphatase, *see* Na/K-ATPase
- Triphosphate, adenosine, *see* ATP
- Troglitazone  
 effects of, on vascular reactivity, Ca and glucose role in, 125-130  
 in HTN, relationship between apo A phenotype and Lp(a) increase due to, 1-2  
 in NIDDM, *see* Troglitazone in NIDDM  
*ob* gene suppressed by, 786-791
- Troglitazone in NIDDM  
 AT distribution in NIDDM men, 1102-1107

- Troglitazone in NIDDM (*Continued*)  
 differential effects of D-chiroinositol and, on glucosamine-induced insulin resistance in NIDDM, 1418-1423
- Trp, *see* Tryptophan
- Trp64Arg variant of  $\beta_3$ -AR gene, *see* Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and; Trp64Arg variant of  $\beta_3$ -AR gene, obesity and
- Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance and in Japanese-American men, 1367-1370  
*see also* Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance, CHD and
- Trp64Arg variant of  $\beta_3$ -AR gene, insulin resistance, CHD and lack of association between insulin resistance and Trp64Arg variant in CHD subjects, 651-654  
 not associated with CHD or insulin resistance in either nondiabetic or NIDDM subjects, 853-856
- Trp64Arg variant of  $\beta_3$ -AR gene, obesity and in Japanese men, phenotypic characterization of *UCP1* gene mutation and, 636-640  
 relationship of, to total body fat but not to percent body fat and insulin level in Thai subjects, 564-567
- Truncal subcutaneous adipose tissue (SAT), visceral and,  $S_1$  and serum TGs in obese white and black women and, 194-199
- Tryptophan (Trp)  
 effects of, on plasma and urinary concentrations of uric acid and uridine, 1024  
 influence of insulin,  $T_3$ , and cortisol on binding of, to hepatic nuclei, 144-152  
*see also entries beginning with terms:* Trp64Arg variant of  $\beta_3$ -AR gene
- L-Tryptophan (Trp), and leucine kinetics, 1379
- TS (Turner syndrome), GH therapy effects on lipid and CHO metabolism in girls with, 7-14
- TSH, *see* Thyrotropin
- Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )  
 and apoptosis of beta cells, 1485-1492  
 circulating, concentrations of, in peripheral versus abdominal obesity, 1332-1335  
 recovery from euthyroid sick syndrome induced by, in cancer patients, 324-329  
 release of, by mitogen-stimulated PBMCs of critically ill multiple-trauma victims, 1397-1401  
 serum, in normoponderal PCOS women, 437-441
- Turner syndrome (TS), GH therapy effects on lipid and CHO metabolism in girls with, 7-14
- Twenty-four hour variations, *see* Circadian variations
- Twins, young identical male, effects of long-term exercise-induced weight loss in, on sex hormones in, 1120-1127
- Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Tyrosine (Tyr)  
 effects of, on plasma and urinary concentrations of uric acid and uridine, 1024  
 metabolism of, in late pregnancy, 849-852
- L-Tyrosine (Tyr), and leucine kinetics, 1379
- UC (ulcerative colitis), metabolic features of, 952-956
- UCP1* gene, phenotypic characterization of Trp64Arg variant of  $\beta_3$ -AR gene and mutation of, in obese Japanese subjects, 636-640
- UCP2* gene mutation in Japanese NIDDM subjects, 581-584
- UDPG (uridyldiphosphoglucose), hepatic, and hepatic nonoxidative glucose metabolism, 1260-1266
- Ulcerative colitis (UC), metabolic features of, 952-956
- Umbilical cord endothelial cells (ECs), IDDM plasma inducing functional modification in, 554-557
- Uncoupling protein (UCP)  
 effects of high-sucrose diet with EPA-E ester and/or lard on, in BAT, 1093-1094  
*see also:* *UCP1* gene; *UCP2* gene
- Unsaturated fat  
 C-lowering properties of, and hepatic Fe levels, 200-204  
*see also* Monounsaturated fatty acids; Polyunsaturated fatty acids
- Untrained subjects, *see* Sedentary men
- Urea, plasma, in STZ-DM, 444
- Uremia, *see* Renal failure
- Uric acid, *see* Hyperuricemia; Plasma uric acid; Serum uric acid
- Uridine, *see* Plasma uridine
- Uridyldiphosphoglucose (UDPG), hepatic, and hepatic nonoxidative glucose metabolism, 1260-1266
- Uridyltransferase, galactose-1-phosphate, galactosemia due to deficiency in, plasma and urinary excretion of galactitol in, 1294-1302
- Urinary excretion  
 AA, isotopic enrichment of, following L-[1- $^{13}$ C]Phe and L-[1- $^{13}$ C]lysine infusions, 732-737  
 adenosine, F and xylitol effects on, 520-524  
 of apo A fragments in IDDM, 369-372  
 Ca, *see* Urinary excretion of Ca  
 catecholamine, high-sucrose diet with EPA-E ester and/or lard, 1092  
 Cl, 1024  
 of C-peptides, effects of soy protein/soluble fiber diet on, 812  
 creatinine, *see* Urinary excretion of creatinine  
 of F $_2$ -isoprostane in NIDDM, effects of fish and exercise on, 1402-1408  
 galactitol, in galactosemia due to GALT deficiency, 1294-1302  
 glucose, imidapril effects on, 1250  
 K, in PH, 299  
 N, effects of CMA and GH on, 765  
 Na, *see* Urinary excretion of Na  
 nitrite/nitrate, in normotensive men and men with essential HTN, effects of acute hyperinsulinemia on, 887-891  
 phosphate, *see* Urinary excretion of phosphate  
 of pyridinoline and DPYR, galactose effects on, 905-907  
 [ $^3$ H]riboflavin, during respiratory infection, 1610  
 of uridine and purine bases, *see* Urinary excretion of uridine and purine bases  
*see also entries beginning with suffix: -uria; for example:* Proteinuria
- Urinary excretion of Ca  
 galactose effects on, 905-907  
 in PH, 299
- Urinary excretion of creatinine  
 AA effects on, 1024-1026  
 in IDDM, 370
- Urinary excretion of Na  
 AA effects on, 1024-1026  
 in PH, 299
- Urinary excretion of phosphate  
 inorganic, AA effects on, 1024, 1026  
 in PH, 299
- Urinary excretion of uridine and purine bases  
 AA effects on, 1023-1027  
 F and xylitol effects on, 520-524  
 glucose effects on, 338-341
- Urinary volume, imidapril effects on, 1250
- Ursodeoxycholate, effects of soy protein/soluble fiber diet on, 813
- Vaccenic acid, effects of, on insulin release, 23
- Val (valine), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- L-Val (valine), and leucine kinetics, 1379

- Valerate, effects of soy protein/soluble fiber diet on, 813
- Valine (Val), effects of, on plasma and urinary concentrations of uric acid and uridine, 1024
- L-Valine (Val), and leucine kinetics, 1379
- Valproic acid therapy, effects of long-term, on carnitine reabsorption, 74-79
- Vanadate, effects of Mg and, on glucose metabolism in STZ-DM, 725-731
- Vascular disease, peripheral, normolipidemia with, net mass transfer of plasma CETPs and lipid transfer proteins in, 1361-1366
- Vascular endothelial growth factor (VEGF) mRNA (messenger ribonucleic acid), regulation of, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178
- Vascular reactivity  
ERT and sex effects on, 227-232  
troglitazone effects on, role of glucose and Ca in 125-130
- Vascular resistance, imidapril improving  $S_1$  by enhancing signal transduction via IRS proteins and improving, 1248-1255
- Vascular smooth muscle, metformin and insulin effects on glucose metabolism in, 1357-1360
- Vasoactive factors, plasma NO and related, following long-term lisinopril therapy for essential HTN, 1256-1259
- Vasoconstriction, NE-mediated, in NIDDM, 1536-1541
- Vasodilation, insulin-induced internal carotid artery, 1470-1473
- VAT, *see* Visceral adipose tissue
- $\dot{V}CO_2$   
in IBD, 954  
in whole-body lipolysis, 475
- Vegetable protein, *see* Soy protein
- VEGF (vascular endothelial growth factor) mRNA (messenger ribonucleic acid), regulation of, in peripheral blood leukocytes of diabetic retinopathy subjects, 1172-1178
- Ventromedial hypothalamus (VMH), long-term infusion of NE and 5-HT into, effects of, on pancreatic islet function, 1287-1289
- Verapamil for HPRL, 1351-1356
- Very-low-density lipoprotein(s) (VLDL)  
effects of triphasic OCs with desogestrel or LN on, 659  
enhanced FA and biliary C synthesis but not secretion of, following PV blockade of hepatic HMG-CoA reductase, 618-626  
plasma, in human apo A-II transgenic mice, 416  
serum, in dyslipidemia, BC/SKF38393 effects on, 1036  
*see also* Very-low-density lipoprotein-cholesterol
- Very-low-density lipoprotein (VLDL) apolipoprotein B-100 (apo B-100), kinetics of, in adult hypopituitarism, 1057-1062
- Very-low-density lipoprotein-cholesterol (VLDL-C)  
diet and, *see* Very-low-density lipoprotein-cholesterol, diet effects on  
effects of triphasic OCs with desogestrel or LN on, 659  
in MHL, 62  
in normolipidemia with peripheral vascular resistance, 1363-1365  
in PCOS, 171  
PP, *see* Postprandial very-low-density lipoprotein-cholesterol  
TFAs and, in young women, 873
- Very-low-density lipoprotein-cholesterol (VLDL-C), diet effects on  
NCEP diet effects on, 824  
in obese NIDDM men, diet and exercise effects, 643
- Visceral adipose tissue (VAT)  
abdominal, *see* Abdominal adipose tissue  
hostility, anger and, in postmenopausal women, 1146-1151  
and LDL particle size in middle-aged and young men, 1322-1327  
serum lipids, GH secretion and, in older men and women, 1426, 1428  
*see also* Visceral adipose tissue, subcutaneous
- Visceral adipose tissue (VAT), subcutaneous  
metabolic risk factors for CHD and, and hypertrophy of subcutaneous adipocytes, 355-362  
 $S_1$  and serum TGs in obese women, race and, 194-199
- Vitamin(s)  
in cereal-based diet with C, 401  
*see also specific vitamins*
- Vitamin A (retinol) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Vitamin A<sub>1</sub> (retinol), serum, effects of campestanol/sitostanol mixture with variable fat intake on level of, 578
- Vitamin B<sub>1</sub> (thiamine) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Vitamin B<sub>2</sub>, *see* Riboflavin; [<sup>3</sup>H]Riboflavin
- Vitamin B<sub>6</sub> in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Vitamin B<sub>12</sub> (cyanocobalamin)  
effects of supplementation with, on Hcy, MMA, and serum folate in relation to C677T MTHFR genotype in ESRD, 631-635  
and hyperhomocysteinuria in epileptic subjects on anticonvulsants, MTHFR genotype and, 1048, 1049
- Vitamin B<sub>12</sub> (cyanocobalamin) in NIDDM, 1097-1099  
in meal-induced oxidative stress and LDL oxidation, 1504
- Vitamin C (ascorbic acid) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- Vitamin D (calciferol)  
in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
serum, effects of campestanol/sitostanol mixture with variable fat intake on, 578
- Vitamin E ( $\alpha$ -tocopherol)  
effects of NAC and, on PS externalization and coagulation induction in glucose-treated erythrocytes, 957-959  
and lipid peroxidation in NIDDM, 900  
in liver cirrhosis, 86-91  
in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504  
serum, effects of campestanol/sitostanol mixture with variable fat intake of, 578
- Vitamin K in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- VLDL, *see* Very-low-density lipoprotein(s)
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol
- VMH (ventromedial hypothalamus), long-term infusion of NE and 5-HT into, effects of, on pancreatic islet function, 1287-1289
- $\dot{V}O_2$   
aortopulmonary shunts and, 1084  
in IBD, 954  
in whole-body lipolysis, 475  
*see also*  $\dot{V}O_2$ , exercise and;  $\dot{V}O_{2max}$
- $\dot{V}O_2$ , exercise and  
and age-related blunting of GH secretion during exercise, SRIH tone and, 667  
in heart failure subjects, 485  
*see also*  $\dot{V}O_{2max}$ , exercise and
- $\dot{V}O_{2max}$  (maximum oxygen consumption)  
and decrease in SM capillary density in men, 1268  
*see also*  $\dot{V}O_{2max}$ , exercise and
- $\dot{V}O_{2max}$  (maximum oxygen consumption), exercise and  
acipimox effects on, 247  
chronic smoking effects on, 240  
*see also*  $\dot{V}O_{2max}$  in exercising men;  $\dot{V}O_{2max}$  in exercising women
- $\dot{V}O_{2max}$  (maximum oxygen consumption) in exercising men  
and effects of apo E genotype and exercise on plasma HDL-C and HDL<sub>2</sub>-C, 944  
middle-aged men, AT-LPL activity and, 183-189  
in weight-reduced men, 18  
*see also*  $\dot{V}O_{2max}$  in older exercising men
- $\dot{V}O_{2max}$  (maximum oxygen consumption) in exercising women  
in Mexican American and non-Hispanic women, PP insulin responses and, 972, 973

- $\dot{V}O_2$ max (maximum oxygen consumption) in exercising women  
(*Continued*)  
older women, exercise effects on HDL-C and, 985  
young women, timing of exercise and diet composition effects on substrate utilization and, 1597
- $\dot{V}O_2$ max (maximum oxygen consumption) in older exercising men  
AT-LPL activity and, 183-189  
exercise effects on HDL-C and, 985
- Waist-to-hip ratio (WHR)  
of CHD subjects, 653, 854, 855  
in childhood-onset IDDM with CAD, 532, 533  
and decrease in SM capillary density in men, 1268  
exercise and, *see* Waist-to-hip ratio of exercising men; Waist-to-hip ratio of older exercising men and women  
of GH-deficient adults, effects of GH therapy and its withdrawal on, 1390  
of IBD subjects, 953, 954  
of Mexican American and non-Hispanic exercising women, PP insulin responses and, 972; *see also* Waist-to-hip ratio of older exercising men and women  
of NIDDM-prone subjects, and peripheral tissue glucose uptake after OGTT, 81  
in premenopausal women, and association of plasma leptin with plasma PAI-1, 961, 962  
serum leptin and, *see* Waist-to-hip ratio, serum leptin and  
VAT and LDL particle size and, 1323  
*see also* Waist-to-hip ratio, and Trp64Arg variant of  $\beta_3$ -AR gene; Waist-to-hip ratio of exercising men; Waist-to-hip ratio of obese subjects
- Waist-to-hip ratio (WHR), insulin resistance and  
in NIDDM, *FABP2* gene polymorphism and, 656  
Trp64Arg variant of  $\beta_3$ -AR gene, 1363
- Waist-to-hip ratio (WHR), serum leptin and  
aging-related changes in sex hormones, serum leptin, and WHR, 380  
serum leptin and serum uric acid association in obesity and, 678, 679
- Waist-to-hip ratio (WHR), and Trp64Arg variant of  $\beta_3$ -AR gene  
insulin resistance and, in Japanese-American men, 1368, 1369  
relationship of mutation to total body fat but not to percent body fat and insulin level, 565  
and *UCP1* gene mutation in obese Japanese men, 637, 638
- Waist-to-hip ratio (WHR) of exercising men  
and long-term weight maintenance in weight-reduced men, 17  
middle-aged men, AT-LPL activity and, 185  
*see also* Waist-to-hip ratio of older men and women
- Waist-to-hip ratio (WHR) of obese subjects  
association of serum leptin and serum uric acid in obesity and, 678, 679  
circulating TNF- $\alpha$  and, 1333  
obese Japanese men, Trp64Arg variant of  $\beta_3$ -AR gene and *UCP1* gene mutation in, 637, 638
- Waist-to-hip ratio (WHR) of older exercising men and women  
AT, serum lipids, GH secretion and, 1426  
chromium picolinate supplementation effects on, 549  
differential effects of exercise and body composition on, 1476
- Waist-to-hip ratio (WHR) of older men and women  
relationship between GH secretion, AT, and serum lipids in, 1426, 1428  
*see also* Waist-to-hip ratio of older exercising men and women
- Water  
in C and HC diet, and  $\omega$ -3 PUFA effects on recovery of cardiac function recovery after cold storage of heart, 1203  
imidapril effects on intake of, 1250  
in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504
- WBCs (white blood cells), *see* Leukocytes; White blood cell count
- Weight, *see* Body weight; Organ weight; Weight gain; Weight loss by exercising men
- Weight gain on high-sucrose diet with EPA-E ester and/or lard, 1091
- Weight loss by exercising men  
and long-term BW maintenance, 15-21  
long-term exercised-induced, in identical twins, effects of, on sex hormones, 1120-1127  
with NIDDM, diet and exercise effects on, 642
- Western blot of syndican, HS and, 1225
- White Americans, *see* Race and ethnicity
- White blood cell(s), *see* Leukocytes; White blood cell count
- White blood cell (WBC) count, and leukocyte lactate output and glycolysis in sepsis and in ex vivo blood, 782
- Whole-body glucose  
disposal of, in HTN, 888  
kinetics of, in cirrhosis, 1263  
uptake of, in CHD, 855
- Whole-body lipolysis, hypoosmolality effects on, 472-476
- Whole-body protein  
FM and toxin-induced infections and, 947  
metabolism of, in late pregnancy, 849-852
- WHR, *see* Waist-to-hip ratio
- Wilson's disease, vitamin E in, 87
- Wine, effects of tannic acid, ethanol, and red, on starch digestibility and glucose tolerance in NIDDM, 1179-1183
- Withdrawal  
effects of GH, on insulin secretion in GH-deficient adults, 1387-1396  
from gemfibrozil and lovastatin therapy of FCHL, 49  
*see also* Discontinuation
- Women  
with eating disorders, leptin in, 217-220  
*see also* Contraceptives; Hormone replacement therapy; Menstrual cycle; Normal subjects; Older women; Polycystic ovary syndrome; Pregnancy; Sex; Women, exercising; Women, obese; Young women and specific conditions
- Women, exercising  
menstrual cycle effects on EPOC in young women, 275-277  
Mexican American and non-Hispanic, response of PP insulin to exercise in, 971-977  
young, diet composition and timing of exercise effects on substrate utilization and sympathoadrenal function in, 1596-1602  
*see also* Exercise; Older men and women, exercising
- Women, obese  
with PCOS, impact of insulin and obesity on metabolic and endocrine variables in, 167-172  
S $_1$  and serum TGs in, race and, 194-199  
*see also* Obesity
- Work capacity, hypocortisolemia effects on, 392
- Xanthine, *see* Plasma xanthine
- Xanthomatosis, cerebrotendinous, simvastatin with CDCA for, 233-238
- X-ray absorptiometry, *see* Dual-energy x-ray absorptiometry
- Xylitol, effects of F and, on urinary excretion and plasma concentrations of adenosine, uridine, and purine bases, 520-524
- Yeast, dried brewer's, in cereal-based diet with C, 401
- Young adults  
with MI, LPL *HindIII* gene polymorphism in, 1157-1161  
NO modulating GH-releasing activity of Hexarelin in, 176-182  
temporal association between obesity and hyperinsulinemia in, 928-934  
*see also* Young men; Young women

## Young men

- exercising, *see* Young men, exercising
- PP TGs, postheparin lipase, and hepatic TG lipase in, racial differences in, 749-754
- sex hormones in, *see* Young men, sex hormones in
- VAT and LDL particle size in, 1322-1327
- see also* Young adults

## Young men, exercising

- blunting of GH secretion, SRIH tone and, 665-670
- identical twins, effects of long-term exercise-induced weight loss on sex hormones in, 1120-1127

## Young men, sex hormones in

- hyperinsulinism, race and, 107-112
- identical twins, effects of long-term exercise-induced weight loss on sex hormones in, 1120-1127

## Young women

- diet composition and timing of exercise effects on substrate utilization and sympathoadrenal function in, 1596-1602
- hyperinsulinic, race, sex hormones and, 107-112
- menstrual cycle effects on EPOC in, 275-277
- TFAs and S<sub>i</sub> in, 870-875
- see also* Young adults

ZG (zona glomerulosa), testosterone effects on cAMP accumulation in, 1108-1114

Zinc (Zn) in meal-induced oxidative stress and LDL oxidation in NIDDM, 1504

Zona glomerulosa (ZG), testosterone effects on cAMP accumulation in, 1108-1114